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In recent years, advances in direct sample to mass spectrometry (MS) techniques have allowed for 
the application of these methods towards quantitative analysis in complex matrices such as 
biofluids and tissue. However, the predictable limitations of these technologies, such as ionization 
suppression, poor sensitivity at trace levels, and narrow linear dynamic range, have been the 
driving force toward the development of methods that efficiently integrate sampling, sample 
cleanup, and analyte collection and ionization. In this context, the direct interface of 
microextraction technologies and MS has undoubtedly revolutionized the speed, efficacy, and 
robustness with which complex matrices can be scrutinized. In this thesis, numerous strategies 
recently developed for the direct and efficient coupling of Solid Phase Micro Extraction (SPME) 
and MS are presented towards the analysis of complex matrices. Aiming to supply a range of 
technologies suited for diverse applications, different SPME geometries such as coated fibers, 
blades and meshes, as well as ionization approaches, such as atmospheric pressure chemical 
ionization (APCI) and electrospray ionization (ESI), were studied. In addition, these workflows 
are compatible with SPME devices that undergo either sampling of tissue or direct immersion into 
liquid samples. The strategies developed as part of this doctoral dissertation include the following: 
SPME-Transmission Mode coupled to MS via Direct Analysis in Real Time (SPME-TM-DART-
MS), SPME coupled to MS via nano-ESI (SPME-nanoESI-MS), SPME coupled to MS via Open 
Port Probe (SPME-OPP-MS), and Coated Blade Spray-MS (CBS-MS). In most of the applications 
herein compiled, total analysis time does not exceed 5 minutes, while sample volumes ranging 
between 1 and 1500 μL can be utilized for analysis. Sampling/sample-preparation is performed 
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either by spotting the sample onto the SPME-device, or by immersing the SPME-device on a vessel 
containing the sample. Despite short extraction times, limits of detection in the pg/mL to sub-
ng/mL range were obtained, while good accuracy (i.e. 80-120%) and linearity (i.e. ppt to ppm) 
were attained for all studied probes (i.e. therapeutic drugs, drugs of abuse, pharmaceuticals, and 
pesticides) in the diverse sample matrices (e.g. phosphate buffer saline, urine, plasma, blood, grape 
juice, orange juice, milk, and ground water). Lastly, this work describes exemplary cases in which 
the mere coupling of SPME to MS is not sufficient to answer relevant analytical questions, and 
the use of a chromatographic step is justified. Hence, supplementary instrumental strategies that 
allow for removal of co-extracted interferences or source artifacts, such as Differential Mobility 
Spectrometry (DMS), tandem MS in time (MSn), and Multiple Reaction Monitoring with 
Multistage Fragmentation (MRM3), are also discussed in this dissertation.  
Although the body of this work is chiefly focused on biofluid analysis, the attained results certainly 
support the implementation of this group of technologies towards the analysis of diverse complex 
matrices of environmental, biological, food, clinical, military, forensic, and pharmaceutical 
significance. We are confident that in a foreseeable future, this work will encourage readers around 
the globe towards the use of SPME-MS as a workhorse for on-site and benchtop analysis. In few 
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Chapter 1: Introduction 
 
1.1. Bioanalytical chemistry: targeted analysis of small molecules in biofluids 
Bioanalytical chemistry is a sub-discipline of analytical chemistry that involves the development 
of methods and instruments that enable sensitive, reproducible, and selective analysis of 
xenobiotics and biotics in biological samples.1 In order to attain this objective, a typical 
bioanalytical workflow integrates multiple technologies, including sampling, sample preparation 
(i.e. enrichment of analytes of interest and clean-up of undesired matrix components), analyte 
separation (i.e. discrimination between analyte and potential matrix interferences such isomers, 
isobars, in-source fragmentation products), and analyte detection (e.g. via tandem mass 
spectrometry).2 Given that bioanalytical chemistry encompasses both the analysis of small and 
large molecules, it should be noted at this juncture that this doctoral dissertation is fundamentally 
focused on the development of methods and devices for analysis of small molecules; hence, all 
topics discussed hereafter are strictly related to the analysis of compounds with molecular weights 
(MW) ranging between 100 and 1250 Daltons (Da). Furthermore, most of the embodiments of this 
thesis describe technologies chiefly used for the analysis of biofluids; likewise, this introductory 
chapter is centered on a discussion of technologies capable of providing quantitative and 
qualitative information of compounds present in biological fluids.  
In definition, a biofluid is a biological liquid that either: a) flows through certain compartments in 
the body and can be accessed with a needle or similar instrumentation (e.g. cerebrospinal fluid or 
blood); b) is excreted/secreted from the body (e.g. urine, saliva or sweat), or c) develops in 
response to a medical condition (e.g. blister). Inspections of biofluids, such as of urine,3 have been 
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carried out since ancient times to diagnose diseases.4 Thanks to outstanding breakthroughs in the 
fields of analytical and bioanalytical chemistry, clinicians possess nowadays tools that provide 
them with more accurate means of understanding the efficacy of a given treatment (e.g. up or 
down-regulation of a biomarker),5 or the plausible negative impact such a treatment might have 
on a patient (e.g. drug concentration above or below its therapeutic range).6 Undeniably, the state 
of the art of mass spectrometry (MS) has played a tremendous role in these advances; for instance, 
absolute compound sensitivity has increased several orders of magnitude since 1980.7 Such 
improvements have enabled the introduction of sub-femtogram quantities of analyte(s) of interest 
for quantification into MS systems, instead of the nanogram quantities achieved years ago 8,9 
Currently, as shown in Figure 1.1, the bioanalytical workflow for inspection of biological fluids 
via mass spectrometry can be divided into three main strategies. The first strategy, herein called 
the “thorough sample preparation” (TSP) approach, is perhaps the most widely used strategy. 
Basically, it consists of taking an aliquot of the biofluid under investigation, then carrying out one 
or multiple sample preparation steps (e.g. liquid-liquid extraction, LLE; protein precipitation, PP; 
solid-phase extraction, SPE; or a combination of those technologies) with aims of extracting and 
enriching analyte(s) of interest from the sample matrix. Subsequently, the sample-extract is 
injected into the analyzer (e.g. mass spectrometer) via a separation system, gas and liquid 
chromatography (GC and LC, respectively) being the most common techniques.10 The second 
approach, herein named the “simplistic sample preparation” (SSP) approach, encompasses the use 
of methods aimed at inducing the release of analytes bound to proteins prior to subsequent 




Figure 1.1 Schematic representation of most common bioanalytical workflows currently used for 
the analysis of small molecules in biofluids via mass spectrometry. 1. Thorough Sample 
Preparation (TSP) approach: one or multiple sample preparation steps, plus separation, plus 
detection approach (“gold standard”); 2. Simplistic Sample Preparation (SSP) approach: rapid 
sample dilution/extraction, plus separation, plus detection approach; 3. Stand Alone MS (SAMS) 
approach: direct interface of the sample extract to the MS system (might or might not include and 
on-line sample preparation step). 
 
 
Such methods are generally carried out via dilution of the matrix (e.g. dilute-and-shoot (DS), 
frequently used in analysis of less viscous biofluids such as urine11) with a mixture of organic-
solvent/water, or through quick precipitation of matrix proteins (e.g. protein precipitation (PP), 
frequently used for analysis of blood, plasma, serum). The third approach, so-called the “Stand 
Alone MS” (SAMS) strategy, completely eradicates the chromatographic separation step inherent 
in the first two workflows by directly injecting the sample extract into the mass spectrometer.12 
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Given the relevance of this approach to the work herein presented, pros and cons of this 
methodology will be thoroughly discussed in the following section.  
Succinctly, the TSP strategy is unquestionably the most comprehensive in terms of sample clean-
up and analyte enrichment. TSP workflows prevent matrix interference with adequate isolation of 
analyte(s) of interest from matrix interferences via chromatographic separation and their 
subsequent selective detection through specific mass spectrometry experiments (e.g. high 
resolution mass spectrometry, HRMS; tandem mass spectrometry, MS/MS; or multistage 
fragmentation, MSn), and they are therefore used as gold standards in the development of novel 
bioanalytical methodologies.13 Nevertheless, such technologies are not without drawbacks; the 
excessive labor, as well as the multiple and tedious steps typically required in such workflows 
have been the driving force towards the development of methods that are capable of providing 
comparable analytical answers while requiring shorter periods of time and less sample handling. 
Recent advances in instrumental automation14,15 permitted the development of unmanned TSP 
methodologies capable of determining small molecules in record times.16–18 Yet, the most efficient 
TSP technologies developed to date are prohibitively expensive for small/mid-size research 
laboratories; thus, the routine use of these technologies is limited to well-funded clinical 
laboratories and pharmaceutical companies of a scale that necessitates the analysis of thousands 
of samples per day, a practice which significantly decreases the cost of analysis per sample and 
affords enough margin to justify their use.13,19,20  
Consequently, in recent years, researchers have also developed workflows, such as SSP, that 
require fewer steps and resources. In spite of the speed, simplicity, and ease of automation of SSP 
protocols,21,22 in certain cases, such methods fail to eliminate sample constituents such as salts or 
phospholipids that maydramatically increase or suppressionization efficiency, thus distorting 
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sample detection.11 Thus, SSP strategies are mainly appropriate for molecules that are easily-
ionizable (e.g. those containing a basic nitrogen atom) and not present at ultra-low concentrations 
(e.g. sub-nanogram mL-1), as such workflows offer limited sensitivity due to the absence of a 
preconcentration step.11,23 
 
1.2. Bioanalysis: towards rapid and reliable determination of small molecules in biofluids 
Commerical MS instruments arrived in routine labs in the 90s7. Their limited sensitivity 
necessitated the use of relatively large samples, which also had to be cleaned up by 
chromatography to prevent matrix interference. The much improved sensitivity of recent 
instruments has made viable the use of SAMS methods, which has greatly decreased sample 
processing time.24 By removing the separation step (i.e. classical LC/GC-MS methods range 
between 10 and 30 min,25 while ultrafast separations can be as fast as 0.5-5 min 26–28), SAMS 
strategies allow for outstanding reductions in total analysis times (≤ 1 min).29,30 The workflow in 
SAMS typically consists of three steps. First, the sample extract is introduced into a “mixing 
chamber”, either by liquid or thermal desorption (see Figure 1.2). 31–33 Subsequently, a pressurized 
liquid or gas carries the introduced analytes towards the ionization chamber (e.g. ESI, APCI, EI), 
where analytes become molecular species suitable for mass spectrometric analysis. Once ionized, 
compounds can then be submitted to detection by a mass analyzer, although certain mass analyzer 
configurations also enable the introduction of additional steps prior to ion detection that aid in 
improvements in the selectivity/sensitivity of the final data (e.g. ion-mobility29 or MSn34). Given 
that in SAMS all analytes are introduced into the mass spectrometer at once, the signal that is 
generated for each analyte/feature by the MS has the shape of a peak or a band (see Figure 1.3A).  
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Figure 1.2 Schematic representation of a SAMS workflow from extract introduction to analyte 















Figure 1.3 Schematic representation of instrumental signals obtained via mass spectrometry 
according to the analytical workflow. A. single peak signal obtained via SAMS approach; B. 
multiple peaks obtained via chromatographic separation after SSP or TSP; C. transient signal 
obtained by employment of the direct-to-MS approach, without a liquid or gas flow pushing the 




In this context, the presence of a single band brings along a series of advantages and disadvantages. 
First of all, by excluding the separation step from their workflows, SAMS methods completely35,36 
or partially29 bypass the removal of compounds capable of causing matrix effects, which in result 
compromise the sensitivity of the method, particularly for poor ionizers. As shown in Figure 1.2, 
contingent on the sample matrix (e.g. whether it is urine37 or plasma38), the physicochemical 
properties of the analyte(s) of interest (e.g. protein-binding and octanol-water partition coefficient, 
LogP), the ionization chamber used (e.g. on-line SPE-ESI39, ESI7, or nano-ESI37), and the 
sensitivity required, SAMS strategies may or may not include an on-line analyte enrichment step 
prior to the introduction of analyte into the MS analyzer.7,40 Undeniably, technologies that include 
an on-line pre-concentration step such as RapidFire™,41 TurboFlow™38 and the column-switching 
approach42 are more robust and less prone to matrix effects. Conversely, aiming to reach desired 
LOQ values, off-line analyte enrichment steps, such SPE, have also been implemented prior to 
direct introduction of sample extract into the MS system.43,44 Indisputably, on-line methodologies 
are faster and maximize the utilization of MS instruments; however, in this case, gains in speed of 
analysis are certainly linked to the cost of the instrumentation being used. For instance, studies 
using the RapidFire™ system by Agilent Technologies (~300-400k CAD) have claimed 
instrumental analysis times in the order of 8-15s per sample,41 whereas similar experiments on the 
cheaper TurboFlow™ system by Thermo Fisher (~90-100k CAD) allow for analysis times in the 
order of 1-2 min per sample.38 Although the analysis speed provided by these systems is hardly 
unbeatable, and certainly unthinkable two decades ago, this doctoral dissertation presents several 
technologies that could make us reconsider whether this is the fastest speed of analysis that can be 
achieved with respect to bioanalytical measurements. Second, the peak width in SAMS is mainly 
governed by the injection band diffusion; mixing occurs as the sample extract travels from the 
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injection chamber to ionization chamber. Hence, the shape of a given analyte peak is dependent 
on the selected instrumental conditions (e.g. carrier flow rate and injection volume43) and the 
configuration of the system (e.g. connecting capillaries and ionization source dimensions45). For 
instance, signal intensity increases as the diameter of the capillary connecting the desorption and 
ionization chamber decreases, or when the fluidics flow rate increases, due to the reduction of 
injection band diffusion. Whatever the peak shape, at least 10 data points, which may not be 
achievable if the peak widths are too narrow. Certainly, narrow peaks also limit the total number 
of compounds that can be analyzed, especially in tandem mass spectrometry applications, as this 
number is dependent on the selected amount of transitions per compound (i.e. single reaction 
monitoring, SRM) as well as the designated dwell time for each transition. Accordingly, optimal 
parameters should allow for sufficient analyte sensitivity while maintaining adequate peak width 
for data collection. In terms of analytical figures of merit and sample analysis throughput (see 
Figure 1.4), the performance of SAMS technologies fall somewhere between those afforded by 
chromatography-MS and ambient mass spectrometry (AMS). While SAMS offers a higher sample 
analysis throughput and simpler methods than chromatography-MS, AMS, a subset of SAMS, 
utterly eradicates from its workflow the sample preparation and separation steps, thus allowing for 
the fastest throughput at the expense of the figures of merit. The following section explores the 
most recent advances in AMS towards the analysis of biofluids.  
 
1.3. Ambient mass spectrometry: a novel avenue for rapid analysis of complex matrices 
The term ambient mass spectrometry, or ambient ionization mass spectrometry, was proposed for 
the first time by professor Zoltan Takáts and his former collaborators at University of Purdue more 
than 10 years ago, aiming to describe a family of techniques that allow for the generation of ions  
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Figure 1.4 Position of SPME-MS relative to chromatography-MS, stand-alone MS, and ambient 
MS in terms of analytical throughput and figures of merit. Figure was adapted from Nanita et al.7 
 
 
Figure 1.5 Color scale presenting the relative scale of ambience and how different SPME-MS 




Figure 1.6 Schematic diagrams of some of the most relevant ambient ionization methods suitable 
for analysis of biofluids. A. Probe electrospray ionization (PESI)47 or touch-spray;48 B. Substrate 
electrospray ionization (e.g. paper spray, PS; leaf-spray or wooden-tip spray);49–51 C. Desorption 
electrospray ionization (DESI)52 and the set-up typically used for MSI; D. Plasma-based 
desorption source (e.g. direct analysis in real time, DART; low temperature plasma, LTP);53,54 E. 




under ambient conditions from ordinary samples in their native environment, without the need for 
sample preparation.52,57 As depicted in Figure 1.5, ambient technologies fundamentally differ from 
any other technology in their ability to measure a given compound(s) in real time,52,53,58 and in 
their proximity to the system under study (e.g. in-vivo or in-situ analysis).59–65 Over the last decade, 
more than forty ambient ionization methods (i.e. comprising pure ambient and direct analysis) 
have been introduced for the analysis of complex matrices. These methods can be classified 
according to the manner in which analytes are extracted from the matrix (i.e. liquid and thermal 
desorption, or laser ablation), the ionization mechanism employed,8,9,46,58,66 and whether the 
process includes more than one step (e.g. mechanical extraction and subsequent ionization via 
electrospray ionization).67 Some of these methods might include a combination of features as well, 
such as thermal desorption from a solid substrate and subsequent ionization via ESI.31 Figure 1.6 
illustrates the methods that are most useful for biofluid analysis.  
Undeniably, the introduction of pure ambient technologies has been a game changer in diverse 
fields such clinical,5,68 food,69,70 and forensic71,72 analysis, given the offered throughput 
capabilities, their simplified workflow, and their easy operation  a particularly useful attribute, 
given that it facilitates operation of this technology by personnel not specialized in analytical 
chemistry.46 Some of the most relevant AMS technologies developed to date include desorption 
electrospray ionization (DESI),73 direct analysis in real time (DART),74 rapid evaporative 
ionization mass spectrometry (REIMS),75 laser ablation electrospray ionization (LAESI),55 low 
temperature plasma (LTP),54 liquid extraction surface analysis (LESA),56 and resonant infrared 
laser ablation (RIR-LA).62 Nonetheless, given that pure ambient ionization methods do not offer 
any analyte enrichment, these technologies are chiefly suited for surface characterization 
applications (e.g. mass spectrometry imaging, MSI76) and sample classification by chemometric 
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tools77–79 via the detection of effortlessly ionizable compounds.80 Therefore, applications of such 
methods towards the quantitation of target compounds present at trace levels (e.g. sub-nanogram 
per milliliter) in biofluids are rarely found in scientific publications, unless such technologies are 
combined with an efficient sample preparation step, as presented in the following sections.81,82  
With respect to the second group, while such technologies allow for the direct analysis of samples 
without prior sample preparation and under ambient conditions, as the analytical process of such 
technologies occurs off-line, these techniques are unable to provide real-time data.83 Such 
technologies, classified in Figure 1.5 as direct analysis technologies, essentially discern from 
SAMS approaches due to their analysis being performed without the use of elaborate equipment 
(e.g. fluidic pumps, pressurized gas, or heating, or laser devices). For instance, substrate spray 
technologies46 such as paper spray (PS)49, probe electrospray ionization (PESI),84,85 and wooden-
tip electrospray ionization (WT-ESI)51 have been proven by scientists as suitable for analysis of 
target analytes in biofluids.58,86 Succinctly, the substrate can be made of any material (e.g. metal, 
wood, paper), and charged droplets can be produced directly from substrates with sharp tips.87 In 
this context, substrate-spray devices function as sample collection devices, where biofluids can be 
either pipetted onto the substrate (e.g. PS8), or the substrate dipped into the biofluid (e.g. PESI47), 
as shown in Figure 1.6. After application, liquid samples are usually allowed to dry on the 
substrate. Subsequently, a droplet of solvent is added onto the substrate to extract the target 
analytes from the dried biofluid. After sufficient time has elapsed so as to allow the substrate to 
become fully wetted with desorption/ionization solvent, a high-voltage is applied to the substrate 
so as to generate an electrospray from the tip of the substrate. Unlike most SAMS approaches, 
substrate-spray technologies typically generate a transient signal rather than a peak (see Figure 
1.3C) that may last for several seconds, provided the substrate does not dry up, and that compounds 
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still remain on the substrate. Employment of transient signals for quantitation offers advantages 
such as the ability to monitor multiple compounds, or perform multiple MS experiments in a single 
analysis; conversely, this approach is limited by loss of sensitivity, since the signal-to-noise ratio 
is sacrificed in such cases (see Figure 1.3D).  
Among the diverse substrate-spray technologies available to date,50 PS is indisputably the most 
popular and widely accepted technique due to its simple operation (i.e. sample is spotted on the 
paper as in dried blood spots);88 low cost (i.e. each device is comprised of just a tiny piece of 
inexpensive filter paper);89 suitability for therapeutic drug monitoring (TDM), point-of-care (POC) 
and pharmaceutical applications (i.e. PS uses small sample volumes, ≤ 20µL);90 and verified 
capabilities for quantitative analysis of target compounds in diverse biofluids at part-per-billion 
levels (e.g. plasma, serum, blood).83,91,92 Furthermore, PS is commercially available from 
Prosolia,93 while devices that allow for the automated coupling of multiple PS to MS94,95 can also 
be purchased by laboratories where high-throughput is needed.96 Certainly, the implementation of 
direct analysis of biofluids via PS-MS leads not only to savings in chromatographic time, but also 
in sample preparation costs. In spite of the multiple advantages of PS and all the fascinating 
applications that can be developed with this technology (e.g. discrimination of bacteria samples 
and quantitation of drugs of abuse in whole blood),97–100 few scientist have objectively discussed 
the drawbacks associated with PS.83,101,102 For example, PS applications lack sufficient sample 
clean-up; accordingly, matrix components soluble in the desorption/ionization solvent can be 
sprayed onto the MS system, which can thwart long-term instrument operation (e.g. due to 
contamination of transfer-tube or exit lenses). Furthermore, due to the lack of analyte enrichment, 
PS offers poor limits of quantitation in the sub nanogram per milliliter range, while also being 
limited to the analysis of small sample volumes.102 Yet, it is important to bear in mind that the 
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problems observed in PS applications are common to any direct-to-MS technology where the 
sample clean-up step is neglected.81 Because they are aware of these limitations, former pure 
ambient mass spectrometrists are moving towards technologies where at least one extraction step 
precedes direct interface to MS.82,102 The following section discusses recently developed novel 
technologies that have as focus the direct interface of sample preparation technologies with mass 
spectrometry.  
 
1.4. Methods based on microextraction (µe) technologies and its direct coupling to mass 
spectrometry  
Although some works claim to not incorporate sample preparation in ambient mass spectrometry, 
it would be more precise to say that some of these methods require no additional sample 
preparation, since the analyte extraction process takes place during the analysis.46 For instance, the 
physical process happening during DESI at the millisecond scale can be considered as a micro-
liquid extraction from the analytes present on the surface of the system under investigation (i.e. 
sampling-spot size is typically less than 150 µm, with a few microliters of solvent per square mm 
performing the extraction). Similarly, an extraction takes place when liquid microjunction (LMJ)24 
devices such as LESA56, nano-DESI,103 or the open port probe (OPP)36,45 are employed. Given that 
the extraction process in ambient ionization occurs directly from the matrix in the majority of 
cases, and that such process is rarely selective or enriching, it did not take several years after its 
conception for many users to realize the quantitative limitations of these technologies when applied 
to trace level detection.104 Besides, since extraction typically occurs from very small sample areas 
(≤ 1 mm), it is quite hard to couple such technologies with well-known, yet cumbersome and 
cumbersome sample preparation technologies such as SPE or LLE. As a consequence, 
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Figure 1.7 Schematic diagram of selected liquid phase microextraction (LPME) approaches. A. 
Large container vessel (e.g. single droplet microextraction, SDME with DESI105,106) versus B. 
Small container vessel (e.g. slug flow microextraction on a nanoESI emitter82). 
 
 
technologies have been introduced as the most logical and suitable technology to overcome the 
encountered issues.104  
Microextraction can be performed with the use of either a liquid (liquid phase microextraction, 
LPME) or a solid sorbent (solid phase microextraction, SPME). As solid phase microextraction 
technologies will be covered in the following sections, a brief discussion of LPME technologies 
directly coupled to MS is presented in this section. Essentially, the workflow in LPME-MS 
consists of 2 simple steps. First, a small amount (≤ 20µL) of liquid extractive phase is exposed to 
the matrix under study to enrich analytes of interest; classically, a liquid organic phase of sufficient 
elutrophic strength.106,107 In the extraction process, analyte partitioning between the biofluid and 
the solvent droplet occurs according to the affinity of the analyte and the set extraction conditions 
(e.g. temperature, convection, time). After extraction, the droplet can be either transferred to a 
device for ESI or APCI (e.g. gas pressure assisted microliquid-liquid extraction via nanoESI108 or 
micro-liquid extraction followed by venture-ESI14,109), or placed in-between an ambient ionization 
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source and the entrance of the mass spectrometer (e.g. microextract is placed and dried on a surface 
for DESI analysis,106 or the extractive droplet is exposed to the jet of DESI micro-droplets105). As 
shown in Figure 1.7, in both scenarios, the extraction process occurs on a large sample container. 
A second option consists of enclosing the liquid extraction phase in a small chamber such as a 
microfluidic device or a nanoESI emitter, where extraction is carried out by fast interactions 
between the liquid phase and the biofluid. For instance, Kirby et al. demonstrated this principle by 
performing analysis of drugs of abuse on dried urine via a microfluidic device directly coupled to 
a portable MS.110 Likewise, Ren et al. have described diverse technologies which involve liquid 
micro-extraction inside a nanoESI emitter.82,89,111 For example, this group of authors reported on 
the quantitative determination of drugs of abuse through extraction of target compounds from a 
piece of paper containing a small dried blood spot,111 or through extraction from diluted blood via 
slug-flow mechanism (i.e. slug-flow microextraction, SFME).82 Certainly, scientific literature 
published to date supports LPME as a great alternative to enrich analytes of interest present in 
biofluids prior to direct-coupling to mass spectrometry. Definitively, a great many novel 
applications can be developed with respect to LPME-MS, and one could foresee a great future in 
workflows that involve novel advances on unmanned systems20 and acoustically levitated micro 
droplets.112 However, liquid extraction methods lack the selectivity provided by tailored coating 
chemistries,113 and are unable to match the stiffness and endurance afforded by SPME-based 
devices; qualities that are highly desired in applications that involve extractions from very complex 






1.5. Solid Phase Microextraction in bioanalytical chemistry 
SPME is a solventless sampling/sample preparation technology conceived in the late eighties by 
Professor Janusz Pawliszyn and collaborators at University of Waterloo.115 While this technology 
was originally envisaged for equilibrium-based extractions of volatile and semi-volatile 
compounds present on the headspace of liquid/solid samples enclosed in a vessel,115–117 over the 
last two decades, SPME has undergone continuous reinventions that have expanded its 
applicability to the direct extraction of target analytes from complex liquid and solid matrices such 
as biofluids and tissue.2,118–121 Furthermore, in recent times, and thanks to dramatic improvements 
in both coating technologies122–125 and mass spectrometer sensitivity,80,81 the use of pre-
equilibrium SPME has gained more relevance, allowing for faster extractions with acceptable 
limits of detection.126–128  
Figure 1.8 Schematic representation of SPME device and different extraction options, such as 









Figure 1.9 Schematic diagram presenting the different geometrical shapes the SPME concept 
embraces. Coating is indicated in red, while solid support is indicated in medium blue.  
 
Conceptually, an SPME device consists of a solid support where a solid or liquid polymer phase 
is coated on a portion of the support (see Figure 1.8). The solid substrate can be made of any 
material (e.g. plastic123, metal129, wood130); however, matrix-compatible supports are generally 
preferred in most applications, as their employment aids in the prevention of potential biofouling 
of matrix components on the surface of the coating.123 Thus, the SPME concept comprises a wide 
group of microextraction technologies with different geometrical configurations113 that efficiently 
integrate sampling and sample clean-up, while also allowing for enrichment of the molar fraction 
of a given analyte in a single step (see Figure 1.9).  
The analytical workflow of SPME typically consists of 3 to 5 steps. First, following their 
manufacture, coatings are cleaned either thermally122 or with solvents,131 depending on the 
manufacturing process used.124 The cleaning of coatings aids in the removal of any byproducts of 
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the manufacturing procedure (e.g. particle polymerization process) that may cause instrument 
contamination or potential interferences during analysis. While the cleaning process is typically 
performed by the manufacturer, given that commercial SPME devices are generally stored in a 
box or a container prior to their use, most coatings need to be conditioned in order to remove 
substances that may have been extracted via passive sampling during their storage.132 Similar to 
the cleaning step, conditioning is performed according to the intrinsic characteristics of the 
coating.2,115,118,133 After their conditioning, coatings can then be exposed to the sample of interest 
for a given period of time to collect analytes from the sample matrix. Finally, analytes are desorbed 
either thermally or in a solvent mixture, this selection being dependent on the coating 
characteristics and the inherent physicochemical properties of the compound(s) under 
investigation.  
 Several calibration approaches have been developed for SPME, while equilibrium extraction is 
historically the most used method. Essentially, after a certain period of time has elapsed during the 
extraction process, concentration equilibrium is established between the sample matrix and the 
extraction phase; consequently, exposing the fiber for a longer period will not result in the 
accumulation of more analytes. Under equilibrium conditions and, provided the analyte has not 
been depleted from the sample or that the coating has not become saturated, the number of moles 
of analyte extracted (n) by the coating at equilibrium can be expressed by Equation 1.1.  
Equation 1.1 
 
where Ve is the fiber-coating volume, Vs the sample volume, Co the initial concentration of the 











Figure 1.10 Typical extraction time profile for SPME  
 
Moreover, Equation 1.1 indicates that the amount of analyte extracted in the coating (n) is linearly 
proportional to the analyte concentration in the sample (Co), which is the analytical basis for 
quantification using SPME. Additionally, when the sample volume is very large, Vs >> KfsVe, 
Equation 1.1 can be simplified to: 
Equation 1.2 
While straightforward in theory, equilibrium extraction may be rendered impractical by the 
potentially very long time required for equilibration. A more expedient alternative is the 
measurement under pre-equilibrium conditions131, which can provide total concentration of a given 
compound in a biofluid via matrix-matched calibration approach. Indeed, equilibrium extraction 
time is influenced by the hydrophobicity of a compound,134 where less polar compounds exhibit 
the largest affinities for SPME coatings, and accordingly the longest equilibration times.135 Such 
long extraction times have unsurprisingly given SPME a reputation as a tedious technology, unable 




generally follows the profile shown in Figure 1.10. Thus, when sampling is longer than t95, 
extraction nearly reaches equilibrium. If the sampling time is less than t95, the extraction is a kinetic 
process; as such, under t50, the mass uptake rate is considered to be linear. Undeniably, linear mass 
uptakes are more beneficial in applications that require fast analysis, and a feature to be targeted 
when developing novel SPME methods for rapid diagnostics. Certainly, the amounts extracted 
under the linear regime are less than those otherwise obtained through equilibrium extraction (see 
Figure 1.10); nonetheless, improvements in sensitivity currently offered by state-of-the-art mass 
spectrometry have certainly facilitated pre-equilibrium applications.136 As discussed in the 
following section, further time reductions in the extraction step have been made possible thanks to 
recent advances in SPME-MS technologies.80  
As briefly mentioned before, the extraction process in SPME can take place either by direct 
immersion (DI) or by headspace (HS) sampling (see Figure 1.8). Although HS-SPME is perhaps 
the most well-known approach of SPME, it is certainly not the best configuration of SPME for 
determination of drugs and metabolites in biofluids (i.e. since many analytes of interest will have 
low volatility and thus not be efficiently transported into the headspace.), or for applications that 
require balanced coverage.137 Essentially, HS-SPME is better suited for extraction of compounds 
with low hydrophilicity and large Henry constants. Such compounds prefer to partition to the 
headspace due to their lower solubility in water-based matrices, and have shown great affinity 
towards commonly used coatings such as PDMS or its combinations with solid adsorbents (e.g. 
PDMS-carboxen, PDMS-Car; or PDMS-divinyl benzene, PDMS-DVB). In addition, as recently 
revised by Souza-Silva et al.138 and Gionfriddo et al.,139 most of the coatings commercially 
available for HS analysis are not matrix compatible140–142 due to their propensity to incur 
biofouling when directly immersed in complex matrices such as biofluids (i.e. highly porous, non-
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smooth surface). Thanks to recent advances in coating technology, and more precisely matrix-
compatible coatings, DI-SPME has gained more relevance in recent years. Recent developments 
in matrix-compatible coatings include the PDMS over-coated fibers,143,144 the polyacrylonitrile 
(PAN) based coatings,1,123,125 and the Polytetrafluoroethylene (PTFE) based coatings,122 among 
others. PAN-based coatings were introduced approximately 10 years ago as biocompatible 
coatings, meaning the coatings do not induce or cause toxic reactions to the system under study. 
Consequently, fouling or adsorption of proteins are not incurred by the coating when the extraction 
phase surface is exposed to a complex matrix such a tissue or plasma.113,124 As an additional 
benefit, the extraction efficiency of SPME for semi-volatile and polar compounds improves 
significantly when DI-SPME is performed, as the diffusion coefficients of the analytes in the 
biofluid, that define the mass transfer properties of the extraction mode, are similar for all small 
molecules present in the system.122,137  
Among the diverse SPME geometries developed to date, fiber (i.e. tiny coated wire, typically with 
a diameter of less than 500µm),115 in-tube (i.e. coating inside a capillary),114,117 membrane (e.g. 
polydimethylsiloxane – PDMS –embedded membrane),145,146 and blade (e.g. rectangular piece of 
coated metal or plastic)123,147,148 configurations are the most well-known and used worldwide. 
Certainly, selection of SPME geometry is dependent on the application of interest. For instance, 
small devices (i.e. tips or fibers) are a better fit for analysis of samples that must be obtained with 
minimal invasiveness, such as tissue.149–153 On the other hand, in analysis of relative large sample 
volumes (e.g. ≥ 100 µL) that seek fast enrichment, devices with larger surface areas (e.g. blades) 
are preferred, as they provide much faster extraction rates due to the larger surface area to 
extraction-phase volume ratio of these geometries (see Equation 1.3).154  
  Equation 1.3  
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In the equation, n is the amount extracted at a given time t, Ds is the diffusion coefficient of the 
analyte, C0 is the initial total concentration on the sample, and A is the coated surface area of the 
device.  
In addition, SPME devices that provide larger extraction volumes are useful in certain applications 
in that they allow for larger amounts of analyte extracted, which leads to better sensitivity (see 
Equation 1.1). Yet, as presented in the following chapters, selection of SPME geometry, 
particularly with respect to direct-to-MS analysis, will also be dependent on factors such as the 
geometry of the interface (e.g. injection port or ambient interface), the transition of the analytes 
from the interface to the MS system (e.g. transmission device or continuous liquid fluidics), and 
the analyte desorption operation principle (i.e. liquid, laser, or thermal desorption).  
As an additional feature, SPME provides balanced coverage of analytes, that is extracts/enriches 
compounds from a broad range of polarities.131 Fundamentally, SPME extracts via free-
concentration, and most SPME coatings have a larger affinity for compounds with medium 
hydrophobicity and above (i.e. LogP ≥ 2)1,2. However, in complex matrices, non-polar compounds 
are likely to be heavily bound to proteins or partition into cells.123,155 Therefore, since the free 
amount of hydrophobic compounds available for extraction is generally lower in complex 
matrices, the coating is unlikely to become saturated by these compounds. On the other hand, polar 
compounds (i.e. LogP ≤ 2) are neither bound to proteins, nor partitioned into cells, and thus, in 
comparison to hydrophobic compounds, are commonly present in high concentrations in complex 
matrices. Yet, since SPME coatings (Kfs) have a lower affinity for polar compounds, the coating 
does not suffer saturation from these compounds either. SPME devices offer an additional 












Figure 1.11 Schematic representation of. A. Extraction from complex matrix. B. Balanced 
coverage concept. C. Extraction of polar compounds, and D. Extraction of hydrophobic 
compounds.  
 
configurations: in comparison to the ‘gold standard’ technology SPE, SPME does not suffer from 
cartridge clogging or compound breakthrough. Since the geometry of the SPME device is open, 
and the principle of extraction is based on equilibration principles,156 SPME devices are not 
susceptible to either of these commonly observed limitations of SPE. Furthermore, the automation 
of an analytical workflow has several advantages, such as faster sample throughput, greater 
reproducibility, and reduced analyst time for both method development and routine analysis.157,158 
Presently, in cases where multiple analyses have to be carried out within a short period of time, 
traditional sample preparation methods such SPE become the bottleneck in the throughput of the 
analysis, owing to the multiple steps that need to be conducted (e.g. conditioning of the cartridge, 
enriching step, washing step, elution step, evaporation of the extract and reconstitution of the 
extract).159 Following the initial disclosure of SPME, the fiber arrangement was shown to be 
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suitable for automation with GC autosamplers due to its similarity to traditional GC syringes used 
for liquid injection.133,160,161 While this original automation was meant for single devices,161 in the 
last ten years, concentrated efforts have been focused on the development of devices that allow for 
automated parallel processing (e.g. 96-well configuration).123,131,162 The development of such 
approaches has allowed for dramatic reductions in total analysis time. Hence, the automation of 
SPME for 96 samples (or more) eliminates time-related drawbacks of traditional techniques, 
rendering SPME an efficient approach towards integration of sample preparation with GC or LC. 
In addition, methods that adapt automated SPME afford several advantages over manual SPME 
methodology. For instance, superior extraction time reproducibility allows for the development of 
multiple, faster non-equilibrium extractions, which are otherwise unattainable through non-
automated methods.133 
To date, the majority of methods involving couplings between SPME and mass spectrometry 
follow the same workflow as that used for TSP approaches. Hence, after extraction, analytes are 
released from the SPME coating either via either thermal or solvent desorption. In the case of LC 
analysis, the desorption step is performed on a vessel (e.g. vial or well plate),131,148,162 while in GC, 
the desorption process classically occurs in a desorption chamber.146,163,164 Subsequently, the 
extracted analytes are transported from the injection port (e.g. six-port valve in the case of an LC-
experiment117) and into the chromatographic column for analyte purification and subsequent 
ionization (see Figure 1.1). Certainly, when aiming for faster analysis times, more efficient ways 
of coupling SPME devices to MS must be further investigated by the scientific community. The 
following section discusses the most relevant advances made towards the interface of SPME and 




1.6. Brief overview on direct coupling of SPME to mass spectrometry (SPME-MS) 
The coupling of SPME directly to MS eliminates the separation step, which greatly reduces the 
time needed for analysis. In addition, since the dilution step (inherent of most SPME-LC 
applications) is removed from the workflow, higher sensitivity and faster analyses can be 
attained.136,151 Furthermore, owing to its intrinsic features (i.e. sample extraction, clean-up, 
enrichment, and matrix normalization), low matrix-suppression effects can be attained via SPME, 
an advantage that is highly beneficial for detection of trace compounds in complex matrices. The 
direct coupling of MS to SPME-based devices dates back more than 20 years, and is under 
continuous exploration. While these advances have been interrupted by pauses, great 
breakthroughs have been made in the last 5 years, driven in part by the advancing state of the art 
in mass spectrometry (see Figure 1.12).80,81 SPME-MS technologies can be categorized according 
to the ionization strategy employed, with the following as the most common approaches: 
inductively-coupled plasma (ICP)-MS;165,166 electron impact (EI)-MS;164,167–170 and atmospheric 
pressure ionization (API, via either ESI or APCI mechanisms)-MS.171,172 In addition, the direct 
coupling of SPME to MS can also be categorized by the desorption mechanism employed, with 
solvent,130,173 thermal,164,174 or laser 175–177 desorption being the three most commonly used. 
Finally, as shown in Figure 1.5, SPME-MS technologies can also be classified according to their 
degree of ambience: SAMS (e.g. open port probe178), direct-analysis (e.g. SPME as substrate-
ESI130,136) or AMS (e.g. via desorption electrospray ionization, DESI179). Given the multiple ways 
of categorizing these couplings, and aiming to have better flow with previous sections, the latter 





Figure 1.12 Timeline event of relevant SPME-Mass Spectrometry developments80 
 
1.6.1 SPME-SAMS technologies 
The first SPME-SAMS technology based on liquid desorption was described by Möder et al. in 
1997180 (see Figure 1.12). In this approach, an SPME fiber, used for extraction of acyl carnitines 
from urine, was statically desorbed on a sealed chamber. Subsequently, by switching a six-port-
valve, the mechanically pumped solvent carried the desorbed analytes towards the ionization 
source.117 Since this first development, in the last twenty years, several publications have followed 
the SAMS-liquid desorption concept, using either ESI or APCI commercial sources.114,172,181,182 
Recently, the use of an open chamber that allows for effortless desorption of SPME devices and 
rapid transfer to the ionization source was reported in the literature. This interface, known as Open 
Port Probe (OPP), was developed by Van Berkel and collaborators36,45 at Oak Ridge National 
Laboratory (ORNL). The first direct coupling of MS to SPME devices that uses this system is fully 























Figure 1.13 Schematic diagrams of some of the most relevant SPME-MS technologies suitable 
for analysis of biofluids. A. SAMS technologies via liquid desorption; B. SAMS technologies via 





However, it is worth noting that, chronologically speaking, the first coupling to MS in a SAMS 
configuration was performed via thermal desorption (circa 1996,183,184 Figure 1.12). In this 
approach, SPME devices can be desorbed on the injection port of the GC system, where analytes 
are subsequently moved towards the MS system with the use of carrier gas. Instead of the classical 
chromatographic process, where separation of analytes occurs on a long coated column, a short 
and non-coated capillary is used to link the injection port with the MS analyzer.30,32,163,167,168,185,186 
Although this configuration has been mainly used for rapid qualitative analysis (e.g. profiling), 
Boyacı et al. recently reported its applicability towards quantitative analysis.164 A second 
arrangement of SPME-SAMS via thermal desorption consists of circumventing the transfer 
capillary by performing the desorption of the SPME device directly at the ionization chamber of 
the mass spectrometer.87,169,170 Although this approach allows for higher sensitivity, its 
configuration cannot be easily set up without affecting the instrument vacuum. Further, the 
technique cannot be easily automated, nor does it allow for easily reproducible results. The last 
SPME-SAMS strategy via thermal desorption does not require gas chromatography hardware. In 
addition, the ionization step, unlike the two previous strategies, occurs under ambient conditions 
(i.e. outside the instrument). As shown in Figure 1.13, thermal desorption takes place on a custom-
made chamber, where analytes are driven towards the ionization chamber prior to MS analysis. 
Analyte ionization can be performed either by ICP,187 Dielectric Barrier Desorption Ionization 
(DBDI),174 or Low Temperature Plasma (LTP),188,189 among others.80  
Similar to SAMS via liquid desorption, one of the greatest advantages of the thermal desorption 
approach lies on its capability to introduce into the MS all analytes extracted onto the SPME device 
in a single band or peak. This feature affords better signal-to-noise ratios in comparison to 
substrate-spray methods and, as a result, outstanding sensitivity.174 Yet, three factors should be 
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kept in mind when selecting SAMS technologies for direct coupling. First of all, depending on the 
materials chosen for the construction of the device, including materials for the desorption chamber, 
transfer tubes, and capillaries that move the analyte towards the MS system, it is possible that 
analyte carry-over may occur as a result of non-specific attachments. Therefore, if analytes are not 
efficiently desorbed/transferred, the analyst should wait until the entire system is purged, either by 
the desorption solvent or the carrier gas, before a second “injection” is made.174 Undoubtedly, such 
an issue might lead to a dramatic reduction in the analytical throughput. This problem can be 
overcome by the use of silanized materials, which are also used in GC and LC to similar effect. 
The second factor, on the other hand, relies on the inherent ionization weaknesses of each 
technology.190 Given that some technologies might be intrinsically unable to ionize certain 
compounds, this factor must be kept in mind with respect to technique selection. In this line, a 
third factor to consider involves the versatility (i.e. capability to rapidly interchange between ESI 
or APCI modes), and the simplicity of set-up (i.e. rapid installation and operation with minimal 
modifications to the system) of a given technology. Based on the last factor, OPP is certainly one 
of the SPME-SAMS technologies with the greatest potential to be further developed in the 
upcoming years.  
 
1.6.2 SPME-AMS technologies 
As mentioned above, most AMS approaches seek to record mass spectra with minimal or no 
sample preparation/analyte pre-concentration.191 Due to the absence of sample pre-treatment, the 
linear dynamic range (e.g. diminished sensitivity by ion suppression81) as well as the selectivity of 
such methods are likely to be sacrificed. Therefore, modifications in the experimental workflow, 
such as addition of an efficient enrichment step,78,192,193 are often needed in order to obtain better 
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analyte quantitation. Given the multiple advantages already mentioned and the easiness of its 
coupling, SPME has aided well-known AMS technologies such as DART and DESI in reaching 
required limits of quantitation.104,144,194–197 
Undeniably, DESI is one the most successful ambient ionization techniques developed to date.52,198 
DESI’s advantage lies in its capability to scrutinize analytes on surfaces, with its high-throughput 
imaging-MS capabilities being one of its major attractions.66,199–201 As suggested by its name, in 
DESI, analytes present on a given surface are initially desorbed/swept, and subsequently ionized.52 
DESI is equally suitable to the desorption/ionization of analytes previously concentrated on SPME 
devices. Accordingly, the first SPME-DESI applications were disclosed only a few years following 
the initial publications on DESI-MS by Cooks and co-workers.76,202,203 Expectedly, authors have 
reported that SPME fibers greatly improved the quantitation capabilities of DESI towards the 
analysis of anabolic steroids spiked on raw urine203 or drugs of abuse (DoA) on real urine 
samples.179 In addition, data showed good agreement between the results obtained by DESI and 
those reported using traditional confirmation methods (i.e. LC-MS/MS and GC/MS protocols).179 
Recently, Strittmatter et al. reported for the first time the direct coupling of blade geometry to 
DESI-MS.104 In this study, devices coated with C18 and a strong cation exchanger were used for 
the targeted and untargeted determination of pharmaceuticals and personal-care product 
components in wastewater samples. One of the greatest advantages of the blade-DESI-MS 
coupling entails the possibility of performing both steps, extraction/pre-concentration and 
desorption/ionization, in an automated fashion.104,118 In addition, one could foresee in the near 
future a combination of SPME fibers and DESI-MS/MS for the determination of the spatial 
distribution of targeted analytes in living samples such as tissues.152,200 While the development of 
new SPME-DESI applications has been pursued vigorously, fundamental studies are still needed 
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in order to fully understand the desorption/ionization process from particle coatings used on SPME 
devices, as well as to determine ideal experimental conditions such as desorption solvent flow,200 
sprayer position,204 and coating thickness.  
At the same time that DESI was developed, Cody and collaborators originated DART, an 
atmospheric pressure chemical ionization (APCI)-based ambient ionization technique.53 In 
applications that couple SPME to DART, analytes are first thermally desorbed from the coating 
surface by a heated gas, and subsequently ionized by excited-state species created in the 
atmosphere proximal to the coating surface.192,205 Initial experiments to couple SPME fibers to 
DART-TOF-MS by Cajka et al. have shown SPME to be a promising tool for determination of 
chemical profiles that allow for rapid authentication of food commodities.206 Due to the large flow 
of heated gas (~ 3L/min), a necessary precaution is that the SPME fiber needs to be properly 
secured when passed in front of the DART source so as to avoid severe fiber swinging and, 
consequently, irreproducible desorption/ionization of extracted  analytes.207,208 Recently, Wang et 
al. reported the coupling of IT-SPME with DART for the determination of trace pesticides in liquid 
food matrices.81 In spite of the great sensitivity attained by this method, the proposed system was 
very intricate, and required solvent assistance to move analytes from the coating for ionization by 
the DART stream. Likewise, due to the inherent design of the IT-SPME device used, the sample 
required centrifugation and filtration to prevent clogging of the extraction material with fibers or 
particulates from the matrix. Concomitantly, Pawliszyn’s group reported the first combination of 
thin-film SPME with DART-MS/MS for the determination of cocaine and diazepam in urine and 
whole blood, respectively.144,194 Essentially, the device consisted of a stainless steel mesh coated 
with a matrix-compatible coating. The idea behind this work was to emulate the transmission mode 
(TM) configuration reported by the Fernandez group.77,209 Yet, while the device had the 
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extraction/enrichment features of SPME, the methodology used during the coating process (i.e. 
brush painting) covered not only the strands, but also the mesh openings.194 Aiming to improve 
ion transmission, tiny, randomly selected holes were placed on the coated mesh to allow the gas 
stream to flow through it. Unfortunately, results were not as good as expected. As a result, Gómez-
Ríos and Pawliszyn redesigned the SPME-TM.192 One distinctive characteristic of the new device 
is that the mesh is exclusively coated on the strands with a thin-layer of particles (Ø ≤ 20 µm).195,196 
Therefore, the stream of gas with metastable helium atoms easily flows through the mesh, and 
efficient desorption and ion transmission can be attained.74,205 In this context, the use of a thin 
coating allowed for faster extraction/enrichment, rapid desorption, and minimal carry-over to be 
achieved. Chapter 2 of this thesis presents the latest developments on SPME-TM configurations, 
as well as its application to the determination of target compounds in complex matrices. 
  
1.6.3 Direct SPME to MS 
Unlike other approaches, direct SPME-to-MS technologies do not require intricate equipment to 
interface to the MS system. These technologies can be separated into two groups: those using 
nanoelectrospray (nanoESI) emitters,210 and those operating as substrate spray devices.46 SPME-
nanoESI-MS, first explored by Walles et al.,210 has been assessed for its qualitative and 
quantitation capabilities in several publications to date.151,173,211–213. The main goal behind the 
interfacing of SPME with MS via nanoESI is to desorb devices on a chamber with very small 
volumes (Vdes ≤ 10 µL) so to have the best enrichment factor (i.e. highest volume of 
extraction/volume of desorption) and fully utilize the molar enrichment factor offered by 
SPME.151,173 Furthermore, nanoESI not only yields higher ionization efficiency when compared to 
ESI, it also allows for longer electrospray events that permit a far greater number of MS 
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experiments. For instance, a single nanoESI emitter could be used for targeted analysis (MSn), 
high-resolution MS experiments (HRMS and HRMS/MS), as well as for its interface with other 
on-line technologies such as ion mobility (IMS).214 However, due to the inner diameter of the 
emitters (Ø ≤ 1000 µm), nanoESI technologies are suitable only for SPME devices with small 
diameters (Ø ≤ 500 µm). Recently, Pawliszyn and collaborators have explored the use of nanoESI 
as a means to improve the quantitation capabilities offered by commercial BioSPME fibers,152,215 
as well as miniature devices manufactured in-house.151 Succinctly, when employed in tandem with 
nanoESI, SPME is capable of reaching sub-part per billion LOQs, even when small sample 
volumes (≤ 20 µL) and short extraction times (≤ 2 min) are used. As a matter of fact, most of these 
developments are described in detail on Chapter 3 of this thesis.  
As shown on Figure 1.12, substrate spray technologies based on SPME devices were described 
prior to the invention of AMS (circa 1999).85 Indeed, Prof. Shiea and his group of collaborators 
were the first to report the use of this technology; by spraying directly from wetted SPME fibers, 
researchers could detected sub-ppb levels of Triton X-100 in aqueous samples. Surprisingly, after 
this breakthrough, almost 15 years passed without major advances in these technologies until 2014, 
when novel technologies such as surface coated wooden-tip ESI,130,216 coated membrane 
spray,217,218 and Coated Blade Spray (CBS)136,151,219,220 were disclosed. Essentially, this group of 
technologies integrates sample preparation and sample introduction into the MS system on a single 
device. Thus, such technologies not only simplify the analytical workflow, they also decrease the 
cost per analysis. Given the material used for its construction (i.e. stainless steel), as well as the 
geometrical characteristics of the substrate (i.e. ~ 300 µm flat sheet, sword-like shape), CBS would 
appear to be not only the best substrate spray strategy developed to date, but also a disrupting 
technology that may shift the paradigm of direct sample introduction to MS. Chapter 4 of this 
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thesis summarizes the development of CBS, as well as its application to the determination of 
exogenous substances in biofluids.  
 
1.7. Research objectives 
In critical care settings (emergency and surgery units), the ability to deliver a rapid prognostic 
metric of a given clinical condition plays a critical role in the successful and timely treatment of 
patients.221 The amount of time spent choosing and implementing a therapeutic strategy could be 
the difference between life and death. For this reason, molecular diagnostic and prognostic 
instruments, which are able to provide doctors with fast and reliable results, are highly desired in 
such facilities for the personalized diagnosis and treatment of patients. Ideally, assessments of such 
molecules (drugs, metabolites, and biomarkers) before, during, and after surgery and/or 
emergency, should be performed in real or close to real time. Nevertheless, such metrics are limited 
by a number of challenges which cannot be easily overcome by standard high-throughput assays, 
such as compound selectivity, space resolution, and analysis of unstable/short-lived metabolites. 
AMS and direct-sample-to-MS methods are advantageous for point of care (POC) and therapeutic 
drug monitoring (TDM) due to their speed, simplicity, and ability to monitor multiple analytes 
simultaneously.8 However, as discussed above, most of these techniques are chiefly limited in 
selectivity and sensitivity due to the lack of an appropriate sample preparation step. Accordingly, 
the performance of modern mass spectrometry instruments in the clinical environment can be 
enhanced with the use of fast, simple, and efficient sample preparation technologies.  
The main objective of the currently presented PhD work encompassed the development of novel 
SPME-MS methods that can be used for rapid diagnosis throughout the patient journey.222 These 
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workflows needed to be suitable for the analysis of SPME devices that undergo either sampling of 
tissue (e.g. in vivo studies) or direct immersion into biofluid samples (e.g. blood, plasma, and 
urine). As a result, the currently presented work can be divided in two lines of research: workflows 
that can be used for either biofluids or tissue analysis (i.e. those involving SPME fibers/tips), and 
methods chiefly focused on the examination of biofluids (i.e. any SPME geometry). Aiming for a 
better understanding of the analytical capabilities of each direct-to-MS technology, this research 
was also focused on assessing the diverse technologies herein described, including: SAMS, AMS, 
and direct SPME to MS. This dissertation compiles my contributions to SPME-MS during the last 
4 years, including: SPME-TM, SPME-nanoESI, SPME-OPP, and CBS. The majority of this work 
is already published in peer-review journals including Analytical Chemistry (3),173,195,219 
Angewandte Chemie (2),136,151 Analytica Chimica Acta (1)223, Chemical Communications (1),192 
Analyst (1)196 and Journal of Pharmaceutical and Biomedical Analysis (1).220 As a result, each 
chapter of this thesis is composed of at least two publications, with the breakdown of the thesis as 
follows. Chapter 2 is chiefly focused on the development of SPME-TM and its application to the 
determination of xenobiotics in biofluids via DART-MS/MS.192 Furthermore, this chapter also 
presents the implementation of this technology to other fields such as food and environmental 
analysis, as well as the coupling of these devices with portable mass spectrometers for on-site 
semi-quantitative determinations and molecular profiling.195,196 Chapter 3 describes work 
performed on commercial BioSPME fibers coupled to nanoESI-MS/MS for examination of target 
compounds on biofluids,173 and discloses the first coupling of SPME-tips to MS via nanoESI for 
the analysis of ultra-small volumes of biological samples (≤ 5 µL).151 Moreover, aiming to offer 
an interface that requires minimal modifications to the front-end of the instrument, and that is 
suitable for desorption of small SPME devices, the direct coupling to MS of BioSPME via OPP 
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178 is also presented in this chapter. Since some target compounds cannot be quantitatively 
determined at low concentration levels due to the presence of a co-extracted interference, in this 
chapter, the suitability of differential mobility spectrometry (DMS) and multistage fragmentation 
(MRM3) were also assessed as on-line MS tools to enhance the selectivity of the workflow without 
affecting the total analysis time. Finally, Chapter 4 introduces CBS and its application towards the 
rapid and high-throughput determination of diverse analytes in biofluids. In addition, Chapter 4 
discloses for the first time the use of an SPME-based technology for the TDM of compounds 
heavily bound to red-blood cells such immunosuppressive drugs. Further, this chapter also reveals 
the suitability of this technology for the quantitative analysis of target substances in biofluid 
droplets, and a novel strategy to dramatically enhance the LOQ of heavily bound compounds. In 
summary, the data herein gathered demonstrates the great potential of SPME-MS in the area of 
rapid analyte detection, particularly in fields that require robust, inexpensive, simple, sensitive, 
and rapid methodologies, such as clinical, drug screening, and forensic sciences. Confidently, in a 
foreseeable future, this work will encourage readers around the globe towards the use of SPME-







Chapter 2 Development of Solid Phase Micro Extraction Transmission Mode 
(SPME-TM) and its application towards the qualitative and quantitative 
analysis of complex matrices via Direct Analysis in Real Time-Mass 
Spectrometry (DART-MS) 
 
2.1 Preamble  
Chapter 2 consists of 3 sections that correspond to three manuscripts already published in 
Chemical Communications, Analytical Chemistry, and Analyst. Most of the data, tables, and text 
presented within this chapter have already been incorporated in the aforementioned manuscripts, 
the details of which are listed below. Section 2.2 describes the development of Solid Phase Micro 
Extraction-Transmission Mode (SPME-TM) and its direct coupling to tandem MS via DART 
towards the quantitative analysis of cocaine and diazepam in urine and plasma samples. Section 
2.3 describes the application of SPME-TM-DART-MS/MS for the quantitation of eighteen 
pesticides with different physicochemical properties in food and environmental matrices such as 
grape juice, orange juice, milk, and surface water. Finally, section 2.4 presents the direct coupling 
of SPME-TM to a portable MS system via DART. In this subdivision, the suitability of the 
proposed workflow is discussed for semi-quantitative analysis of seven pesticides in grape juice, 
and for the molecular profiling of milk samples from assorted animal and vegetal sources.  
Section 2.2 includes the following manuscript: 
1. Gómez-Ríos, G.A., Pawliszyn, J., Solid phase microextraction (SPME)-transmission mode 
(TM) pushes down detection limits in direct analysis in real time (DART), Chem. Commun., 
2014, 50, 12937-12940, DOI: 10.1039/C4CC05301J (open access) This article is licensed 
under a Creative Commons Attribution 3.0 Unported Licence. 
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Text, tables, and figures are reprinted from this publication with permission from the Royal Society 
of Chemistry (Copyright 2014 Royal Society of Chemistry). 
I participated at all stages of the manuscript preparation process: the planning of experiments, 
manufacturing of devices, method development, sample preparation and analyte extraction 
procedures, data processing, manuscript writing and submission, as well as in manuscript replies 
to reviewers.  
 
Section 2.3 includes the following manuscript: 
2. Gómez-Ríos, G.A., Gionfriddo, E., Poole, J., Pawliszyn, J., Ultrafast Screening and 
Quantitation of Pesticides in Food and Environmental Matrices by Solid-Phase 
Microextraction–Transmission Mode (SPME-TM) and Direct Analysis in Real Time (DART), 
Anal. Chem., 2017, 89 (13), 7240–7248, DOI: 10.1021/acs.analchem.7b01553 
Text, tables, and figures are reprinted from this publication with permission from the American 
Chemical Society (Copyright 2017 American Chemical Society).  
I participated at all stages of the manuscript preparation process: the planning of experiments, 
manufacturing of devices, method development, in sample preparation and analyte extraction 
procedures, data processing, manuscript writing and submission, as well as in manuscript replies 
to reviewers. The contributions of co-author Justen Poole included the manufacture of SPME-TM 
devices, execution of selected experiments, and data processing. Dr. Emanuela Gionfriddo was 
involved in the planning of experiments, writing of the manuscript, extraction execution, and data 
processing.  
I, Justen Poole, authorize German Augusto Gómez-Ríos to use this material for his thesis. 




Section 2.4 includes the following manuscript: 
3. Gómez-Ríos, G.A., Vasilejvic, T., Gionfriddo, E., Yu, M., Pawliszyn, J., Towards on-site 
analysis of complex matrices by solid-phase microextraction-transmission mode coupled to a 
portable mass spectrometer via direct analysis in real time, Analyst, 2017, 142, 2928-2935, 
DOI: 10.1039/C7AN00718C  
Text, tables, and figures are reprinted from this publication with permission from The Royal 
Society of Chemistry (Copyright 2017 The Royal Society of Chemistry). 
I participated at all stages of the manuscript preparation process: the planning of experiments, 
manufacturing of devices, method development, sample preparation and analyte extraction 
procedures, data processing, manuscript writing and submission, as well as in manuscript replies 
to reviewers. The contributions of co-author Tijana Vasilejvic included the manufacturing of 
SPME-TM devices, execution of selected experiments, and data processing. Dr. Emanuela 
Gionfriddo was involved in the planning of experiments, execution of extractions, and data 
processing. Dr. Miao Yu was involved in data processing for metabolic profiling experiments.  
I, Tijana Vasilejvic, authorize German Augusto Gómez-Ríos to use this material for his thesis. 
I, Emanuela Gionfriddo, authorize German Augusto Gómez-Ríos to use this material for his thesis. 






Section 2.2 Solid phase microextraction (SPME)-transmission mode (TM) pushes down 
detection limits in direct analysis in real time (DART) 
 
2.2.1 Introduction  
In the last decade, ambient ionization methods have changed the way samples are analysed by 
mass spectrometry (MS).57 Several techniques, such as direct analysis in real-time (DART), 
desorption electrospray ionization (DESI), and paper spray (PS) have provided the scientific 
community with key tools for screening, pass/fail analysis, fingerprinting, and native sample 
imaging applications.46,53,58,74,81,224,225Today, most ambient MS approaches seek to record mass 
spectra without the need for sample preparation.46,53,57,58 Hence, the scientific community, usually 
trained on standard sample preparation/separation methods, may have numerous inquiries 
regarding ambient MS techniques, including their performance in terms of accurate and fast 
quantitative analysis. This includes inquiries over the suitability of such methods for trace 
analysis (e.g. low pg mL-1) in complex matrices, circumventing all sample preparation steps. With 
the use of such methods, analyses cannot always be performed in exceptionally short periods of 
time (i.e. ≤ 1 minute).49,225,226 Generally, given that there is no sample pre-treatment, both the 
analysis time (i.e. time required to dry the sample onto the paper substrate)49 and the linear 
dynamic range (i.e. diminished sensitivity by ion suppression) are likely to be sacrificed.77,227 As 
recently reviewed by Monge et al. and Venter et al.,3-4 improvements in the experimental 
workflow are still needed in order to obtain better in situ analyte quantitation. Therefore, rather 
than subscribing to a no sample treatment technique, the use of minimal sample preparation could 
result in lower detection limits and more efficient analysis. To address the shortfalls described 
above, a solid phase microextraction (SPME)115,124,228 device that can be coupled as a 
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transmission mode (TM)209,229,230 substrate to DART was developed. Succinctly, SPME-TM has 
been devised to act as an effective integration between sample preparation and ambient 
ionization.81 Essentially, the device consists of a stainless steel mesh (74 x 74 in-1 wires, wire 
diameter 0.004 in) precisely coated on the strands with a biocompatible polymer (C18-PAN).133 
As an SPME approach, the coated mesh (Ø ≤ 20μm, Figure 2.1) concurrently isolates and 
enriches the analytes of interest present in the sample matrix.228 Additionally, given that 
undesirable interferences that might provide ionization suppression/enhancement are excluded 
from the sample during extraction (i.e. sample clean-up), detection limits are significantly 
enhanced.133,144As a TM substrate,77 the coated mesh is positioned between the DART source and 
the mass spectrometer inlet (with all three coaxial to one another, 0º angle); the stream of gas 
with metastable helium atoms flows through the mesh performing simultaneous 
desorption/ionization of the compounds sorbed on the surface of the coating particles.74 
Subsequently, ions of the extracted/pre-concentrated analytes are transported into the 









Figure 2.1 SPME-TM coating characteristics: A. Microscope image of a bare SS mesh; B. 
Microscope image of a mesh coated with C18 particles; C. SEM image of the same mesh; D. SEM 
















Figure 2.2 Experimental set up for SPME-TM extraction from complex matrices and 
desorption/ionization using DART-MS/MS. 
 
 
Figure 2.3 Schematic of UW-12 SPME-TM holder for DART. The holder was developed at the 
machine shop of the University of Waterloo. It can be used to perform concomitant extractions on 
a 96 well-Concept autosampler (PAS technologies)131, as well as automated and stable 
desorption/ionizations. The system is compatible with the automated rail commercialized by 
IonSense. Up to 12 SPME-TM devices can be easily installed/removed from the holder, and spatial 
position can be accurately adjusted on the Z and Y axis.  
 
 
As illustrated on Figure 2.2, the analytical process by SPME-TM-DART-MS/MS consists of 
three simple steps. First, a pre-conditioned coated mesh is immersed in a vial containing the 
sample matrix (300-1500 µL) and fast enrichment is performed by agitating the sample at a high 
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speed (e.g. vortex agitator; t ≤ 1 min). Afterwards, the mesh is rapidly rinsed in a vial containing 
water (t ≤ 10s) to remove potential artefacts (contaminants/particulates) adhered to the coating 
surface. Lastly, the mesh is installed on a mesh-holder that allows for easy and fast replacement 
of up to twelve SPME-TM devices, and is adapted in an automatic linear rail that moves the mesh 
to the front of the DART source (Figure 2.3). 
To date, different geometries of SPME (i.e. fibre, in-tube, and thin-film) have been coupled to 
DART.144,194,197,206 However, most of them have evident drawbacks (Figure 2.4). For example, as 
described by Cajka et al.,206 the traditional SPME fibre requires cautious adjustment in front of the 
source to avoid severe fibre swinging and, consequently, irreproducible desorption/ionization of 
the analytes extracted. Although the early thin-film configuration reported by Mirnaghi et al. and 
Rodriguez-Lafuente et al. provided most SPME benefits,144,194 it was not an ideal TM substrate, 
since the coating, applied using brush painting144, covered not only the strands but also the mesh 
openings. Although tiny random holes were placed on the coated mesh to allow the gas stream to 
flow through it, ion transmission was unfavourably affected (Figure 2.4).194 Thus, the potential of 
the combination SPME-TM was not fully realized. Recently, Wang et al. disclosed the first on-
line coupling of the in-tube (IT) configuration to DART.197 In this work, the authors demonstrated 
that IT-SPME is a sensitive method for the determination of trace pesticides in juice/water (Limit 
of quantitation (LOQ) ~ 0.2 ng mL-1). However, the operation of the system is cumbersome and 
requires extra instrumentation (i.e. syringe pump to control solvent desorption flow). In addition, 
prior to the IT-SPME sampling, the sample requires centrifugation and filtration; otherwise, the 
extraction material might get clogged with particulates, fibres, or proteins from the matrix.197 In 
contrast to the applications listed above, the present contribution describes multiple SPME-TM 












Figure 2.4 A. In-Tube Solid-Phase Microextraction with Direct Analysis in Real Time Mass 
Spectrometry; image was adapted from the original source published by Wang and collaborators 
197. B. Thin-film solid-phase microextraction and direct analysis in real time; image was adapted 
from the original source published by Rodriguez-Lafuente and collaborators. 144,194 
 
between the DART source and the mass spectrometry inlet (Figure 2.3).  In addition, given that 
the mesh is exclusively coated on the strands, efficient desorption/ionization and ion transmission 
is obtained. Finally, unlike IT-SPME, SPME-TM requires neither additional apparatus nor sample 
pre-treatment. Although the method herein described is not the first coupling of SPME to DART-
MS, it is undeniably the most comprehensive and simple approach proposed to date.81 
 
2.2.2 Experimental Section 
Biological samples 
A phosphate-buffered saline solution (PBS) (pH 7.4) was prepared by adding 8.0 g of sodium 
chloride, 0.2 g of potassium chloride, 0.2 g of potassium phosphate and 1.44 g of sodium phosphate 
to 1 L of nanopure water. Pooled human plasma and whole blood from healthy donors in potassium 
ethylenediaminetetraacetic acid (EDTA) were purchased from Lampire Biological Laboratories 
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(Pipersville, PA, USA). Urine samples were collected from one healthy volunteer. Collection of 
urine from healthy volunteer for this particular study was under the approval of the Office of 
Research Ethical Board of University of Waterloo. 
 
Mass Spectrometry 
Experiments were performed with the use of a triple quadrupole mass spectrometer TSQ Vantage 
(Thermo Scientific, San Jose, USA). A DART-Standardized Voltage and Pressure (DART-SVP) 
model ion source (IonSense, Saugus, MA USA) was coupled to the MS system via a Vapur® 
interface (IonSense, Inc.). The DART-SVP was fitted with a single dimensional motorized linear 
rail controlled through the DART-SVP web-based software so as to reproducibly and 
consecutively automatically position the SPME-TM devices in front of the DART source (speed 
of 0.2 mm s-1 was used). The DART source was operated using the following conditions: positive 
ion mode; high voltage (HV) electrode, −3000 V; discharge electrode, +350 V; grid voltage, +350 
V. The gas heater was optimized at 350 °C, which yielded the optimum intensities for the selected 
analytes. 
 
Materials and supplies 
Cocaine and diazepam were selected as model analytes to evaluate SPME-TM. Deuterated 
analogues of each analyte were used for correction of intra- and inter-experiment variability. 
Further details about compounds properties and SRM transitions are provided on Table 2.1. LC-
MS grade solvents (acetonitrile, methanol, and water) used in all the experiments were purchased 
from Fischer Scientific. Calibration curves of each analyte were prepared on each matrix between 
0.01 and 100 ng mL-1. 
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Table 2.1 SRM parameters used for monitoring diverse controlled substances131 in positive mode with C18-PAN SPME-TM devices  









1 Amphetamine 1.76 136.099 91.114 17 36 + 112 
2 Methamphetamine 2.07 150.112 91.120 19 45 + 20 
3 Nikethamide 0.33 179.100 108.102 18 76 + 17 
4 Salbutamol 0.64 240.143 148.103 18 59 + 1474 
5 Propranolol 3.48 260.123 116.138 17 89 + 31 
6 Metoprolol 1.60 268.140 116.146 18 94 + 108 
7 Trenbolone  2.27 271.133 165.106 56 97 + 31 
8 Clenbuterol 2.61 277.068 203.049 15 70 + 13 
9 Diazepam 2.91 285.050 193.113 32 102 + 19 
10 Testosterone 3.32 289.157 97.123 21 91 + 10 
11 Exemestane 3.70 297.173 121.118 19 72 + 17 
12 Codeine 1.20 300.105 152.092 64 104 + 46 
13 Cocaine 2.30 304.142 182.173 18 87 + 2 
14 Bisoprolol  2.14 326.160 116.135 17 102 + 45 
15 6-acetylmorphine 0.42 328.126 165.092 37 122 + 21 
16 Stanozolol 5.53 329.229 81.108 44 130 + 22 
17 Strychnine 1.93 335.155 184.129 36 136 + 33 
18 6-acetylcodeine 2.08 342.124 165.092 45 165 + 7 
19 Formoterol 2.20 345.133 121.090 32 85 + 831 
20 Heroin 1.52 370.133 165.097 48 119 + 13 
21 Toremifene 6.80 406.210 72.167 24 108 + 42 
22 GW501516 6.29 454.091 257.068 29 108 + 352 
 




The SPME-TM device was prepared as follows: a stainless steel mesh (74×74 wires/in, wire 
diameter 0.004 in) with a length of 30 mm and width of 4 mm was etched for 5 min in concentrated 
hydrochloric acid (37% vol/vol), washed with water, and cleaned by sonication in methanol (see 
Figure 2.1). The coating was applied on an etched mesh by dipping the mesh into a vessel 
containing a suspension of extraction particles in a biocompatible coating solution (i.e. 0.18 wt/wt 
PAN/C18 particles ratio and 1% wt/wt PAN/DMF ratio). Essentially, 10 mm of the mesh were 
immersed in this solution for 15 seconds and then removed at a speed of about 0.5 mm per second. 
Then, a flow of nitrogen of 1.5 L/min was used to remove the excess of coating slurry accumulated 
on the openings of the mesh. After applying one layer of coating, the mesh was passed through a 
heater at an elevated temperature (i.e. 1 min at 125 °C). The steps noted above were repeated five 
or less times until a thickness ≤ 20 µm was attained (see Figure 2.1). Finally, the non-coated area 
of the mesh was arc welded to a support handle made of a stainless steel sheet that is 42×4 mm 
(L×W). In order to provide a strong attachment between the mesh and the solid substrate, the mesh 
was welded on 6 points (as illustrated in Figure 2.5).  
 
 




2.2.3 Results and discussion 
In the past, it has been incorrectly assumed by scientists not familiar with SPME that 
extraction/enrichment cannot be performed in short periods of time53,57,58, and that extractions 
exclusively performed at equilibirum can achieve low LOD/LOQ.115,231 However, contrary to 
general assumptions, direct coupling of SPME to mass spectrometry easily outperforms traditional 
detection limits with remarkably brief extraction times due to several reasons. First, the dilution 
factor inherent in most SPME-LC methods is removed from the analytical procedure.25 Second, a 
large contact surface area between the extraction phase and matrix facilitates high mass transfer 
rates, while thin coatings ensure rapid equilibration times and efficient desorption to the mass 
spectrometer. Hence, the LOD is mainly constrained by the detection capabilities of the MS system 
rather than by the built-in features of the coating.124 Preliminary experiments in our laboratory 
using thin-film microextraction devices (TFME, blade geometry231) showed that 15 seconds is 
sufficient to extract a quantifiable amount of analyte at the low ppb level even when using the 
traditional LC/MS approach (Figure 2.6). Indeed, if lower LODs are required, the interaction time 
between the coating and the sample matrix can be increased.115 For instance, LOQs as low as 2 
and 19 pg mL-1 were reached when performing 1 minute extractions from 1.5 mL of phosphate 
buffered saline (PBS) spiked with cocaine and diazepam (DZP), respectively.  
Furthermore, the linear dynamic range of the method, evaluated from 10 pg mL-1 up to 50 ng 
mL-1, showed astounding linearity (Figure 2.7) It is worth emphasizing that higher concentration 
levels are not a limitation for SPME;115 thus, the scope of this report is to introduce the remarkable 
quantitation capabilities at trace levels of the SPME-TM-DART-MS/MS. However, in cases where 
a compound is present at a high concentration (i.e. ppm levels) and the affinity of the coating for 
the analyte is strong, even shorter extraction times (e.g. ≤ 30 s) can be performed. 
50 
 
A noteworthy feature SPME-TM devices in comparison with other ambient mass spectrometry 
apparatus is their reproducibility and potential for reusability.144 Extractions performed with 9 
independent SPME-TM devices (n=36) from 1.5 mL of PBS solution spiked with cocaine and 
diazepam showed intra-/inter-device reproducibility lower than 4.7 and 3.2 %, respectively (Tables 
2.2 to 2.4). In addition, the extraction phase is able to withstand well the extraction/desorption 
cycles. However, although a decrease in the peak area signal use for quantitation after four 
consecutive uses was not observed, further experiments are required to determine the long-term 













Figure 2.6 Extraction time profiles for A. diazepam and B. cocaine, respectively. Extractions were 
performed using a vortex agitator set-up at maximum speed (3200 rpm). Extractions from 1.5 mL 
of PBS spiked with 50 ng mL-1 of each analyte with 3 different TFME devices (n = 6). Extracts 

























Figure 2.7 A. Quantitative analysis of PBS spiked with cocaine (10 pg mL-1 to 50 ng mL-1) and 
its isotopologue [D3] cocaine (12 ng mL-1). B. Quantitative analysis of PBS spiked with diazepam 







Table 2.2 SPME-TM inter-device reproducibility; SD, standard deviation; RSD, relative standard 
deviation. Ratio results correspond to the average of extractions performed with 9 independent 
devices (n=36) from a PBS solution spiked with 20 ng mL-1 of each analyte.  
 





Diazepam 1.8 0.05 3 5.0 0.3 
Cocaine 1.6 0.05 3 2.4 0.2 
 
Certainly, it has been confirmed that by using thin-coatings, efficient mass transfer of analytes 
(fast extractions) and effective desorptions can be achieved.228 Furthermore, while the signals 
obtained on a second desorption/ionization cycle (carry-over) were approximately 5% of the signal 
used for quantitation of DZP (Figure 2.8) it is important to highlight that detection of DZP and 
cocaine was performed concomitantly. Thus, DART experimental conditions were not exclusively 
optimized for DZP, which could explain why a small fraction of the analytes still remained after 
the first desorption/ionization cycle.232 Nevertheless, by implementing a cleaning step shortly after 
the desorption/ionization cycle (i.e. mixture of methanol, isopropanol and acetonitrile; 50:25:25) 
negligible carry-over was attained (≤ 0.4%). Undeniably, the cleaning step should be optimized 
according to both the chemistry of the coating and its affinity towards the analyte of interest.115 In 
cases where there is an extensive variation in analyte concentration among samples (i.e. low ppt 
to ppm levels), SPME-TM devices should be restricted to a single use. Otherwise, a small portion 
of the analytes could remain on the coating, even after the cleaning cycle, which could lead to 
potential false positives.25 A possible solution while working with compounds at concentrations 
greater than 50 ppb and with high affinity towards the coating would be to perform shorter 
extractions (≤ 30s). Thus, the amount of analyte enriched would be diminished and the exhaustive 




Table 2.3 Intra-mesh reproducibility (n=4). Results are reported as ratio of analyte (diazepam) versus internal standard isotopologue 
[D5] diazepam. 1 min extractions were performed using vortex agitator set-up at maximum speed (3200 rpm). Extraction from 1.5 mL 
of PBS spiked with 20 ng mL-1 of diazepam. Analyses were performed using Thermo TSQ on SRM mode. SD, standard deviation. RSD, 
relative standard deviation.  
Experiment Mesh_1 Mesh_2 Mesh_3 Mesh_4 Mesh_5 Mesh_6 Mesh_7 Mesh_8 Mesh_9 
Replicate 1 1.91 1.84 1.87 1.77 1.79 1.75 1.75 1.78 1.78 
Replicate 2 1.87 1.80 1.77 1.80 1.80 1.80 1.75 1.77 1.71 
Replicate 3 1.76 1.84 1.76 1.81 1.77 1.82 1.76 1.83 1.77 
Replicate 4 1.80 1.84 1.94 1.86 1.83 1.82 1.77 1.74 1.78 
Summary 1.83 1.83 1.84 1.81 1.80 1.80 1.76 1.78 1.76 
SD 0.07 0.02 0.09 0.04 0.02 0.04 0.01 0.03 0.03 
RSD 3.65 1.15 4.65 2.07 1.36 1.99 0.71 1.93 1.86 
 
Table 2.4 Intra-mesh reproducibility (n=4). Results are reported as ratio of analyte (cocaine) versus internal standard isotopologue [D3] 
cocaine 1 min extractions were performed using vortex agitator set-up at maximum speed (3200 rpm). Extraction from 1.5 mL of PBS 
spiked with 20 ng mL-1 of cocaine. Analyses were performed using Thermo TSQ on SRM mode. SD, standard deviation. RSD, relative 
standard deviation.  
Experiment Mesh_1 Mesh_2 Mesh_3 Mesh_4 Mesh_5 Mesh_6 Mesh_7 Mesh_8 Mesh_9 
Replicate 1 1.48 1.51 1.53 1.62 1.53 1.58 1.59 1.61 1.62 
Replicate 2 1.54 1.54 1.59 1.57 1.62 1.58 1.59 1.64 1.59 
Replicate 3 1.51 1.50 1.56 1.52 1.57 1.59 1.67 1.55 1.50 
Replicate 4 1.55 1.52 1.47 1.54 1.45 1.53 1.61 1.55 1.53 
Summary 1.52 1.52 1.54 1.57 1.54 1.57 1.62 1.59 1.56 
SD 0.03 0.02 0.05 0.04 0.07 0.03 0.04 0.04 0.05 






















Figure 2.8 SPME-TM inter-mesh reproducibility; ion chronograms (non-smoothed) obtained after 
1 min extraction from a solution spiked with 20 ppb of cocaine (green line) versus A. carry-over 
measured subsequently after the desorption/ionization cycle (blue line) and B. carry over measured 
after cleaning the SPME-TM device (red line) on 1.5 mL of a mixture of methanol, isopropanol 
and acetonitrile (50:25:25) for 30 minutes.  
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Despite the advantages of paper spray (PS) for the analysis of small volumes of untreated samples, 
Li et al. and Espy et al. reported that the use of paper substrate requires a drying step, either with 
air or electromechanical assistance, prior to desorption/ionization, which extends the total time of 
analysis.100,226 In contrast to PS, analytes extracted by SPME-TM can be desorbed immediately 
after a quick rinse in water (t ≤ 10 s) and gentle removal of excess water with a cleaning tissue (t 
≤ 2 s). An exceptional characteristic of SPME-TM is the mechanical strength provided by the 
mesh-blade arrangement used to build its structure (Figure 2.5) As a result, deformation/damage 
of the device hardly occurs regardless of the sample dimensions or its characteristics. Thus, SPME-
TM could be used to perform extractions from limited sample volumes (e.g. extractive blood 
spot144) up to large volumes (e.g. on-site monitoring of a creek/river228). 
MS analysis provides significant amounts of information about complex samples.57 However, 
sample pre-treatment required before MS analysis not only is labour-intensive and time-
consuming, but also intricate.46,58 Contrastingly, due to its speed and ease of use, SPME-TM is an 
ideal device for the screening of controlled substances in biological samples as well as for 
therapeutic drug monitoring (TDM).25,144,194 To demonstrate its applicability, SPME-TM was used 
for the quantification of cocaine and DZP in urine and plasma. Figures 2.9 and 2.10 summarize 
the exceptional linearity achieved in both matrices. Similar to PBS, LOQs of 2 and 5 pg mL-1 were 
determined for cocaine in urine and plasma, respectively. Thus, matrix effects are significantly 
minimized by the sample clean-up provided by SPME-TM, and analytes with low binding present 
comparable detection limits independently of the matrix.115 By removing salts and biomolecules 
that mechanically attach to the coated strands during the extraction, the rinsing step extends the 
operative time of the mass spectrometer, providing reliably high instrumental sensitivity as well 
























Figure 2.9 A. Quantitative analysis of plasma spiked with cocaine (50 pg mL-1 to 50 ng mL-1) and 
its isotopologue [D3] cocaine (12 ng mL-1). B. Quantitative analysis of urine spiked with cocaine 
























Figure 2.10 A. Quantitative analysis of plasma spiked with diazepam (500pg mL-1 to 50 ng mL-1) 
and its isotopologue [D5] diazepam (12 ng mL-1). B. Quantitative analysis of urine spiked with 





Unlike cocaine, the LOQ for DZP in plasma (497 pg mL-1) was significantly higher in comparison 
to urine and PBS (19 and 28 pg mL-1, respectively). However, it is worth mentioning that DZP is 
98% bound to plasma proteins and, as an SPME-based approach, the TM configuration only 
extracts the free-portion of analytes in the sample.133 In addition, since the TM configuration 
guarantees homogeneous interaction between extracted and ionizing species, standard-free 
quantitation is also feasible with SPME-TM. Nevertheless, given that extraction is not performed 
at equilibrium (t ≤ 1 min), precise variables should be cleverly controlled in order to obtain 
reproducible and repeatable results, namely sampling time, convection, as well as coating 
thickness homogeneity.133 Definitely, devices having consistent coating distribution, composition, 
and thickness are needed to ensure reproducible extraction of the analytes to the coating and 
desorption of the analytes from the coating. Different to other direct ionization techniques, given 
that no sample matrix is placed in front of the mass spectrometer, homogeneous coatings are 
required to normalize the sample matrix by always extracting the same amount of analyte of 
interest independently of the device used. Hence, reproducible coatings not only minimize sample 
interferences, but also provide reproducible instrumental response and no internal standard is 
required to achieve reproducibility below 15 % RSD (Figure 2.11)  
As a proof-of-concept, SPME-TM was used to simultaneously monitor 21 prohibited substances 
spiked on PBS at 20 ng mL-1.233 Selected reaction monitoring (SRM) was used to exclusively 
identify each compound. LOD were tentatively predicted based on the results obtained for cocaine 
and DZP in PBS. Even though DART source parameters were not optimized for each analyte, all 
substances were detected, and 16 compounds provided hypothetical detection limits lower than 50 
pg mL-1 (e.g. heroin [Log P 1.52], propranolol [Log P 3.48], and stanozolol [Log P 5.53]; Figure 
























Figure 2.11 SPME-TM internal standard free calibration (n=3). A. Quantitative analysis of urine 
spiked with cocaine (500 pg mL-1 to 50 ng mL-1) B. Quantitative analysis of urine spiked with 


























Figure 2.12 Ion chronograms of three controlled substances: heroin (A), propranolol (B), and 
stanozolol (C). 1 min extractions were performed using vortex agitator set-up at maximum speed 
(3200 rpm). Simultaneous extraction from 1.5 mL of PBS spiked with 20 ng mL-1 of 21 substances 
described on Table 2.1. Analyses were performed using a Thermo TSQ on MRM mode. 
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Insofar as SPME-TM derives its sensitivity and selectivity from the physicochemical properties of 
the extraction phase, current research is focused on the development of new devices with greater 
affinity towards specific target compounds. Certainly, the ability of SPME-TM to screen numerous 
substances in a single analysis, without forfeiting sensitivity or quickness, is a noteworthy 
characteristic of this technique, which could be used in other applications such as monitoring of 
personal care products in waste water or pesticides in food commodities.228 
An asset of the mesh-blade arrangement of SPME-TM is that it can be used to perform either 
individual extractions (i.e. from a vial containing sample) or high-throughput extractions in a 
multi-well plate format (Figure 2.13). Similar to other SPME geometries, SPME-TM can be 
adapted to concurrently analyse up to 96 samples in a single run.133,231 Hence, by automating the 
extraction/rinsing step, as well as the desorption step with the aforementioned system, a total 
analysis time of 60 seconds or less could be attained per sample. Undoubtedly, the multiple 
benefits of SPME-TM, such as low detection limits and minimal matrix interferences, should 
stimulate the scientific community to use a swift sample preparation approach prior to direct 








Figure 2.13 SPME-TM configuration for individual extractions and B. SPME-TM 12-strips 





In summary, a novel SPME device that can be easily coupled to DART for targeted and 
quantitative trace analysis (ppt to ppm levels) was developed. Given the structural configuration 
of the apparatus, it can be used to perform extractions independently of the sample complexity and 
its dimensions. Contrary to popular belief,57,58analyte-enrichment and sample-clean-up with 
SPME-TM can be performed in less than 1 minute, with total analysis time not exceeding 3 
minutes. In addition, since no solvent is required in the entire process, and the device can be used 
on-site, the whole analytical process with SPME-TM is “green”. Unquestionably, better 
understanding of the fundamentals driving the extraction, as well as ion transportation would lead 
to lower the detection limits further currently attained by SPME-TM.232 Continuous improvement 
in design of instrument sensitivity will aid this goal. Moreover, sensitivity can be enhanced by 
precisely tuning features of both techniques such as: a. the substrate characteristics (i.e. mesh 
material type, empty space diameter, consecutive hole to hole distance, and strand size);234 b. the 
coating features (i.e. polymeric phase chemistry, particle size, porosity, thermal conductivity, 
thermal stability, and affinity for the analyte of interest),124 and c. the position of the substrate in 
which there is a balance between efficient neutral generation by thermal desorption and transport 
into the mass spectrometer (i.e. DART source operative conditions such as: gas temperature and 
flow, discharge voltage, grid electrode voltage, spatial position of the mesh in relation to the ion 
source nozzle).209,232 A comprehensive optimization of the variables described above will certainly 
boost the performance of SPME-TM technique herein discussed.  
Although SPME-TM reusability is advantageous for high-throughput applications in which a large 
number of samples should be processed daily, it is also envisaged as a disposable device for in situ 
trace analysis and this research is currently undergoing in our research group.13 By coupling 
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SPME-TM to deployable MS/MS systems, truly “real-time” and quantitative analysis of complex 
mixtures will be delivered on-site (see Section 2.4).226,235 Therefore, due to the unique combination 
of speed, selectivity, sensitivity, reproducibility and simplicity, SPME-TM-DART-MS/MS is a 
suitable rapid screening and quantitation technique not only for point-of-care TDM, but also in 




Section 2.3 Ultrafast Screening and Quantitation of Pesticides in Food and Environmental 
Matrices by Solid-Phase Microextraction–Transmission Mode (SPME-TM) and Direct 
Analysis in Real Time (DART) 
 
2.3.1 Introduction 
To date, among the different analytical methods used for analysis of pesticides in food 
commodities, QuEChERS (Quick, Easy, Cheap, Effective, Rugged, and Safe) has gained the 
broadest acceptance within the scientific community236. The success and widespread use of 
QuEChERS can be attributed to its convenient approach; as it combines well-known extraction 
and clean up methods,237 trained analysts are not required to learn new procedures to utilize this 
method. However, the Achilles heel of this sample preparation strategy lies in its extensive number 
of steps, and in most cases, the various challenges associated with its automation. Thus, 
QuEChERS is not only tedious, but its use may also lead to large systematic errors.120 Furthermore, 
the extensive use of organic solvents and the production of waste from the salts and sorbents 
employed in this method are additional factors that would make an alternative, comparably 
reliable, and sensitive green sample preparation technique desirable for multiresidue analysis of 
pesticides.  
Solid phase microextraction (SPME) has been widely reported as a convenient alternative method 
for the analysis of pesticides in food and environmental matrices.119,120 Historically, the use of 
SPME for the analysis of foodstuffs was confined to headspace (HS) sampling due to the short 
lifespan of commercially available coatings submitted to direct immersion in complex sample 
matrices139. Moreover, the results and limits of quantitation achievable by HS-SPME were limited 
by the vapor pressure of the pesticide analyzed; very often, further matrix modifications were 
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needed to promote the mass transfer of the analytes from the matrix to the HS. In addition, sensitive 
and accurate analysis could not be carried out by HS-SPME for polar and non-volatile analytes 
due to their low Henry’s law constant. To address the shortcomings of HS-SPME, several attempts 
towards an effective direct immersion (DI) method were carried out; however, all developed 
methodologies included sample pre-treatment prior to SPME extraction.238–240 These limitations 
were addressed with the introduction of new matrix-compatible SPME coatings (in fiber format) 
able to endure direct immersion in complex matrices for repetitive cycles of 
extraction/desorption.241,242 This new coating opened the door to applications of SPME for 
multiresidue analysis in complex matrices, greatly improving the throughput of the methods and 
minimizing, or completely avoiding in most cases, the need for sample pre-treatment. In addition, 
comparative studies showed the ability of these novel SPME coatings to reach lower limits of 
detection than those attained by QuEChERS, with the further advantage of cleaner chromatograms 
being attained by such SPME coatings in comparison to QuEChERS as well.138,243 However, in 
spite of all the benefits offered by matrix compatible SPME devices, the fastest throughput 
achievable was 30 minutes per sample (including an extraction time of 15 minutes, followed by 
15 minutes of gas-chromatographic separation).243 Undoubtedly, the long extraction-separation 
procedure may have thwarted the practice of this method for the expeditious determination of 
pesticides in food/environmental samples.  
Not long ago, the concept of an analytical method capable of assessing the concentration of 
agrochemicals in food commodities with minimal sample handling and without a chromatographic 
separation step would have been regarded as chimerical by most food analysts.244 However, recent 
developments in ambient mass spectrometry (AMS) technologies,65,232,245 characterized as a group 
of technologies that allow for the generation of ions under atmospheric conditions from untreated 
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samples, have challenged whether the long and cumbersome protocols typically used for the 
determination of pesticides/contaminants in foodstuffs are necessary. 
As shown in Figure 2.14, AMS allows for the rapid analysis of food samples; this can be 
accomplished by placing the untreated material between a jet of charge species31 and the mass 
spectrometer (e.g. desorption electrospray ionization, DESI246–250; direct analysis in real time, 
DART69,74,78,193,249,251–253; atmospheric pressure solid analysis probe, ASAP254; or low-temperature 
plasma ambient ionization, LTP54,255,256), by spiking/spotting a portion of the sample on a solid 
substrate that is interfaced with the mass spectrometer to generate ionic species (e.g. paper spray, 
PS257–261; probe electrospray ionization, PESI262; touch spray ionization263; thermal-desorption-
ESI264), or by sampling the surface with a continuous flowing liquid (e.g. liquid extraction surface 
analysis, LESA56; nanoextractive electrospray ionization, nanoEESI265). Although pure direct 
coupling methods have demonstrated fast and simple identification/quantitation of agrochemicals 
in several untreated matrices, their suitability for the determination of these analytes at trace-levels 
in complex food matrices still remains to be demonstrated. Consequently, the direct coupling of 
sample preparation technologies and mass spectrometry151,173,174,197,266,267 has emerged as a 
solution to these unmet needs. Undeniably, microextraction-based approaches have outclassed 
other sample preparation technologies due to their intrinsically small configuration, rendering its 
direct coupling simpler and, in most cases, tremendously efficient.136 SPME is not the exception 
to this trend, and multiple direct couplings of SPME to MS have shown its great potential in 
significantly shortening the total sample analysis time of complex matrices, as well as in 
diminishing potential matrix effects and instrument contamination, owing to the ability of SPME 
to provide clean sample extracts.151,174 
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Figure 2.14 Schematic representation of ambient mass spectrometry (AMS) technologies versus 




Recently, an alternative geometry of SPME was introduced for the direct coupling to mass 
spectrometry: a metallic mesh coated with adsorbent particles glued together by polyacrynonitrile 
(PAN). The device was successfully coupled as a transmission mode substrate (i.e. SPME-TM) for 
DART.205,267 This approach drastically lowered the analysis time for determination of drugs in 
biofluids as well as considerably pushed down the limits of detection achievable by traditional 
sample spot DART determination.58,74,268 The challenge taken up in this study encompassed the 
application of SPME-TM for the quantitative multiresidue analysis of pesticides in food and 
environmental matrices without any sample pre-treatment (e.g. filtration or solvent 
extraction)197,269, with the additional goal of minimizing total analysis time269. In order to set a 
representative system and thoroughly evaluate the performance of the developed SPME-TM-
DART/MS system, the matrices under study, namely Concord grape juice, orange juice, cow milk, 
and surface water, were selected on the basis of specific characteristics representative of the 
different challenges associated with complex matrix analysis, and their varied nutritional and 
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physical attributes. Analytes of interest, in turn, were selected from various classes of pesticides, 
covering a broad range of polarities, molecular weight, and functional groups. In addition to 
demonstrating the suitability of SPME-TM-DART/MS for quantitative analysis of multiresidue 
pesticides in complex matrices, the presented work also demonstrates the aptness of single SPME-
TM devices to perform targeted quantitation as well as retrospective analysis of the same sample. 
 
2.3.2 Experimental section 
Materials and supplies  
The analytes used in this investigation were purchased from Sigma Aldrich, and are listed in Table 
2.5 alongside relevant information pertaining to their physical chemical properties, pesticide 
classification, and monitored SRM transitions. Individual stock solutions were prepared in 
acetonitrile, methanol, acetone, and dichloromethane at concentrations ranging from 9 to 15 
mg/ml. Working solutions at 100, 10, and 1 µg/ml were prepared by mixing the analytes in 
acetonitrile. The internal standards used, namely atrazine-D5, metalaxyl-D6, and cyprodinyl-D6, 
were purchased from Toronto Research Chemicals (Toronto, ON, Canada). Stock solutions of the 
internal standards were prepared in acetonitrile at a concentration of 1 mg/ml for atrazine-D5 and 
metalaxyl-D6, and at a concentration of 5mg/ml for cyprodinyl-D6. A working solution comprising 
all the internal standards was prepared in acetonitrile at 10 µg/ml. Samples of concord grape juice, 
orange juice (with pulp), and cow milk (2%, Milk Fat, M.F.) were purchased from local grocery 
stores (Waterloo, ON, Canada). Surface water samples were retrieved from Grand River (Waterloo 
Region, ON, Canada). Samples were prepared by spiking appropriate amounts of analytes and 
internal standards, with care given so that the total amount of organic solvent added never exceeded 
1% (v/v) of the total amount of matrix. The spiked samples were equilibrated for at least two hours 
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Table 2.5 Target analytes, class type, molecular weight (MW), molecular structure, hydrophobicity (expressed as LogP), and monitored 
SRM transitions for each model compound in positive ionization mode with DART-MS/MS. 
 
Compound  Class Type MW (g/mol) LogP (pH=7, 20ºC) 
Parent ion 
[m/z] 
Product ion #1  
[m/z] 
Product ion #2 
[m/z] 
Acephate Organophosphate  I 183.17 -0.85 184.031 95.065 143.056 
Omethate Organophosphate  I, A 213.20 -0.74 214.038 125.045 183.048 
Dimethoate Organophosphate  I, A 229.26 0.70 230.014 125.057 199.006 
Metalaxyl Phenylamide  F 279.33 1.65 280.157 192.167 220.181 
Azoxystrobin Strobilurin  F 403.40 2.50 404.131 344.095 372.114 
Imazalil Imidazole  F 297.18 2.56 297.055 159.013 201.007 
Atrazine Triazine  H 215.68 2.70 216.112 68.158 174.112 
Malathion Organophosphate I, A 330.36 2.75 331.054 99.101 127.113 
Pyrimethanil Anilinopyrimidine  F 199.11 2.84 200.130 107.144 168.129 
Cyproconazole Triazole  F 291.78 3.09 292.121 70.158 125.062 
Tebuconazole Triazole  F 307.82 3.70 308.162 70.166 125.078 
Cyprodinil Anilinopyrimidine  F 225.29 4.00 226.133 77.137 93.139 
Pyraclostrobin Strobilurin  F 387.82 4.25 388.114 149.073 194.095 
Quinoxyfen Quinoline  F 308.13 4.29 308.003 162.039 197.002 
Difenoconazole Triazole  F 406.26 4.36 406.070 188.038 250.984 
Trifloxystrobin Strobilurin  F 408.37 4.50 409.140 145.060 186.069 
Pyriproxyfen Unclassified  I 321.37 5.37 322.154 78.139 96.126 
Fenproprathrin Pyrethroid  I 349.42 6.04 350.167 97.273 125.163 





at 1500 rpm to guarantee that binding equilibria between analytes and matrix components were 
established, thus obtaining samples that closely represent real contamination scenarios. SPME-TM 
devices were manufactured in-house using stainless steel mesh (74 × 74 wires per in, wire diameter 
0.004 in). The mesh’s strands were precisely coated with a biocompatible polymer (slurry of 5 µm 
hydrophilic-lipophilic balance (HLB) particles and polyacrylonitrile as a binder) at a thickness of 
less than 20 µm and a length of 1 cm following the protocol described in section 2.2. As previously 
reported by our group, HLB particles were selected with the objective of providing wider analyte 
balance coverage, which is critical when performing multiresidue analysis123,151. 
 
DART-MS set up  
A DART-Standardized Voltage and Pressure (DART-SVP) model ion source (IonSense, Saugus, 
MA USA) was coupled to either a triple quadrupole mass spectrometer (TSQ Vantage) or an 
Orbitrap (Exactive) by Thermo Scientific (San Jose, California, USA) via a Vapur® interface 
(IonSense, Inc.). The DART-SVP was fitted with a single dimensional motorized linear rail 
controlled through the DART-SVP web-based software so as to reproducibly and consecutively 
automatically position the SPME-TM devices in front of the DART source (speed of 0.2 mm s-1 
was used). In order to guarantee good reproducibility and higher throughput of the desorption 
process, a custom-made holder (UW-12) able to allocate up to twelve SPME-TM devices was 
developed.267 The DART source was operated using the following conditions: positive ion mode; 
high voltage (HV) electrode, −3000 V; discharge electrode, +350 V; grid voltage, +350 V. The gas 





Figure 2.15 Schematic representation of the analytical workflow for the ultrafast determination of 
pesticides in food and environmental matrices by Solid Phase Microextraction-Transmission Mode 








Figure 2.16 Relevance of the rinsing step on SPME-TM devices for the quantitative determination 
of pesticides in food/environmental matrices. Left picture portrays the SPME-TM after extraction 
from orange juice with pulp, while the left picture shows the mesh after subsequent 10 seconds 
rinsing in LC/MS water.  
 
Sample preparation/analyte enrichment  
As shown in Figure 2.15, the analytical procedure consisted of the following steps: 1. SPME-TM 
devices were rinsed (10 s) in water in order to eliminate any organic solvent residue (from the 
preconditioning step) that could potentially affect the extraction capability of the devices. 2. 
SPME-TM devices were exposed to the sample matrices (1.5 ml), and extraction was carried out 
for 1 minute at 3200 rpm. 3. SPME-TM devices were then quickly rinsed (10 s) in water in order 
to remove any loosely attached matrix constituents that could induce ion 
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enhancement/suppression, be irreversibly carbonized onto the coating surface during the 
desorption process, or cause instrumental contamination (see Figure 2.16, relevance of rinsing 
step). Finally, SPME-TM devices were positioned in the UW-12 holder and thermally desorbed. 
The total run time for 12 samples was approximately 4 minutes. It is worth mentioning that SPME-
TM devices were used as consumables in this study (single use).  However, as reported by Gomez-
Rios et al267, the devices can be reused by implementing a thorough cleaning step after the 
desorption/ionization cycle (e.g. immersing them on a mixture of methanol, isopropanol, and 
acetonitrile; 50:25:25 for half-hour). 
 
2.3.3 Results and discussion  
A novel technology for rapid screening and quantitative analysis of food and environmental 
samples  
Aiming to thoroughly investigate the suitability of SPME-TM-DART-MS for quick multiresidue 
analysis of pesticides, four matrices with completely different nutritional and physical 
characteristics were carefully chosen. First, Concord grape juice was selected due to the high 
amount of anthocyanin pigments and sugars (20% w:w) present in this commodity. Previous 
studies have reported that the co-extraction of these compounds by SPME might induce the 
production of artefacts during thermal desorption on the GC injector (i.e., Maillard reactions139). 
The second matrix, orange juice (10% w:w of sugar) composed of a substantial amount of pulp, 
was selected owing to the membranous content of its pulp, which could be easily entangled onto 
the coated mesh after analysis, leading to non-reproducible results. Cow milk (2%, M.F.), as a third 
matrix, was selected due to its composition as a matrix rich in fat and proteins, which can 
irreversibly deposit onto the SPME coating, thus compromising the mass transfer of the analytes. 
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Finally, surface water from a local river was selected so as to represent an environmental matrix 
where the presence of pesticides would be highly relevant in real world applications. All of these 
matrices present different challenges for chemical analysis, and many reported methods employ 
extensive sample preparation procedures in order to obtain concentrated extracts that can be 
introduced into the analytical system without the risk of instrumental contamination and matrix 
interferences. With the purpose of developing a fast and simple method for multiresidue analysis 
in complex matrices, no sample pre-treatment was carried out for the matrices studied. This is 
possible in view of the intrinsic nature of SPME, which allows for simultaneous isolation and 
concentration of analytes from a given matrix, thus providing a “clean-extract” for introduction 
into the analytical system. In addition, the TM geometry of SPME not only offers faster throughout 
in comparison to automated SPME-GC/LC methods161, it also offers increased sensitivity, as 
analytes can be introduced onto the MS system without further dilution. Moreover, in comparison 
with SPME’s fibre geometry,207 the mesh configuration provides a larger surface area available for 
extraction, leading to dramatic improvements in enrichment kinetics and the limits of quantitation 
(LOQ) attainable. Furthermore, coating fouling and deterioration, due to irreversible attachment 
of matrix components onto the coating surface, could be avoided owing to the short extraction 
time needed to achieve the desired method sensitivity for the analytes of interest.270 
 
SPME-TM for pesticide determination: method validation.  
Validation of the method was carried out using the matrix-matched calibration approach, with 
calibration functions constructed on the basis of the signal ratio of the analyte and the internal 
standard (A/Is) for twelve points in three independent experiments, covering a range between 0.1 
and 100 ng g-1. 
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Table 2.6 Figures of merit for the determination of multiresidue pesticides in four different matrices via SPME-TM-DART-MS/MS. 
LDR: lineal dynamic range; LOQ: limit of quantitation  
 
Compounds  LogP 





















Acephate  ‐0.9  5‐100  0.9988  5  0.5‐50  0.9997  0.5  5.0‐25  0.9996  5  1.0‐50  0.9916  1 
Pyrimethanil  ‐0.7  0.1‐100  0.9997  0.1  0.25‐100  0.996  0.25  0.25‐10  0.9998  0.25  0.1‐100  0.9995  0.1 
Omethoate  0.7  0.1‐100  0.9997  0.1  0.1‐50  0.9905  0.1  0.1‐100  0.9984  0.1  0.25‐100  0.9974  0.25 
Atrazine  1.7  0.1‐100  0.9998  0.1  0.1‐100  0.9981  0.1  0.1‐100  0.9998  0.1  0.1‐100  0.9996  0.1 
Cyprodinyl  2.5  0.1‐100  0.9987  0.1  0.1‐100  0.9925  0.1  0.1‐100  0.9983  0.1  0.25‐100  0.9972  0.25 
Dimethoate  2.6  0.25‐100  0.9987  0.25  0.1‐100  0.9975  0.1  0.25‐100  0.9995  0.25  0.25‐100  0.9982  0.25 
Metalaxyl  2.7  0.25‐100  0.9987  0.25  0.1‐100  0.9989  0.1  0.1‐100  0.9958  0.1  0.1‐100  0.9997  0.1 
Cyproconazole  2.8  0.1‐100  0.9937  0.1  0.1‐100  0.9999  0.1  0.25‐100  0.9993  0.25  0.25‐100  0.9948  0.25 
Imazalil  2.8  0.25‐100  0.9945  0.25  0.1‐100  0.9999  0.1  0.5‐100  0.9982  0.5  0.1‐100  0.9997  0.1 
Quinoxyfen  3.1  0.1‐100  0.9995  0.1  0.25‐100  0.9967  0.25  0.25‐10  0.998  0.25  ‐  ‐  ‐ 
Tebuconazole  3.7  0.25‐100  0.9994  0.25  0.1‐100  0.9991  0.1  0.1‐10  1  0.1  0.25‐100  0.9975  0.25 
Flusilazole  4.0  0.25‐100  0.9981  0.25  0.1‐100  0.9984  0.1  0.1‐100  0.9972  0.1  0.25‐100  0.9938  0.25 
Pyriproxyfen  4.3  0.1‐10  0.9964  0.1  0.25‐100  0.9981  0.25  ‐  ‐  ‐  ‐  ‐  ‐ 
Malathion  4.3  0.1‐100  0.9924  0.1  0.25‐100  0.9981  0.25  0.25‐100  0.9975  0.25  1‐100  0.9979  1 
Pyridaben  4.3  0.25‐50  0.9974  0.25  0.25‐100  0.9993  0.25  ‐  ‐  ‐  ‐  ‐  ‐ 
Pyraclostrobin  4.5  0.25‐50  0.9874  0.25  0.1‐100  0.9968  0.1  0.25‐100  0.9774  0.25  ‐  ‐  ‐ 
Azoxystrobin  5.4  0.25‐100  0.9929  0.25  0.25‐100  0.9955  0.25  ‐  ‐  ‐  ‐  ‐  ‐ 
Difeconazole  6.0  0.25‐100  0.9924  0.25  0.25‐100  0.9959  0.25  ‐  ‐  ‐  ‐  ‐  ‐ 
Trifloxystrobin  6.4  0.1‐50  0.9990  0.1  0.25‐25  1  0.25  0.1‐50  0.9975  0.1  ‐  ‐  ‐ 
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Table 2.7 Multiresidue pesticide determination in orange juice by SPME-TM-DART-MS/MS. 
Method accuracy (%) and precision (Relative Standard Deviation, RSD, %) at three different 
validation levels. 
 
Accuracy, % (RSD, %; n=6) 
  
Compound 0.3 µg/kg 7 µg/kg 75 µg/kg IS Weight 
Acephate <LOQ 105 (8) 91 (8) Atrazine d5 No weight 
Pyrimethanil 109 (4) 88 (6) 100 (8) Atrazine d5 1/X 
Omethoate 128 (10) 101 (11) - Atrazine d5 1/X 
Atrazine 118 (6) 108 (4) 105 (5) Atrazine d5 1/X 
Cyprodinil 110 (3) 100 (3) 96 (4) Cyprodinyl d6 1/X2 
Dimethoate 116 (6) 117 (10) 105 (6) Atrazine d5 1/X 
Metalaxyl 116 (6) 99 (7) 97 (4) Metalaxyl d6 1/X 
Cyproconazole 89 (6) 90 (7) 100 (7) Metalaxyl d6 1/X 
Imazalil 121 (6) 118 (10) 102 (7) Cyprodinyl d6 1/X 
Quinoxyfen 111 (11) 88 (6) 101 (8) Metalaxyl d6 1/X 
Tebuconazole 97 (8) 90 (8) 99 (8) Metalaxyl d6 1/X 
Flusilazole 108 (9) 94 (7) 103 (6) Metalaxyl d6 1/X 
Pyriproxyfen 79 (13) 96 (7) 104 (10) Atrazine d5 1/X2 
Malathion 109 (17) 113 (4) 111 (8) Atrazine d5 1/X 
Pyridaben 78* (17) 77 (9) 100 (6) Atrazine d5 No weight 
Pyraclostrobin 110 (13) 96 (8) 112 (6) Atrazine d5 1/X 
Azoxystrobin 130 (6) 117 (12) 99 (9) Atrazine d5 1/X 
Difeconazole 124 (3) 113 (8) 110 (3) Atrazine d5 1/X 
Trifloxystrobin 68 (22) 110 (9) - Metalaxyl d6 No weight 
* Linear range 0.25-10 µg/kg 
 
It is important to note that the calibration range brackets the maximum residue levels (MRLs) of 
10 ng g-1, imposed by the European Regulation (EC) N˚ 396/2005 of the European Parliament for 
most food commodities. All calibration curves were processed with each of the IS selected, using 
no weight, weight 1/X, and weight 1/X2. Limits of quantitation were calculated according the 
directives of the Food and Drug Administration (FDA), with the lowest calibration level providing 
less than 20% deviation from the nominal concentration in the constructed calibration curve, and 
with precision not exceeding 20% of the CV. Results obtained for all tested matrices, including 




Table 2.8 Multiresidue pesticide determination in Concord grape juice by SPME-TM-DART-
MS/MS. Method accuracy (%) and precision (Relative Standard Deviation, RSD, %) at three 
different validation levels. 
 
Accuracy, % (RSD, %; n=6) 
  
Compound 0.3 µg/kg 7 µg/kg 75 µg/kg IS Weight 
Acephate - 91 (10) 112 (12) Atrazine d5 1/X 
Pyrimethanil 96 (9) 77 (7) 100 (8) Atrazine d5 1/X 
Omethoate 97 (6) 117 (10) 110 (10) Atrazine d5 1/X 
Atrazine 95 (5) 96 (5) 97 (5) Atrazine d5 1/X 
Cyprodinyl 96 (4) 105 (3) 105 (2) Cyprodinyl d6 1/X2 
Dimethoate 98 (7) 94 (9) 97 (5) Atrazine d5 1/X 
Metalaxyl 102 (6) 111 (6) 98 (6) Atrazine d5 1/X 
Cyproconazole 91 (7) 100 (5) 93 (9) Atrazine d5 1/X2 
Imazalil 91 (8) 78 (10) 111 (10) Atrazine d5 1/X 
Quinoxyfen 97 (9) 122 (7) 98 (8) Atrazine d5 1/X 
Tebuconazole 80 (10) 103 (7) 103 (7) Atrazine d5 1/X 
Flusilazole 96 (10) 106 (9) 83 (8) Atrazine d5 1/X 
Pyriproxyfen 85 (8) 93 (7) - Atrazine d5 1/X 
Malathion 77 (8) 95 (9) 102 (7) Atrazine d5 1/X 
Pyridaben 113 (10) 126 (12) - Atrazine d5 No weight 
Pyraclostrobin 118 (15) 89 (12) - Atrazine d5 1/X 
Azoxystrobin 126* (7) 69 (5) 87 (3) Cyprodinyl d6 No weight 
Difeconazole 108 (6) 125 (11) 89 (8) Atrazine d5 1/X 
Trifloxystrobin 116 (8) 123 (9) - Atrazine d5 1/X2 
* Linear range 0.25-10 µg/kg 
 
Results pertaining to the precision and accuracy of the method for each of the examined matrices 
are summarized in Tables 2.7 to 2.10. As can be seen in Table 2.6, most of the target analytes 
provide outstanding linearity, and LOQs below the imposed MRLs for the majority of the matrices. 
Figure 2.17 succinctly presents calibration curves obtained for four different pesticides spiked into 
the four analysed matrices. Unlike grape and orange juice, particular analytes spiked in surface 
water (i.e., Pyriproxyfen, Pyridaben, Azoxystrobin, and Difenoconazole) and cow milk (i.e., 
Quinoxyfen, Pyriproxyfen, Pyridaben, Pyraclostrobin, Azoxystrobin, Difeconazole, and 




Table 2.9 Multiresidue pesticide determination in surface water by SPME-TM-DART-MS/MS. 
Method accuracy (%) and precision (Relative Standard Deviation, RSD, %) at three different 
validation levels. 
 
Accuracy, % (RSD, %; n=6) 
  
Compound 0.3 µg/kg 7 µg/kg 75 µg/kg IS Weight 
Acephate < LOQ 102 100* Atrazine d5 No weight 
Pyrimethanil 111 (4) 111 (6) 92* (7) Atrazine d5 No weight 
Omethoate 124 (4) 114 (13) 106 (10) Atrazine d5 1/X 
Atrazine 110 (3) 95 (4) 98 (3) Atrazine d5 1/X 
Cyprodinyl 106 (3) 100 (2) 99 (2) Cyprodinyl d6 1/X 
Dimethoate 81 (10) 101 (9) 97 (8) Atrazine d5 1/X 
Metalaxyl 104 (4)  94 (3) 97 (4) Metalaxyl d6 1/X 
Cyproconazole 114 (6) 93 (10) 102 (9) Atrazine d5 1/X 
Imazalil < LOQ 74 (6) 96 (6) Cyprodinyl d6 1/X 
Quinoxyfen 92 (5) 93(2) - Atrazine d5 1/X 
Tebuconazole 112 (9) 119 (12) - Atrazine d5 1/X 
Flusilazole 93 (3) 72 (4) 71 (8) Metalaxyl d6 1/X2 
Pyriproxyfen 91 (3) 84 (5) 110 (9) Atrazine d5 1/X 
Malathion 84 (13) 84 (11) 73 (8) Atrazine d5 1/X 
Pyridaben 102 (11) 115 (12) - Atrazine d5 1/X 
Pyraclostrobin < LOQ 102 100* Atrazine d5 No weight 
Azoxystrobin 111 (4) 111 (6) 92* (7) Atrazine d5 No weight 
Difeconazole 124 (4) 114 (13) 106 (10) Atrazine d5 1/X 
Trifloxystrobin 110 (3) 95 (4) 98 (3) Atrazine d5 1/X 
* Linear range 25-100 µg/kg 
 
Certainly, this outcome can be explained by the intrinsic physicochemical characteristics of these 
analytes, and their interaction with the matrices/sample-containers. For instance, the 
abovementioned analytes possess medium to high hydrophobicities (expressed as LogP), and 
potentially demonstrate significant binding to the employed containers or the suspended matter 
present in these sample matrices.  
Undoubtedly, milk represents a food matrix with a higher degree of complexity when compared to 
grape juice and orange juice due to its composition. Milk, is an emulsion of fat globules and casein 
micelles, which are suspended in an aqueous phase that contains solubilized lactose, whey 
proteins, and some minerals.  
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Table 2.10 Multiresidue pesticide determination in cow milk by SPME-TM-DART-MS/MS. 
Method accuracy (%) and precision (Relative Standard Deviation, RSD, %) at three different 
validation levels. 
Compound 
Accuracy % (RSD%, n=6)  
0.3 µg/kg 7 µg/kg 75 µg/kg IS Weight 
Acephate <LOQ 92 (14) - Atrazine d5 No weight 
Pyrimethanil 82 (8) 86 (3) 90 (8) Atrazine d5 1/X2 
Omethoate 114* (10) 102 (4) 108 (10) Atrazine d5 No weight 
Atrazine 96 (6) 99 (4) 103 (5) Atrazine d5 No weight 
Cyprodinil 114 (10) 110 (6) 120 (6) Cyprodinyl d6 1/X 
Dimethoate 85 (5) 107 (8) 105 (10) Atrazine d5 1/X 
Metalaxyl 103 (3) 96 (5) 103 (4) Metalaxyl d6 1/X 
Cyproconazole 74 (5) 116 (7) 105 (8) Atrazine d5 1/X 
Imazalil 70 (12) 80 (9) 92 (15) Atrazine d5 1/X 
Tebuconazole 72 (8) 96 (12) 85 (8) Atrazine d5 1/X 
Flusilazole 70 (9) 100 (12) 82 (9) Atrazine d5 1/X 













Figure 2.17 Quantitative analysis of surface water, Concord grape juice, orange juice, and cow 
milk spiked with four pesticides (100 pg ml−1 to 100 ng mL−1). Internal standards (Metalaxyl-d6, 
Cyprodinil-d6, and Atrazine-d5) used for correction were spiked at a fixed concentration in all 




Therefore, it is important to bear in mind that the various phases that constitute milk also 
participate in the partition equilibria established between the matrix and the extraction device. 
Consequently, considering the hydrophobicity of the matrix and the hydrophobicity of the 
aforementioned analytes, it is not surprising that these analytes are more likely to partition into the 
matrix rather than onto the extraction phase. Hence, the extraction of the above listed analytes for 
both matrices could have been improved by performing further matrix modifications with aims to 
either promote the release of the analytes from the sample, and preventing its adhesion to the 
glassware surface by using silanized equipment.271. However, this is out of the scope of the 
presented work, which had as a goal an assessment of system performance without further matrix 
modifications.  
 
Towards highly reproducible devices, and the minimization of internal standard use  
Previously, Gómez-Ríos et al.267 demonstrated that suitable control of the manufacturing of 
SPME-TM devices plays a critical role in guaranteeing matrix normalization, which fundamentally 
translates into the increased ability of any SPME device to extract the same amount of analyte of 
interest, independently of the device being used. As a result, reproducible instrumental response 
and linear calibration curves can be attained without the need of the deuterated analogue of the 
targeted analyte. As shown in Figure 2, calibration curves for all studied analytes were built based 
on the best correction attained by one of the three internal standards spiked on the samples. Thus, 
in comparison to direct sample to MS technologies, the matrix normalization offered by SPME-
TM is quite convenient. As a proof-of-concept, Figure 2.18 presents calibration curves obtained 
without the use of an internal standard for four diverse analytes (Metalaxyl, Pyrimethanil, 




Figure 2.18 Quantitative analysis of Concord grape juice spiked with four pesticides (100 pg ml−1 
to 10 ng mL−1). No internal standard was used for correction. 
 
Despite the attainment of satisfactory results for the analytes of interest, it is important to highlight 
that a linear increment on the instrumental response was only observed for 2 orders of magnitude 
(i.e. 0.1-10 ng mL-1). The lack of linearity obtained without the use of an internal standard above 
10 ng mL-1 can be attributed to either source or MS detector saturation. Certainly, rather than bad 
news, it is quite impressive that a 1 minute extraction from a complex matrix is sufficient to reach 
required detection limits. Practically speaking, if the goal of a given application is to extend the 
linear dynamic range without the need of an internal standard, one can simply increase the scanning 
speed at which the mesh passes in front of the DART source, or decrease sampling time, or 
decrease the dwell time, or both of which can reduce the amount of analyte being introduced into 
the MS system. 
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Retrospective analysis by SPME-TM  
Interest in retrospective analysis is continuously growing, as it allows agrochemicals to be 
investigated in samples after initial MS acquisition, and allows the user to screen sample sets at a 
later date when perhaps more information regarding the system is available.272 Retrospective 
analysis, as a post-targeted analysis approach, is quite efficient for the screening of a larger number 
of compounds, such as those not listed by international regulation agencies at the time of initial 
analysis (e.g. transformation products of pesticides).273 Yet, state-of-the-art retrospective analysis 
is chiefly focused on tedious sample preparation methods coupled to GC/LC-HRMS,274,275 making 
this type of examination quite laborious. Therefore, methods that enable both retrospective and 
quantitative analysis in a “point-and-shoot” fashion are highly desirable in food analysis.276  
In addition to the speed and sensitivity herein presented, an alluring feature provided by SPME-
TM lies in the possibility of performing retrospective examinations of a given sample using the 
same sampling device. Given the size of the coated area on the SPME-TM device (5 mm wide by 
15 mm length), more than one analysis can be performed by thermally-desorbing a different 
section of the coated mesh, as approximately only 25 mm2 (area of 5 mm x 5 mm) of the mesh 
comes into contact with the stream of helium supplied by the DART source per scanning event. 
Consequently, an SPME-TM device primarily used for targeted determinations can be adequately 
stored (e.g. kept at -80 ̊ C) so as to guarantee analyte stability for further retrospective studies using 
high-resolution mass spectrometry. Aiming to evaluate the appropriateness of SPME-TM for 
retrospective analysis, several devices previously used for extraction from grape juice spiked at 25 
ng ml-1 were stored at -80°C for 4 months. Subsequently, DART analyses were carried out by 
means of an Orbitrap mass analyser. As can be seen in Figure 2.19, a second desorption of the 
stored devices revealed the presence of all pesticides spiked in the matrix.  
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Figure 2.19 Retrospective analysis of an SPME-TM device stored at -80˚C for 4 months after 
prior targeted inspection of one segment. Mass spectra was attained using an Orbitrap-Exactive in 
full scan mode [m/z 100-500]. 
 
Certainly, these results are encouraging, as they pave the way for the implementation of SPME-
TM for rapid on-site screening by means of portable instrumentation,65,277 with the possibility of 
subsequent confirmation of results via benchtop instruments.278  
 
SPME-TM versus direct-sample-to-MS  
Although the direct interface of food samples to MS via DESI279, LESA56, LTP255, REIMS70, and 
DART69 typically offers astonishingly fast results for the determination of pesticides, these 
technologies are truly useful only when the agrochemicals under study are present at high 
concentrations, typically above the MRLs set by food legislation280. In view of these limitations, 
sample pre-treatments prior to “direct” coupling to MS have been implemented to match the 
requirements enforced by regulatory authorities.174,197,281 However, some of these sample 
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preparation approaches are inefficient and, in most cases, difficult to integrate with the ambient 
ionization process. In view of these facts, SPME-TM is undeniably a tool that not only provides 
the required sensitivity needed to attain the required levels of detection without sacrificing speed 
of analysis, it additionally minimizes the chance of instrument contamination due to its intrinsic 
ability to provide ‘clean extracts’. Hence, the obtained results in this study can be posed as an early 
call to international legislating agencies towards the establishment of new guidelines that allow 
for the routine use of microextraction-MS technologies for the rapid screening of multiresidue 
pesticides in food commodities. In addition, we foresee SPME-TM as a promising new tool to 
tackle various analytical problems in other disciplines that require fast and clean analyte 
introduction. 
To date, chromatographic separations, by either GC-MS or LC-MS, are still the platform of choice 
for the determination of pesticides, as the analysis specificity may suffer from the loss of a 
separation dimension. For instance, interferences may be observed when the target analyte is co-
extracted from the matrix with isomeric species that share the same fragmentation pattern. 
Certainly, this is an issue inherent of any direct-sample-to-MS approach (not only SPME). 
Although SPME-TM devices are capable of performing ultra-fast extraction/enrichment from food 
matrices, it is important to highlight that the coatings developed up to date are not selective enough 
to discriminate between the compound of interest and a potential isobar or isomer. Hence, as 
recently demonstrated by our group178, there is need of front-end separation technologies, such ion 
mobility spectrometry (IMS)12 or differential mobility spectrometry (DMS)178, that allow for 
analyte-interference separation without sacrificing the total analysis time282. Nevertheless, one 
should bear in mind that the main purpose of direct-to-MS technologies, including SPME-MS, is 
84 
 
not to fully replace chromatographic-based technologies, rather to alleviate the laboratories loads 
through a fast analysis.  
 
2.3.4 Summary 
The results herein presented evidence the great potential of SPME-TM as a tool for fast 
concomitant screening and quantitation of agrochemicals in complex matrices. Limits of 
quantitation in the sub-nanogram per millilitre range were attained. Further, total analysis time did 
not exceed 2 minutes per sample, a remarkable feat considering that SPME-TM probes were 
individually and sequentially introduced to the analysis platform. Unquestionably, further 
development of novel substrates geometries that allow for faster analysis by means of high-
throughput devices131 would reduce the total analysis time to less than 1 minute per sample. 
Although these results are essentially a proof-of-concept, as a next logical step, we foresee in the 
near future the undertaking of an inter-laboratory validation study of SPME-TM for the rapid 
determination of pesticides and others contaminants in food and environmental liquid matrices.283 
Compared with other currently used methods, SPME-TM offers significant advantages, including 
complete elimination of solvents, minimal use of sorbents, method simplicity, and tremendous 
time and labour savings. Certainly, SPME-TM is a technology not limited to DART and it could 
be easily interfaced to other ambient ionization approaches such DESI, LTP, Atmospheric Solids 
Analysis Probe (ASAP)284 or Direct Surface Analysis (DSA)58,209,229. Our work currently focuses 
on the implementation of this technology to portable instrumentation that would allow for on-site 
screening of pesticides65 as well as food profiling for food-fraud investigations.70,285 Similarly, 
further research is focused on the evaluation of rapid on-mesh derivatization methods aimed at 
improving limits of quantitation for poorly-ionisable compounds.286  
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Section 2.4 Towards on-site analysis of complex matrices by solid-phase microextraction-
transmission mode coupled to a portable mass spectrometer via direct analysis in real time 
 
2.4.1 Introduction 
Recently, remarkable research efforts are directed towards development of instruments and 
methods that facilitate the on-site analysis of a system5,9,65. On-site analysis helps to reduce the 
analytical errors associated with sample alteration during storage and transportation, as well as to 
eliminate the time delays and costs associated with these steps287. Preferably, the entire analytical 
process (sampling, sample preparation, and instrumental analysis) should be conducted on-site, as 
doing so favours repeated measurements in space and time and allows for the real time 
characterization of the processes occurring in the investigated system5,288. The ultimate goal of on-
site analysis is to deliver accurate and precise measurements that allow quick decision in critical 
scenarios (e.g. point-of-care applications8 or in-field chemical detection276,289). Undeniably, the 
miniaturization of mass spectrometry (MS) instrumentation has facilitated the development of 
multiple on-site methodologies that can rapidly characterize samples (e.g. profiling) and efficiently 
quantitate target compounds in clinical, forensic, food, and environmental applications9,65,226,244. 
Certainly, ambient ionization technologies, such as direct analysis in real time (DART)53 and low-
temperature plasma ionization (LTP)52,290, have enabled simpler and quicker ways of interfacing 
the system under investigation with these portable mass spectrometers 65. However, the inherent 
lack of sample preparation in these technologies restricts their use in quantitative trace analysis 
(low parts-per-billion, ppb)82,291. Therefore, in addition to instrument portability, another ideal 
feature of an on-site method is the ability to efficiently integrate the sampling strategies prior to 
instrumental quantification.  
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Solid-phase microextraction (SPME) is a technology that proficiently integrates sampling and 
sample preparation into a single step, while also allowing the analyte-enriched device to be 
introduced conveniently into the analytical equipment simply and conveniently via liquid, thermal, 
or laser desorption80,228.  As a matter of fact, on-site analysis via SPME and portable 
instrumentation has been extensively explored for a broad variety of matrices over the past twenty 
years292. A number of different analysers have been tested for this purpose, including flame 
ionization detector (FID), electron capture detector (ECD), dry electrolytic conductivity detector 
(DELCD)292,293, ion mobility163,294, ion trap-MS87 and toroidal-MS146,295,296. As recently 
shown146,286, directly interfacing SPME-based devices (e.g. thin film membranes, needle traps or 
fibres) with portable gas chromatography-MS (GC-MS) systems offers on-site quantitation limits 
in aqueous and air samples (i.e. low/sub-nanogram per millilitre) that are well below what was 
thought possible for field instrumentation. Furthermore, recent results reported by Grandy et al. 
offer an accurate and complete on-site solution for determining contaminants in environmental 
water; however, the total analysis time for this method ranges between 20 and 25 min per 
sample146. Given this, there is still room for improvement in terms of reducing the total analysis 
time. Hence, the goal of this manuscript is to introduce solid-phase microextraction-transmission 
(SPME-TM)192 coupled to a portable mass spectrometer (compact single quadrupole, Waters-
QDA297), via DART, to enable the rapid profiling of samples and the semi-quantitation of trace 
analytes in complex matrices. Although this mesoscale MS system has previously been used with 
ambient ionization approaches in profiling or semi-quantitative applications277,298,299, this is the 
first work where SPME-TM is evaluated as an efficient tool for rapid analyte enrichment (t ≤ 2min) 
prior to analysis by portable mass spectrometers. Essentially, SPME-TM is a device based on the 
transmission mode concept originally reported by Chipuk et al. in which analytes are efficiently 
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transmitted into the MS system via DART and desorption electrospray ionization (DESI)209,229. 
Unlike the standard TM device developed by Fernandez’s group (i.e. bare stainless steel 
mesh)209,300, SPME-TM is a mesh with strands that are exclusively coated with an extractive 
composite phase (e.g. SPE particles, ≤ 10 µm) that can be used to enrich analytes that are present 
in either a gas or a liquid sample192,195,205,301. Our previous work has shown that, when used in 
combination with benchtop instruments (e.g. triple quadrupole and orbitrap), SPME-TM is suitable 
for quantitating target analytes in food, environmental, and biological matrices192,195. This study 
demonstrate that SPME-TM is a green analytical approach195,302 that improves the simplicity, 
sensitivity, and speed of the on-site screening of pesticides in food (grape juice). Furthermore, we 
assess SPME-TM-DART-QDA’s potential as a tool that can provide quasi-real-time molecularly-
resolved information. This information would enable food samples to be examined more rapidly, 
and it could also potentially enable frauds to be identified more efficiently70,276, while at the same 
time minimizing the risk of instrument contamination. As a proof-of-concept, our work focused 
on the analysis of milk samples from diverse animal (cow and goat) and vegetal (almond, coconut, 
and soy) sources303.  
 
2.4.2 Experimental section 
Reagents and materials 
The analytes used in this investigation were purchased from Sigma-Aldrich, and they are listed in 
Tables 2.11 alongside the relevant information pertaining to their hydrophobicity properties (LogP) 
and nominal mass (m/z ratio). Individual stock solutions were prepared in acetonitrile, methanol, 
acetone, and dichloromethane at concentrations ranging from 9 to 15 mg/ml. Working solutions at 
100, 10, and 1 µg/ml were prepared by mixing the analytes in acetonitrile or methanol. The internal 
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standards used for pesticide analysis—namely, atrazine-d5, metalaxyl-d6, and cyprodinyl-d6—
were purchased from Toronto Research Chemicals (Toronto, ON, Canada). Stock solutions of the 
internal standards were prepared in acetonitrile at a concentration of 1 mg/ml for atrazine-d5 and 
metalaxyl-d6, and at a concentration of 5mg/ml for cyprodinyl-d6. A working solution composed 
of all the internal standards was prepared in acetonitrile at 100 µg/ml. Samples of Concord grape 
juice, almond milk, coconut milk, soy milk, goat milk, and cow milk (2% , Milk Fat, M.F.) were 
purchased from local grocery stores (Waterloo, ON, Canada). The samples were prepared by 
spiking them with appropriate amounts of analytes and internal standards, while ensuring that the 
total amount of organic solvent added never exceeded 1% (v/v) of the total amount of matrix. The 
spiked samples were equilibrated for at least two hours at 1500 rpm to guarantee that equilibria 
between the analytes and matrix components were established, thus obtaining samples that closely 
represent real contamination scenarios. SPME-TM devices were manufactured in-house using 
stainless steel mesh (74 x 74 mesh per in, wire diameter 0.0037 in). The mesh’s strands were 
precisely coated with a biocompatible polymer (slurry of 5 µm hydrophilic lipophilic balance 
(HLB) particles and polyacrylonitrile as a binder) at a thickness of less than 20 µm and a length of 
1 cm. As previously reported in Section 2.2 151,304, HLB particles were selected with the objective 
of providing wider analyte balance coverage. 
 
Mass Spectrometry 
A DART-Standardized Voltage and Pressure (DART-SVP) model ion source (IonSense, Saugus, 
MA USA) was coupled to a single-quadrupole mass spectrometer (ACQUITY QDa; Waters 
Corporation, Manchester, UK) via a Vapour® interface (IonSense, Inc.).The DART-SVP was fitted 
with a single-dimensional motorized linear rail that was controlled with the DART-SVP web-based 
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software so as to reproducibly and consecutively automatically position the SPME-TM devices in 
front of the DART source (a speed of 0.2 mm s-1 was used). To guarantee good reproducibility and 
higher throughput in the desorption process, a custom-made holder (UW-12) that could allocate 
up to twelve SPME-TM devices was used. The DART source was operated under the following 
conditions: positive ion mode; a high-voltage electrode set at -3000 V; a discharge electrode set at 
+350 V; and a grid voltage of +350 V. The gas heater was set to 350 °C, which yielded the optimum 
intensities for the majority of the analytes that were analysed.  
Figure 2.20 Schematic representation of the analytical workflow for analysis of complex matrices 
by Solid-Phase Microextraction-Transmission Mode (SPME-TM) coupled to a portable mass 
spectrometer (Waters-QDA) via Direct Analysis in Real Time (DART). 
 
Sample preparation 
As shown in Figure 2.20, the analytical procedure consisted of four simple steps. First, the SPME-
TM devices were rinsed (10 s) in water to eliminate any organic solvent residue (from the 
preconditioning step) that could potentially affect the enrichment capabilities of the devices. 
Second, the SPME-TM devices were exposed to the sample matrix (1.5 ml for grape juice or milk), 
and extraction was carried out for 1 min using vortex agitation (i.e. 3200 rpm). In the third step, 
the SPME-TM devices were quickly rinsed (10s) in water to remove any loosely attached matrix 
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constituents that could either be irreversibly carbonized on the coating surface during the 
desorption process, induce ion enhancement/suppression, or cause instrumental contamination. 
Lastly, SPME-TM devices were positioned in the UW-12 holder and thermally desorbed. The total 
analysis time for 1 sample was less than 2 min. 
 
2.4.3 Results and discussion 
Semi-quantitative analysis of pesticides in grape juice 
Recently, we demonstrated that SPME-TM via DART is a suitable technology for rapidly 
quantitating pesticides in diverse liquid food matrices195. However, in spite of the speed and 
sensitivity attained, our method is not suitable to provide an analytical answer on-site, as the 
experiments were performed using high-end benchtop mass spectrometers such a triple 
quadrupole-MS or Orbitrap-MS. In this study, we explored whether a compact single-quadrupole 
mass spectrometer (Waters QDA) was a suitable tool for the semi-quantitative analysis of seven 
pesticides from different classes and with different molecular weights and polarities; namely: 
pyrimethanil, atrazine, cyprodinil, metalaxyl, imazalil, pyraclostrobin and azoxystrobin. Figure 
2.21 depicts the typical mass spectrum attained after 1 min of extraction from 1.5 mL of grape 
juice that had been spiked with 100 ng mL-1 of each standard. The red colour bars identify the 
target analytes (7), while the blue colour bars identify the internal standards (3). It is important to 
note that isotopically-labelled internal standards for pesticides are either expensive or non-existent 
for each targeted pesticide. Hence, the calibration curves for all of the analytes were constructed 
using the 3 available internal standards on the basis of the signal ratio and the internal standard 
(A/Is) for 9 concentration levels in three independent replicates from 5 ng·mL-1 to 500 ng·mL-1.  
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Figure 2.21 Mass spectrum profile obtained on a Waters-QDA after 1 min extraction from 
Concord grape juice spiked with pesticides at 500 ng mL-1. Red bars represent the analytes of 
interest, while blue bars represent the internal standards listed in Table 2.11. 
 
Figure 2.22 Semi-quantitative analysis of Concord grape juice spiked with the following 
pesticides: (A) cyprodinil (15 ng ml−1 to 350 ng mL−1); (B) imazalil (15 ng ml−1 to 500 ng mL−1); 
(C) metalaxyl (15 ng ml−1 to 350 ng mL−1); and (D) pyrimenthanil (25 ng ml−1 to 500 ng mL−1). 
Metalaxyl-d6, cyprodinil-d6, and atrazine-d5 were used as internal standards and were spiked at a 




Figure 2.23 Semi-Quantitative analysis of Concord grape juice spiked with the following 
pesticides: (A) atrazine (15 ng ml−1 to 350 ng mL−1); (B) pyraclostrobin (25 ng ml−1 to 500 
ng mL−1); and (C) azoxystrobin (25 ng ml−1 to 500 ng mL−1). Atrazine-d5 was used as the internal 
standard, and it was spiked at a fixed concentration in all samples (100 ng mL−1). 
 
 
Table 2.11 Figures of merit for the semi-quantitation of several pesticides in Concord grape juice 
by using Solid-Phase Microextraction-Transmission Mode (SPME-TM) coupled to a portable 
mass spectrometer (Waters-QDA) via Direct Analysis in Real Time (DART). 
 
As can be seen in Figures 2.22 and 2.23 good linearity (R2 ≥ 0.998) was attained for all the 















Pyrimenthanil 2.8 Atrazine-d5 10 10 25 102 1.2 
Atrazine 2.7 Atrazine-d5 10 5 15 106 2.3 
Cyprodinil 4.0 Cyprodinil-d6 10 5 15 95 0.6 
Metalaxyl 1.7 Metalaxyl-d5 10 5 15 103 1.2 
Imazalil 2.6 Cyprodinil-d6 10 5 15 93 5.0 
Pyraclostrobin 4.3 Atrazine-d5 10 10 25 122 15 
Azoxystrobin 2.5 Atrazine-d5 10 10 25 103 28 
* Data source: http://www.chemspider.com/ 
**  REGULATION (EC) NO 396/2005 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 23 February 
2005 on maximum residue levels of pesticides in or on food and feed of plant and animal origin and amending Council 
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adequate accuracy (93-122%) and precision (0.6-15 %) were attained for the majority of the 
compounds at the validation point of 100 ng mL−1 (see Table 2.11). Although the LOQ reached for 
all the pesticides was above 15 ng mL-1, the limits of detection (LOD; 5-10 ng mL-1) were  less 
than or equal to the maximum residue levels (MRLs) allowed for most food commodities under 
the regulations set forth by the European Parliament (European Regulation (EC) N˚ 396/2005) (i.e. 
10 ng mL-1). Given that we were previously able to attain LOQ below 0.25 ng mL-1 for all the 
selected compounds while using the same enrichment time195, the higher LOQ achieved in this 
study can be attributed to the lack of selectivity offered by a single MS event. However, taking 
into account the speed of analysis and the manoeuvrability offered by the DART-QDA system, the 
LOQ obtained in the present study can be considered satisfactory (i.e. 15-25 ng/mL). Thus, aiming 
to enhance LOQ offered by our prospective on-site protocol, the analyst could either increase the 
extraction time (e.g. 5 min), or the sample volume (e.g. 10 mL of sample), or both, as to assure 
that a larger amount of analyte is collected on the coating.  
Nonetheless, it is important to keep in mind that lowering the LOQ may also result in lowering the 
upper limit of quantitation. For instance, as shown in Figure 2.24, our results showed that a 
continuous increase in the amount of target analyte extracted on the coating (i.e. increase on 
analyte signal) led to a continuous decrease in the internal standard signal, thus limiting the upper 
linearity of atrazine’s calibration curve. These results suggest a potential saturation of the detector 
or ionization source. Hence, in developing a method for on-site analysis using the proposed system, 
one should be aware that there may be limitations in interpreting the data that will be generated. 
Furthermore, this observation suggests that the internal standard should be spiked on the sample 
in approximately the middle/upper part of the targeted concentration range to account for a 
decrease in signal. 
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Figure 2.24 Semi-quantitative analysis of Concord grape juice spiked with atrazine: (A) atrazine 
(15 ng ml−1 to 350 ng mL−1); (B) atrazine (15 ng ml−1 to 500 ng mL−1); and (C) raw data of atrazine 
(pink diamonds) and atrazine-d5 (blue circles). Atrazine-d5 was used as the internal standard, and 
it was spiked at a fixed concentration in all samples (100 ng mL−1). 
 
 
Milk profiling  
As recently demonstrated by Hajslova’s and Fernandez’s groups77,300,305, one cannot place the 
matrix under study directly onto the transmission mode mesh for thermal desorption, as doing so 
could result in thermal degradation of the sample, mass spectrometer contamination, and dramatic 
ion suppression. Consequently, profiling studies that use TM-DART-MS typically require a sample 
pre-treatment approach such liquid-liquid extraction, lyophilisation, or protein precipitation. 
Nevertheless, the abovementioned steps take at least 15-20 min per sample. Given that SPME-TM 
efficiently integrates both the sample preparation device and the interface with the ambient mass 
spectrometry source, we propose SPME-TM-DART-QDA as a feasible approach for rapid, on-site, 
and high-throughput profiling.  
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Table 2.12 Nutritional facts of tested milks for untargeted molecular profiling. 
Samples Fat* (g) Carbohydrate* (g) Sodium* (mg) Protein (g) 
Coconut milk  #1 4.5 1 35 0 
Coconut milk  #2 4.7 1 26 0 
Coconut milk  #3 5.2 1 156 0 
Cow milk  #1 5 13 110 8 
Cow milk  #2 5 12 100 5 
Cow milk #3 5 12 100 9 
Cow milk #4 5 12 110 9 
Goat milk #1 5 11 100 7 
Almond milk #1 2.5 <1 160 1 
Almond milk #2 2.5 13 180 1 
Almond milk  #3 3 1 110 1 
Soy milk  #1 4 8 90 6 
Soy milk  #2 4 4 75 7 
Soy milk  #3 4 8 115 1 
 
Since milk fraud is one of the most serious issues currently facing the dairy industry, we elected 
to evaluate the system’s ability to discriminate between milk samples originating from different 
species and farming systems as proof-of-concept303. Essentially, we performed 1 min extraction 
from 1.5 mL of sample prior to DART analysis using the same instrumental conditions as in the 
previous two trials. Different kinds of milk samples (soy, almond, coconut, goat and cow milk) 
from diverse manufacturers were selected for this trial (see Table 2.12 for further details). After 
DART-QDA acquisition (see mass spectra profiles for each kind of matrix on Figure 2.25), the raw 
data was processed using XCMS. The peaks were extracted using the ‘matchFilter’ method and 
then grouped via the ‘density’ method306–308. Univariate data analysis was completed using 
MetaboAnalyst 3.0 and PCA plots were attained after the data had been normalized using the 
median, log transformation, and pareto scaling. As can be seen in Figure 2.26, our results showed 
that 1 min of extraction from each milk sample was sufficient to reach clustering according to the 
respective matrix category. Additionally, Figure 2.27 presents the random forest plot and its 
























Figure 2.25 Mass spectra profile obtained after 1 min extraction from 1.5mL of (A) coconut, (B) 

























Figure 2.25 (continuation) Mass spectra profile obtained after 1 min extraction from 1.5mL of 










Figure 2.26 Three-dimensional PCA plot for identification of milk samples from different species 
and farming systems. Letters on the figure denote the milk type investigated: (A) almond milk, (C) 
cow milk, (CT) coconut milk, (G) goat milk, (QC) quality control-sample-mix, and (S) soy milk. 










Figure 2.27 Cumulative error rates by Random Forest classification. The overall error rate is 
shown as the black line; the red and green lines represent the error rates for each class. Table on 
figure presents the confusion matrix of random forest. The out-of-bag (OOB) error is 0.0213. 
Figures and table were generated using MetaboAnalyst 3.0. 
Class A C CT G QC S
Class 
Error
A 8 0 0 0 0 0 0
C 0 11 0 0 0 0 0
CT 0 0 9 0 0 0 0
G 0 0 0 6 0 0 0
QC 0 0 0 0 4 1 0.2
S 0 0 0 0 0 8 0
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Although these results prove this technology’s feasibility for rapid sample identification (out-of-
bag (OOB) error ≤ 0.0213), further work with larger data sets is required for it to be thoroughly 
validated. 
 
2.4.4 Summary  
Our experimental results demonstrate the suitability of SPME-TM for on-site semi-quantitative 
analyses of target analytes in complex matrices via DART coupled to portable mass spectrometry. 
In spite of lacking of a separation step (either chromatographic or ion-mobility) or MS/MS-
fragmentation features (only in-source collision-induced dissociation feature is available) on this 
MS system, semi-quantitative results in the ranges required by the regulatory agencies were 
obtained when analysing pesticides in grape juice (LOD ~ 5 ng/mL and LOQ ~ 15 ng/mL). It is 
important to highlight that further improvements in LOQ can be attained by modifying the 
experimental conditions outlined in this section (e.g. using larger sample volumes or longer 
extraction times). Additionally, we demonstrated the suitability of SPME-TM-DART-QDA to 
perform profiling studies of complex matrices such as milk from different species and farming 
systems. Our preliminary results showed that, when combined with real-time recognition software, 
the proposed profiling methodology has great potential for field applications in which fast sample 
screening and identification with minimal sample preparation is required68,79. Undeniably, further 
improvements in MS miniaturization (i.e. smaller and more sensitive devices)65, as well as in 
sample preparation devices that are more efficient and selective113, will facilitate the transfer of 
these technologies from the hands of experts and into those of non-conventional users, such as 




Chapter 3 Development of Novel SPME-MS interfaces suitable for in-vivo and 
on-site analysis 
 
3.1 Preamble  
Chapter 3 consists of 4 sections that correspond to an equal number of manuscripts published in 
Analytical Chemistry (2), Angewandte Chemie, and Analytica Chimica Acta. Most of the data, 
tables, and text presented within this chapter have already been incorporated in the aforementioned 
manuscripts, the details of which are listed below. For instance, section 3.2 describes the first 
coupling of Biocompatible SPME (Bio-SPME) fibers to MS via nanoelectrospray ionization 
(nanoESI) for the analysis of xenobiotics in diverse biofluids such urine, plasma, and blood. 
Section 3.3 introduces novel mini-SPME devices (SPME tips) used towards the analysis of sample 
volumes under 10 µL. In view of the current limitations of SPME-nanoESI, section 3.4 introduces 
SPME coupled to MS via open port probe (OPP) as a robust and easy-to-use interface. The 
technology was examined for the simultaneous quantitation of buprenorphine and fentanyl in urine 
samples. Aiming to improve the selectivity of this method, which is lost due to the absence of a 
chromatographic separation step, this section presents an assessment of Multiple Reaction 
Monitoring with Multistage Fragmentation (MRM3) for the quantitation of clenbuterol in urine 
samples. Finally, section 3.5 embraces the use of differential mobility spectrometry (DMS) as 
another on-line technology to enhance analyte selectivity and sensitivity in SPME-MS 
experiments. This technology was evaluated for the quantitation of codeine and hydrocodone, two 
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Section 3.2 Biocompatible Solid-Phase Microextraction Nanoelectrospray Ionization: An 
Unexploited Tool in Bioanalysis 
 
3.2.1 Introduction 
The capability of scrutinizing samples without sample pre-treatment, or with minimum sample 
preparation, is the key feature of ambient mass spectrometry (AMS) that has promoted its use 
around the globe46,58, comprising a variety of applications from monitoring chemical 
transformations309 up to discerning between healthy and cancerous tissues at the surgery room61. 
However, no technique is perfect, and predictable limitations of pure AMS when analysing 
complex matrices such as blood and urine (e.g. ionization suppression, poor sensitivity at trace 
levels, and narrow linear dynamic range), prompted the development of methods that efficiently 
integrate sample clean-up, analyte extraction/enrichment, and ionization82,102,136,218,267,310. This 
modern era of mass spectrometry (MS), where sample preparation devices are directly coupled to 
MS instrumentation, is certainly a growing branch where micro- and nano-extraction approaches 
excel. Some of the most relevant methods recently developed in this field include the use of micro-
solid phase extraction (SPE)102,110,311, slug-flow microextraction (SFME)82, single drop 
microextraction (SDME)105, liquid phase microextraction (LPME)106,108, membrane 
extraction107,218, and polymer monolith microextraction (PMME)310. Solid Phase Microextraction 
(SPME), a world-wide recognized green sample preparation technique for GC118 and 
LC2,123,131,148,271,312,313 applications, certainly was not left behind314. As a matter of fact, the direct 
coupling of SPME fibres to MS instrumentation is not new, and it has been explored for almost 
two decades81,180,210 (i.e. earlier than most popular AMS methods were reported52,53). Currently, 
diverse geometrical configurations of SPME have been coupled to mass spectrometry for a broad 
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range of applications including food, environmental and bioanalytical81,136,267. Surprisingly, to the 
best of our knowledge, few have exploited the genuine potential of the most known configuration 
of SPME: the fibre182. In this study, we present the direct coupling of biocompatible-SPME (Bio-
SPME) fibres152,182,242,313,315 to mass spectrometry via nano-ESI emitters as an useful tool for 
screening and quantitative analysis of small molecules present in samples of bioanalytical 
relevance. Major advantage of matrix compatible SPME devices that no matrix components, which 
can potentially block the nanospray opening, are introduced to the emitter.  
 
3.2.2 Experimental Section 
Mass Spectrometry 
Experiments were performed with the use of a triple quadrupole mass spectrometer TSQ Vantage 
(Thermo Scientific, San Jose, USA). Nano-electrospray emitters: Econotip (Econo10, 1.0/0.58 
OD/ID, mm), coated Glasstip (1.0/0.58, OD/ID, mm; 1 and 2 μm tip), were obtained from New 
Objective Inc. (Woburn, MA, USA). An in-house ionization source was built at the machine and 
electronic shop of the University of Waterloo (see Figure 3.1) to accurately position nano-ESI 
emitters in front of the mass spectrometer. 
 
Reagents and materials 
The following compounds were selected as model analytes to evaluate BioSPME-nanoESI: 
cocaine, diazepam, salbutamol, codeine, oxycodone, methadone, amitriptyline and imatinib. 




Table 3.1 Target analytes, manufacturer, and SRM transitions monitored for each model compound in positive ionization mode. 








Diazepam Cerilliant 1 PBS 2.91 98 285.050 193.113 32 102 
Diazepam-d5 Cerilliant  PBS - - 290.075 198.179 33 113 
Cocaine Cerilliant  PBS 3.08 5 304.122 182.139 19 90 
Cocaine-d3 Cerilliant  PBS - - 307.140 185.190 20 91 
Methadone Cerilliant  Urine 4.20 90 310.189 265.281 14 82 
Methadone-d3 Cerilliant  Urine - - 313.199 268.304 15 77 
Codeine Cerilliant  Urine 1.20 - 300.136 152.146 63 124 
Codeine-d3 Cerilliant  Urine - - 303.139 152.135 64 118 
Salbutamol Cerilliant  Urine 0.01 - 240.146 148.179 17 70 
Salbutamol-d3 Cerilliant  Urine - - 243.144 151.170 19 67 
Oxycodone Cerilliant  Urine 1.67 45 316.121 241.215 29 100 
Oxycodone-d3 Cerilliant  Urine - - 319.140 244.246 28 100 
Amitriptyline Sigma-Aldrich 2 Blood 4.92 ≥ 90 278.148 233.461 16 86 
Amitriptyline-d6 TRC 3 Blood - 
 
284.140 233.473 19 82 
Imatinib  Sigma-Aldrich Blood 2.48 95 494.180 394.790 26 123 
Imatinib-d3 TRC Blood - - 497.204 394.785 28 128 
 
1. Cerilliant (Round Rock, TX, USA), 2. Sigma-Aldrich (Sigma-Aldrich (Oakville, ON, Canada), 3.TRC, Toronto Research Chemicals 
(Toronto, ON, Canada); Log P, logarithm of its partition coefficient between n-octanol and water. Dwell time was 100 ms for all the 
analytes with a total spraying time of 45 seconds per replicate at 1.3 kV and 3 mm from the MS ion-transfer capillary. All the experiments 







Figure 3.1 In-house ionization source for Bio-SPME-nano-spray. The 3D-moving stage (Newport 
Corporation, Irvine, CA) not only adjust the position with a precision of 0.02 mm in each 
dimension (25 mm moving path), but also tunes the spraying tip at different angles on the Z 
dimension (± 0.01º per moving mark). In order to ensure optimum ion transmission, the nano-
spray emitter was position at 3 mm from the ion-transfer capillary.  
 
Further details about compounds suppliers, properties, and SRM transitions are provided on Table 
3.1. LC-MS grade solvents (acetonitrile, methanol, and water) used in all the experiments were 
purchased from Fischer Scientific. Biocompatible SPME mixed mode probes (i.e. C18-SCX 
particles, 45 μm thickness, 15 mm coating length) were kindly provided by Supelco (Bellefonte, 
PA, USA). The phosphate-buffered saline solution (PBS) (pH 7.4) was prepared according to the 
procedure listed in Section 2.2.2. Pooled whole blood from healthy donors in potassium (K2) 
ethylenediaminetetraacetic acid (EDTA) was purchased from Bioreclamation IVT (Baltimore, 
MA, U.S.A.). Urine samples were collected from two healthy volunteers (one female and one 
male). Collection of urine from healthy volunteers for this particular study was under the approval 




3.2.3 Results and Discussion 
Rediscovering SPME-MS: Bio-SPME-nano-ESI, a new era   
The direct interface of SPME fibres with MS analyzers has been investigated since the late 
1990s180,316. For this purpose, different strategies have been followed by several groups around the 
world. Some of the most relevant approaches involve placing the fibre at the electron impact region 
of the MS87, thermally desorbing the fibres prior to Inductively Coupled Plasma-MS (ICP-MS) 
analysis165, desorbing the fibres in a solvent with high affinity for the analytes of interest preceding 
atmospheric pressure ionization (API), either by ESI181or APCI172, ablating the analytes from the 
fibre surface with a laser either at vacuum317 or at atmospheric pressure175–177, and interfacing the 
fibres with AMS instrumentation, for instance DESI179,203 or DART206,207. Although initial 
attempts to couple SPME fibres to MS using small desorption volumes were performed more than 
10 years ago (Vdes ≤ 10 µL, via nano-ESI210 or substrate spray316), recent endeavors have been 
focused on either developing new SPME-fibre based substrates136,211,216 or desorbing SPME fibres 
on a large desorption/ionization chamber (Vdes ≥ 100 µL)182. For example, in a recent work 
reported by Ahmad et al.182 an innovative approach to couple SPME to MS was proposed; 
however, given that the volume of the desorption chamber was greater than the optimum, the 
enrichment factor provided by Bio-SPME was not fully exploited. With the aim of taking 
advantage of the pre-concentration offered by SPME, this work continues the approach initially 
proposed by Walles et al.210 In essence, it is intended to demonstrate that by using Bio-SPME 
fibres together with small desorption volumes117,211 (i.e. Vdes ≤ 4 µL, on nano-ESI 
emitters82,111,318,319) remarkably low detection limits and satisfactory figure of merit can be attained 
with exceedingly short sample preparation times136,267. We used a home-made 
desorption/ionization that comprised a holder, in which a ball-end clamping screw enabled 
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straightforward connection of high voltage (HV) to the nano-ESI emitter, and ready and fast 
replacement of emitters between experiments (Figure 3.1). We used commercial emiters in order 
to make it easier for others to reproduce our method; we do, however, expect to improve 
performance using custom-made parts instead in the near future. Custom-made coatings113,242 and 
emitters111,319 enabling to tune the protocols for given applications even further are also expected 
to be used in near future.  
The analytical workflow consisted of four main steps: extraction/pre-concentration, rinsing, 
desorption, and ionization (Figure 3.2). First, a preconditioned Bio-SPME fibre was inserted in a 
vial containing the sample matrix (e.g. Vext ~ 10–1500 μL), and quick extraction/enrichment of the 
analytes was performed by agitating the sample at high speed (agitation at 3200 rpm, t≤ 2 min). 
Then, the fibre was rinsed in a vial containing LC/MS grade water (t ≤ 15 s) in order to remove 
matrix components that could potentially adhere to the coating surface. Subsequently, the fibre 
was introduced into an emitter prefilled with desorption solution. Lastly, and after allowing some 
time for the analytes to be desorbed in the selected solvent, a high electrical field between the 
emitter and the mass spectrometer was applied, and analytes were ionized via electrospray 
mechanisms52,82,318. 
Figure 3.2 Experimental set up for Bio-SPME extraction from complex matrices and desorption–
ionization using nano-ESI-MS/MS.  
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When optimizing SPME-nano-ESI desorption/ionization conditions, several factors should be 
taken into consideration. Some of the most important parameters include a) the chemistry of the 
target molecule, and its affinity for the coating and for the desorption solution; b) analyte 
desorption kinetics into a particular solvent; c) the geometrical characteristics of the emitter and 
its ionization efficiency136,318,319; and d) position relative to the mass spectrometer entrance. In 
regards to the SPME extraction phase, mixed mode was selected for this study due to its better 
performance when extracting polar analytes compared to C18. Emitter selection was performed 
according to its internal volume (i.e. small as possible to enhance the enrichment factor115, but 
large enough that fiber could freely move in and out the emitter without being damaged), spray-
current stability, intra- and inter-experiment reproducibility, and its cost. Among the studied 
emitters described in the experimental section, Econo10 provided the best compromise in terms of 
inter-analysis reproducibility/stability (Table 3.2) and price (i.e. ~ 6 US dollars per analysis).  
Table 3.2 Inter-emitter reproducibility of commercial emitter commercialized by New Objective 
suitable for Bio-SPME-nano-ESI experiments. RSD, Relative Standard Deviation (n=3).   
Compound 
RSD [%] n=3 
Econo10 BG75-2 BG75-4 
Cocaine 6.1 5.8 6.1 
Cocaine-d3 6.0 5.5 6.0 
Ratio 0.2 0.4 0.2 
Diazepam 3.3 12.7 3.3 
Diazepam-d5 2.0 11.3 2.0 
Ratio 2.0 1.5 2.0 
 
All the experiments herein reported were performed using the aforementioned glass coated 
emitters (1.0/0.58 mm, OD/ID) filled with few microliters of acidified methanol (i.e. 0.1% formic 
acid) unless otherwise stated. Desorption volumes were set according to the length of the coating, 
always ensuring that the whole coating was completely immersed into the solvent (e.g. 4 µL for 
15 mm fibres and 1 µL for 4 mm fibres). Considering the small tip size of these emitters (1 ± 0.5 
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µm), and aiming to prevent clogging and unstable spray-current, desorption solvent was filtered 
and degassed with helium prior to analysis.  
Here, it is important to highlight that a slightly dry Bio-SPME fiber, for example, due to an 
excessive delay time preceding its introduction into the emitter, could be per se a significant source 
of bubbles that can distort the Taylor-cone formation and electrospray ionization320. Based on our 
experience, if the delay-time between the fibre rinsing step and its insertion into the emitter is 
longer than 30 seconds, bubble generation inside the emitter (Figure 3.3) can be anticipated as a 
result of microscopic dry spots/pores on the coating. This could be related to the low intrinsic 
wettability of the C18-SCX particles used to manufacture mixed-mode Bio-SPME fibres123. 
Consequently, for all the experiments described in this manuscript, stable electrospray was 
guaranteed by using short fibre transition times from the rinsing vial to the nano-ESI emitter (ttrans 
≤ 15 s). Indeed, when the affinity of the coating for the target analyte is high (i.e. large fibre 
constant, Kfs2,115,118), as well as the analyte hydrophobicity113,131,152, fibres can be transported to the 
emitter inside the rinsing vessel with minimal/negligible analyte losses, thus preventing bubble 
Figure 3.3 15 mm dry SPME fibre (A) versus wet SPME fibre (B) inserted into a nano-ESI emitter 




formation due to dry surface. An alternate solution to this problem would be the use of coatings 
with better water-wettability123, such as HLB (m-divinylbenzene and n-vinylpyrrolidone 
copolymer), and/or substrates with lower thermal conductivity, so the evaporation rate of the water 
is slower and the coating particles remain wet for longer times321.  
Given the slow flow rates inherent in nano-ESI (i.e. 20-80 nL min-1; depending on solvent 
composition, voltage applied, and emitter tip architecture322,323), 4 µL of desorption solvent is 
enough to perform at least four instrumental replicates per fibre from a single emitter (Figure 3.4). 
Desorption time (tdes ≤ 5 min) was selected in such a way that the monitored ion signal was 
reproducible between consecutive replicates (i.e. RSD ≤ 15 %, n =4, calculated using the area 
under the curve for each repetition as shown in Figure 3.4 and Table 3.3). In essence, a steady 
signal among experimental replicates means that the partitioning equilibrium between the fibre 
coating and the desorption solvent was reached and, consequently, it could be assumed that the 
amount of analyte in the desorption solvent is not statistically changing over the time. However, 
this does not necessarily mean that total desorption of the analyte extracted has been achieved. The 
amount of analyte desorbed from the fibre is certainly dependent on the strength and, in this 
particular approach, on the volume of the desorption solvent 117. Undeniably, fibre desorption is 
the bottleneck step in the entire analytical process herein proposed. Given that the desorption time 
is selected based on the desorption kinetics of the analyte117 and this depends, in addition to the 
affinity of the analyte for the coating, on the coating thickness and the agitation/thermal conditions 
in the desorption vessel, our current efforts are focused on the development of thinner fibre 
coatings (e.g. thickness ≤ 10 μm; mono or dual-layer coatings115,267), a heated desorption chamber 
(i.e. to decrease Kfs117 and increase the diffusion coefficient of the analytes324), and a fibre vibration 
system, such the desorption step keeps pace with the entire analytical workflow.  
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Figure 3.4 Cocaine ion-chronograms obtained using the same nano-ESI emitter (n=4). Signals 
correspond to 1 min extraction from 1.5 mL of PBS spiked with 75 ng mL-1 of the analyte. 
Extractions were performed using a 15 mm BioSPME mix mode fibre. The desorption volume was 
4 µL and the desorption time was 5 minutes. Spraying voltage was 1.3 kV with an acquisition time 
of 0.9 min.    
 
Table 3.3 Experimental replicate using a single nano-ESI emitter. (n=4). Signals correspond to 1 
min extraction from 1.5 mL of PBS spiked with 75 ng mL-1 of the analyte. Extractions were 
performed using a 15 mm Bio-SPME mix mode fibre. The desorption volume was 4 µL and the 
desorption time was 5 minutes. Spraying voltage was 1.3 kV with an acquisition time of 0.9 min.    
Compound 
Replicate [area counts, au] 
Average SD RSD [%] 
2 3 4 
Diazepam 25026413 27691475 29623102 27446997 2308076 8.4 
Diazepam-d5 4120991 4486829 4756566 4454795 318996 7.2 
Ratio 6.1 6.2 6.2 6.2 0.08 1.3 
Cocaine 177866820 175990773 173211262 175689618 2342344 1.3 
Cocaine-d3 31055950 29983291 29548704 30195982 775806 2.6 
Ratio 5.7 5.9 5.9 5.8 0.08 1.4 
 
Bio-SPME-nano-ESI-MS/MS: an unexploited tool 
Not long ago, sample-preparation techniques directly coupled to MS were were avoided, because 
they were considered laborious58. In addition, for some microextraction techniques such SPME, 
the quantitation capabilities and throughput of the analysis was questioned due to the low analyte 
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recoveries and the long extraction times needed to achieve practical detection limits136. In contrast 
to what is normally believed, recent developments have demonstrated that different geometries of 
SPME not only allow quantitative analysis from complex matrices at trace levels (i.e. pg mL-1 
levels), but also in short periods of time (text ≤ 1 min)136,267.  Up to date, the quantitation potential 
of Bio-SPME fibres has not been exploited to its maximum113,182,242, considering that during the 
desorption (inherent of SPME–LC methods), analytes are significantly diluted and non-efficiently 
ionized117. Herein, as a proof of concept, we demonstrated that Bio-SPME-nano-ESI can reach 
limits of quantitation (LOQs) of 34 and 100 pg mL-1 upon 1 min extraction from 1500 µL of PBS 
spiked with cocaine and diazepam, respectively (calibration functions were constructed on the 
basis of the signal ratio of the analyte and its isotopologue (A/Is) in three independent experiments; 
Figure 3.5). Furthermore, exceptional linearity in the range of 50 pg mL−1 up to 1 μg mL−1, and 
outstanding accuracy (i.e. 87-98 %) at three different levels (i.e. 0.3, 7.5 and 200 ng mL−1) was 
attained (see Table 3.4).  
Certainly, higher concentration levels are not a limitation for Bio-SPME fibres. Thus, in cases 
where the affinity of the coating for the analytes is high, and analytes are present at concentrations 
larger than 100 ppb, shorter extraction times (≤ 1 min) could be used. Although the best 
combination of desorption/ionization conditions for SPME-nano-ESI (e.g. strength of desorption 
solution, emitter size, and fibre thickness) were not investigated in this study, the results obtained 
were rewarding113,118,182. Certainly, design of experiments (DOE)311 would aid not only to improve 



















Figure 3.5 A. Quantitative analysis of PBS spiked with cocaine (50 pg ml−1 to 10 ng mL−1) and its 
isotopologue [D3] cocaine (12 ng mL−1). B. Quantitative analysis of PBS spiked with diazepam 
(10 ng ml−1 to 1 µg mL−1) and its isotopologue [D5] diazepam (12 ng mL−1). Bars represent the 
standard deviation of analyses for three replicates with independent fibres and nano-ESI emitters. 
Red triangles represent the accuracy levels evaluated for both compounds.  
 
Table 3.4 Figures of merit, concomitant analysis of diazepam and cocaine in PBS. 
Compound  
Accuracy concentration Level (%) LOD 
[pg/mL] 
LOQ 
[pg/mL] 300 [pg/mL] 7.5 [ng/mL] 200 [ng/mL] 
Diazepam 91 ± 3.9 97 ± 0.1 98 ± 0.9 34 102 
Cocaine 92 ± 2.3 97 ± 1.3 87 ± 2.9 11 34 
 
Analysis of controlled substances in urine samples 
Due to the non-invasive sample collection and the typically large sample volumes available, urine 
is the most traditional matrix employed when monitoring abuse of illicit drugs325 or doping in 
sport326. Since the amount of parent drug excreted in urine is typically low (e.g. parent drug could 
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be metabolized by the liver), analytical methods capable of providing sensitive analysis in the sub-
ng per millilitre levels are needed110,148. Recently, Boyacı et al.148 and Reyes-Garcés et al.123,131 
demonstrated that different geometrical formats of SPME were capable of meeting the Minimum 
Required Performance Levels (MRPL) set by the World Anti-Doping Agency (WADA) for the 
analysis of prohibited substances in urine. As a proof-ofconcept, we present the application of Bio-
SPME fibres coupled to nanoESI-MS/MS for the determination of salbutamol, codeine, 
oxycodone, and methadone in urine. As can be seen in Figure 3.6 and Table 3.5, 1 minute 
extraction from 700 μL of urine was sufficient to achieve LOQs ranging between 100 and 500 pg 
mL-1. As a matter of fact, LOQ values not only were below the MRPL levels (i.e. 50-100 ng mL-
1)148,325, but also rewarding correlation coefficients (>0.999) were observed for all the probes in 
the range evaluated (i.e. 100 pg mL-1 up to 500 ng mL-1; see Figure 3.6). Since SPME derives its 
sensitivity and selectivity from the physicochemical/geometrical characteristics of the coating 
used, current research is directed towards the development of thinner coatings with greater affinity 
for the target analytes (e.g. HLB131), aiming to provide lower limits of detection without 
compromising total analysis time136. Although it was not evaluated in this manuscript, we foresee 
that SPME-nanoESI in combination with tandem-mass/high-resolving-power instruments could 
be used for the simultaneous screening of multiple controlled substances in a single 
analysis123,131,136,148,267.  
Table 3.5 Figures of merit, concomitant analysis of salbutamol, codeine, methadone, and 
oxycodone in pooled urine. 
Compound  
Accuracy concentration Level (%) 
LOD [ng/mL] LOQ [ng/mL] 
2.5 [ng/mL] 75 [ng/mL] 
Salbutamol - 90 ± 1.4 1.1 3.3 
Codeine - 89 ± 1.2 2.1 6.4 
Methadone 90 ± 1.8 89 ± 1.4 0.1 0.2 





Figure 3.6 A. Quantitative analysis of urine spiked with methadone (100 pg ml−1 to 5 ng mL−1) 
and its isotopologue [D3] methadone (10 ng mL−1). B. Quantitative analysis of urine spiked with 
codeine (1 ng ml−1 to 500 ng mL−1) and its isotopologue [D3] codeine (12 ng mL−1). C. 
Quantitative analysis of urine spiked with salbutamol (1 ng ml−1 to 500 ng mL−1) and its 
isotopologue [D3] salbutamol (10 ng mL−1). B. Quantitative analysis of urine spiked with 
oxycodone (1 ng ml−1 to 500 ng mL−1) and its isotopologue [D3] oxycodone (12 ng mL−1). Bars 
represent the standard deviation of analyses for three replicates with independent fibres and nano-
ESI emitters. Green squares and blue circles represent the accuracy levels evaluated for both 
compounds. MRPL, Minimum Required Performance Level.  
 
Bio-SPME-nanoESI as a tool for Therapeutic Drug Monitoring (TDM) 
In the era of personalised medicine, the development of bioanalytical methods that are capable of 
rapidly quantifying systemic concentrations of drugs with low therapeutic index or narrow 
therapeutic range, is crucial. Indeed, such methods should provide not only equal or better 
performance than the existing approaches (e.g. immunoassays and liquid chromatography-MS) in 
terms of accuracy and linear dynamic range, but also lower cost per sample and simpler operation. 
In order to fulfil these objectives, techniques such SFME82 and SPE-Paper Spay (SPE-PS)102 have 
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recently arisen as exciting alternatives for point-of-care TDM of diverse analytes in blood and 
plasma with minimal sample consumption and reasonable sample preparation. Although SPME 
has also been used in TDM applications113,327, depending on the physicochemical properties of the 
analyte and its affinity for the extracting particles113, relatively long sample preparation times (i.e. 
text ≥ 10 min) and moderately large sample volumes (Vs ≥ 1 mL) were needed to achieve 
quantitative results via LC-MS/MS131. In view of this, Bio-SPME-nano-ESI is herein introduced 
as a simpler and faster approach for the quantitation of target analytes in whole blood samples. 
Given that SPME extracts via free concentration113, it is expected that analytes largely bound to 
plasma proteins would provide extremely low extraction recoveries (i.e. worst-case scenario for 
SPME)131. Thus, aiming to evaluate the method under “extreme” conditions, two probes with 
protein biding larger than 90%, amitriptyline and imatinib328, were selected.  Unlike SFME and 
SPE-PS, when using Bio-SPME fibres, neither sample dilution82 nor sample drying102 is required. 
However, in comparison with the analysis of urine or PBS, additional rinsing steps123 are needed 
to remove clusters of macromolecules that lingered to the coating surface during the extraction 
process that could potentially clog the nano-ESI emitter. Thus, for blood analysis the analytical 
process is the following: first, a pre-conditioned fibre (i.e. methanol/water, 1:1) is rinsed 10 
seconds in LC-MS water prior to sampling in order to minimize attachment of proteins and cells 
on the coating/wire surface123. Then, extraction is performed by immersing the fibre 2 min in the 
vial containing the sample, and subsequently the fibre is rinsed for 5 seconds on a new vial 
containing LC-MS grade water. Afterwards, the fibre coating is carefully cleaned with a Kimwipe 




Figure 3.7 Experimental set up for Bio-SPME extraction from whole blood and desorption–
ionization using nano-ESI-MS/MS. The analytical process can be summarized in 7 steps. 1. Fibre 
pre-conditioning; 2. Fibre rinsing in water to remove excess of methanol that might enhance 
protein/cell precipitation (10s); 3. Extraction from whole blood (2 min); 4. Fibre rinsing in water 
to remove cells and proteins attached to coating surface (5s); 5. Fibre cleaning with a piece of Kim 
wipe tissue (5s); 6. Additional rising step to remove small particles that might remained attached 
to the surface (5s); 7. Desorption/ionization step using acidified methanol (0.1% FA).  
 
Finally, the wet fibre is inserted on the nano-ESI emitter for desorption/ionization (Figure 3.7 
summarizes the modified analytical procedure). It is important to stress that given the small tip 
size of the emitter used for the urine and PBS analysis (i.e. ~ 1± 0.5 µm), clogging might happen 
while performing instrumental replicates (i.e. multiple ionizations from the same emitter). 
Therefore, whole blood experiments were performed using emitters with a slightly larger tip size 
(i.e. ~ 2 ± 1 μm; BG-10-58-2-AP-20). When using these emitters plugging was never observed. 
Certainly, nano-ESI devices with larger emitter tip (e.g. 4-20 μm) would provide more robust 
analysis, especially when considering these for unattended high-throughput applications37. Even 
though the technique has not yet been optimized, we here have already demonstrated that limits of 
detection (LODs) in the sub-nanogram per millilitre range were achieved for amitriptyline and 
imatinib when performing 2 minutes extraction from 300 µL of whole blood (see Table 3.6). In 
addition, great accuracy (i.e. 91-93% at 100 ng mL-1, Figure 3.8) and linearity were attained for 
















Figure 3.8 A. Quantitative analysis of whole blood spiked with amitriptyline (100 pg ml−1 to 5 
ng mL−1) and its isotopologue [D6] amitriptyline (10 ng mL−1). B. Quantitative analysis of whole 
blood spiked with imatinib (1 ng ml−1 to 50 ng mL−1) and its isotopologue [D3] imatinib (12 
ng mL−1). Bars represent the standard deviation of analyses for three replicates with independent 
fibres and nano-ESI emitters. Blue squares represent the accuracy levels evaluated for both 
compounds.  
 
Table 3.6 Figures of merit, concomitant analysis of amitriptyline and imatinib in whole human 
blood.  
Compound  
Accuracy (%) LOD 
[ng/mL] 
LOQ 
[ng/mL] 100 [ng/mL] 
Amitriptyline 110 ± 1.8 1.6 4.9 
Imatinib 107 ± 1.0 2.3 7.0 
 
Hence, due to speed of the analysis, the suitability of performing extraction/enrichment on-site, 
and the simplicity of the method, BioSPME could be used as an ideal tool for the fast correlation 
of drugs to its therapeutic efficacy or toxicity while treating a patient152,313,315.  
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Towards targeted analysis in small blood volumes 
Until now, the use of SPME fibers for quantitative analysis of target analytes in limited sample 
volumes (Vs ≤ 50 μL) of biofluids, such as blood, has remained overall unexplored. Challenges 
involving getting reliable quantitative data at practical concentration ranges while keeping a simple 
sampling/sample preparation protocol have hindered the implementation of SPME in such cases. 
Chiefly, analytes with high protein binding coefficients typically provide extremely low recoveries 
by SPME; therefore, it is difficult to achieve useful quantitation limits by LC-MS/MS, unless long 
extraction times or larger coating surface areas are used2,113. Further, classical SPME fibers, with 
a coating length of 10-15 mm, are too long to be entirely in contact with small sample volumes 
unless a miniature vessel, such as a glass capillary or vial conical insert, is used for such purpose329. 
Finally, there are currently no appropriate protocols in place that ensure both total contact between 
fiber coating and sample329, and efficient desorption/transmission of analytes into the mass 
spectrometer. To the best of our knowledge, the use of SPME fibers for the quantitation of target 










Figure 3.9 Small sample volume analysis using 15 and 4 mm mix-mode Bio-SPME fibers.  
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In order to challenge the new Bio-SPME-nano-ESI platform, it was used for the quantitative 
analysis in volumes ranging between 10 and 1500 μL. As shown in Figure 3.9, to ensure that the 
entire fiber remained immersed in the sample, glass vials with a fused-in conical insert and fibers 
with a coating length of 4 mm were used. At the outset, we wanted to demonstrate that 
independently of sample volume, the ratio of analyte to internal standard extracted by the fiber 
remained constant and that good signal was attained. As can be seen in Figure 3.10, 1-minute 
extractions from PBS spiked with cocaine and diazepam at 25 ng mL-1 yielded non-statistical 
differences among the five volumes evaluated (i.e. 10, 50, 100, 300, and 1500 μL). Therefore, 
based on these results, we proceeded to perform similar experiment in 20 μL of whole blood spiked 
with amitriptyline at concentrations of clinical relevance (i.e. 5-250 ng mL-1). As can be seen in 











Figure 3.10 Comparison of analyte-to-internal standard ratios for cocaine and diazepam spiked at 
20 ng mL−1 in five different volumes of PBS. Results were normalized for easier visualization. 
Internal standards were spiked at 10 ng mL−1. Bars represent the standard deviation of analyses for 
three replicates with independent fibers and nano-ESI emitters.  
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Figure 3.11 A. Quantitative analysis of whole blood spiked with amitriptyline (5 ng ml−1 to 250 
ng mL−1) and its isotopologue [D6] amitriptyline (100 ng mL−1). Sample volume is 20 µL with 2 
min extraction/enrichment using 4 mm mix-mode Bio-SPME. Bars represent the standard 
deviation of analyses for three replicates with independent fibers and nano-ESI emitters. B. Ion 
chronogram of amitriptyline (top) and [D6] amitriptyline (bottom) for an acquisition time of 45 s. 
C. SPME sampling from 20 µL of whole human blood using a 300 µL glass insert vial. 
 
Although this application is just a proof-of-concept demonstrating the quantitation capabilities of 
Bio-SPME-nano-ESI, we anticipate its use in forensic and clinical applications where only 
minimal sample volumes are available. Currently, our group is working on the development of 
miniature devices that allow for the analysis of sample volumes below 10 μL (i.e. single cells211,330, 
small pieces of tissue263, and biofluids) without sacrificing analysis time or the extraction 
capabilities of SPME. Unlike other sampling devices coupled to nano-ESI331,332, mini-SPME 
devices truly collect analytes of interest based on their affinity towards the extraction phase, while 






In this section, the Bio-SPME-nano-ESI platform was shown to rapidly and accurately determine 
total concentrations of target compounds in complex matrices. Furthermore, the suitability of these 
biocompatible probes to extract, identify, and quantify analytes present in small sample volumes 
was demonstrated for the first time. Through the selection of appropriate experimental conditions, 
the entire analytical process was completed in less than 7 min per sample with outstanding figures 
of merit. In addition to the abovementioned advantages, the Bio-SPME approach has a built-in 
clean-up step, which allows for the incidence of capillary plugging to be substantially reduced. In 
light of the results herein presented, we foresee the combination of SPME with nano-ESI as a rapid 
diagnosis tool for in vivo and in situ analyses of endogenous and exogenous substances in 
biological fluids242 and tissue152 samples. Certainly, the direct coupling of SPME-nanoESI to 
miniature mass spectrometers (MMS)65,333 should bring a new dimension to what we know until 
now as on-site analysis in clinical, environmental, and forensic applications. Indeed, SPME-
nanoESI and MMS, in combination with robotic platforms334 is projected to be an ideal analytical 
tool for non-assisted time-resolved mass spectrometry applications335 such monitoring at remote 
locations. Furthermore, in near future, Bio-SPME fibres in combination with Ion Mobility 
Spectrometry will be a key combination towards the analysis of compounds otherwise difficult to 




Section 3.3 Fast quantitation of target analytes in small volumes of complex samples by 
matrix-compatible Solid Phase Microextraction devices  
 
3.3.1 Introduction 
The development of new analytical technologies capable of providing high quantitation 
performance while delivering simplified and fast analysis of small amounts of biological samples 
(i.e. V ≤ 10 μL) can undoubtedly impact the precision and efficiency of biological investigations 
in drug-development and point-of-care (POC) diagnosis8,82,173,318. Facilitated by the improved 
sensitivity and specificity provided by modern mass spectrometry (MS) instrumentation, the 
replacement of traditional complex laboratory procedures with integrated miniaturized methods 
has become a growing trend in POC diagnosis65. In recent years, advances in direct sample to mass 
spectrometry techniques such as paper-spray ionization, probe electrospray ionization, and touch 
spray48,65,82,332 have allowed for the application of these methods towards the quantitative analysis 
of small volumes of biofluids. However, the sensitivity and precision typically achieved in the 
laboratory through adequate sample preparation prior to the MS quantification is traded off. 
Therefore, techniques capable of isolating and enriching target analytes from complex matrices 
with minimal processing time and adequate sample clean-up are highly desirable for applications 
that require direct introduction to MS 8,82,136,149,173.  
As a concept, SPME embraces solventless microextraction technologies with different geometrical 
configurations that efficiently integrate sampling and sample clean-up, while also allowing for 
enrichment of the molar fraction  of a given analyte in a single step113. Given the multiple 
advantages of this technique, including its feasibility to be coupled to different analytical 
instruments, SPME has been widely used for analysis of complex matrices such as biofluids, 
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tissues, and food samples2,113,149,173,304. The main objective of this report is to introduce a new 
SPME-device that allow for the analysis of samples characterized by a small volume and/or size. 
The proposed device consists of a polypyrrole (PPy) coated stainless steel micro-tip (Figure 3.12) 
which is capable of extracting the analytes by immersing the mini-fibre into few micro-litter of 
matrix. The micro-tip can be conveniently interfaced with MS instrumentation via 
chromatography, or directly interfaced via nano-electrospray-ionization (nano-ESI) for qualitative 






Figure 3.12 (a) SEM image of a 150 μm (100x) tip coated with a 5 μm layer of PPy; (b). SEM 
image of nano-structured PPy (5000x). Devices were made according to a protocol developed by 
Piri-Moghadam et al.151 
 
3.3.2 Experimental section 
Materials and reagents 
The following compounds were selected as model analytes to evaluate PPy-tips: cocaine, 
diazepam, salbutamol, oxycodone, methadone and amitriptyline. Deuterated analogues of each 
analyte were used for correction of intra- and inter-experiment variability. Further details about 
compounds suppliers, properties, and SRM transitions are provided on Table 3.1. The phosphate-
buffered saline solution (PBS) (pH 7.4) was prepared according to the procedure listed on Section 
2.2.2. Pooled whole blood and pooled plasma from healthy donors in potassium (K2) 
ethylenediaminetetraacetic acid (EDTA) was purchased from Bioreclamation IVT (Baltimore, 
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MA, U.S.A.). Urine samples were collected from six healthy volunteers (three female and three 
male). Collection of urine from healthy volunteers for this particular study was under the approval 
of the Office of Research Ethical Board of University of Waterloo). 
 
Mass Spectrometry 
Experiments were performed with the use of a triple quadrupole mass spectrometer TSQ Vantage 
(Thermo Scientific, San Jose, USA). Nano-electrospray emitters: Econotip (Econo10, 1.0/0.58 
OD/ID, mm) were obtained from New Objective Inc. (Woburn, MA, USA). An in-house ionization 
source was built at the machine and electronic shop of the University of Waterloo (see Figure 3.1) 
to accurately position nano-ESI emitters in front of the mass spectrometer. 
 
Sample preparation 
The established analytical workflow consisted of four main steps: extraction/pre-concentration, 
rinsing, desorption, and ionization. First, a preconditioned probe was inserted in a vial containing 
the sample matrix (Vext ~ 5 μL), and quick extraction/enrichment of the analytes was performed (t 
≤ 2 min, static conditions). Next, the probe was rinsed in a vial containing LC/MS grade water (t 
≤ 5 s) to remove matrix components that could potentially adhere to the coating surface. 
Subsequently, the probe was introduced into a conical vial containing the desorption solution. 
Lastly, and after allowing some time for the analytes to be desorbed in the selected solvent, the 
solution was transferred to the nano-ESI emitter using a small syringe. Then, a high electrical field 
between the emitter (1.3 kV, positive mode; 2.5 kV, negative mode) and the mass spectrometer 




Figure 3.13 Experimental set-up for PPy probe extraction from complex matrices and desorption–
ionization using nanoESI-MS/MS or nanoESI-HRMS. 
 
 
3.3.3 Results and discussion 
The use of miniaturized SPME probes not only facilitates the analysis of samples characterized by 
limited availability of sample (e.g. single cells211), but can also diminish potential damage caused 
during in vivo sampling149. Although the use of small metal probes for the analysis of single cells 
and tissue has already been reported211,332, due to the low sorption capacity and non-specific 
affinity of the metal surface (poor inter-device reproducibility), their application is limited to the 
determination of compounds present at high concentrations (e.g. phospholipids). In applications 
that require analysis of tissue or biofluids, device biocompatibility, defined not only as the 
capability to extract analytes of interest without significantly disturbing the system, but also in the 
sense of not co-extracting cell substructures and macromolecules (e.g. organelles, proteins, 
lipoproteins) needs to be examined with extreme care2,304. If the chosen materials are insufficiently 
biocompatible with the matrix under study, significant matrix effects are likely to occur, leading 
to poor or non-quantitation capabilities.304 Accordingly, the determination of compounds at trace 
levels in small volumes and single cells requires biocompatible polymeric coatings with high 
affinity toward the compounds of interest. PPy, a biocompatible2 material frequently used in 
biosensors337 and biomedical engineering338, is a well-known SPME extracting media for in vivo 
and in vitro bioanalysis113. However, the fabrication of miniature coated sampling devices has not 
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been extensively explored to date due to the multiple challenges associated with the fabrication of 
such devices (e.g. mechanical stability and thickness of the coating).113 In this work, acupuncture 
needles with a diameter of 120 µm were electrochemically etched to a tip with a diameter size of 
approximately 5 µm. Then, PPy was electrochemically coated onto the surface according to a 
protocol developed by Piri-Moghadam et al.151 Aiming to have a better understanding of the 
quantitation power afforded by the PPy tips, direct coupling to MS instrumentation was performed 
via nano-ESI emitters (Figure 3.13)173. Quantitative determinations of therapeutics and drugs of 
abuse in urine, plasma, and blood were carried out by performing static extractions from 5 µL of 
sample for 2 minutes. Subsequently, tips were rinsed for 3 seconds in water and then desorbed in 
2 µL of solvent for 2 minutes. Limits of quantitation (LOQs) in the low-ng/mL range were obtained 
for all target analytes, with a total analysis time of less than 5 minutes in urine (see Figure 3.14 
and Table 3.7). Likewise, rewarding results were obtained for oxycodone, salbutamol and 
methadone when analyzing plasma samples spiked with these target analytes (see Figure 3.15 and 
Table 3.8). 
  
Figure 3.14 A. Quantitative analysis of urine spiked with cocaine (0.1 ng mL−1 to 100 ng mL−1) 
and its isotopologue [D3] cocaine (50 ng mL−1). B. Quantitative analysis of PBS spiked with 
diazepam (1 ng mL−1 to 100 ng mL−1) and its isotopologue [D5] diazepam (50 ng mL−1). Bars 
represent the standard deviation of analyses for three replicates with independent PPY-tips and 
nanoESI emitters. Dots in different colors represent accuracy validation points.  
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Table 3.7 Quantitative analysis of urine spiked with diazepam and cocaine. Accuracy and 
reproducibility obtained for mini-tips and nanoESI emitters (n=3). 
 RSD [%] 
Concentration [ng mL-1] Diazepam Cocaine 
0.1 - 1.5 
0.5 - 0.6 
1 24.1 1.6 
5 1.0 0.0 
10 14.0 2.3 
50 6.1 1.2 
100 1.4 0.8 
 Accuracy [%] 
2.5 - 82 
25 82 88 
 
Figure 3.15 Quantitative analysis of plasma spiked with oxycodone (a), salbutamol (b) and 
methadone (c), (1 ng ml−1 to 100 ng mL−1) and their isotopologue. Bars represent the standard 
deviation of analyses for three replicates with independent PPY tips and nano-ESI emitters. Dots 
in different colors represent accuracy validation points at 100 ng mL-1.  
 
As expected, due to its small coated surface area, mini-tips cannot provide the same quantitation 
capabilities as the commercial coatings (see Figure 3.16 and Table 3.9) for the analysis of 
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amitriptyline in whole blood (LOQ ~ 25 ng mL-1). Yet, the results are acceptable given the sample 
size and the therapeutic range of this drug (i.e. 50-150 ng mL-1). 
Table 3.8 Quantitative analysis of plasma spiked with salbutamol, methadone, and oxycodone. 
Accuracy and reproducibility obtained for SPME-tips and nano-ESI emitters (n=3). 
 RSD [%] 
Concentration [ng mL- Salbutamol Methadone Oxycodone 
5 - - 3.8 
10 3.3 5.5 10.8 
25 3.7 5.0 4.3 
50 1.2 1.6 5.8 
75 7.1 1.1 1.7 
250 5.1 0.1 1.0 
500 2.1 1.0 6.1 
 Accuracy [%] 








Figure 3.16 Quantitative analysis of whole blood spiked with amitriptyline (5 ng ml−1 to 250 
ng mL−1) and its isotopologue [D6] amitriptyline (100 ng mL−1). Bars represent the standard 
deviation of analyses for three replicates with independent PPY tips and nano-ESI emitters.  
 
Table 3.9 Quantitative analysis of blood spiked with amitriptyline. Accuracy and reproducibility 
obtained for Coated Blade Spray when performing spot analysis (n=3). LOD, 5 ng/mL. 
 RSD [%] 












3.3.4 Summary  
SPME acts as a chemical biopsy tool by enriching small molecules carrying chemical information 
about the investigated system without removing tissue, thus providing a much cleaner extraction. 
Currently, our group is working on the development of versatile biocompatible coatings (e.g. HLB-
based) for miniature devices that allow for the extraction of a broader range of compounds, with 
potential for a variety of applications in fields such as plant biology and oncology, where small 
objects need to be scrutinized. Likewise, the application of SPME tips for in-vivo tissue “imaging” 
is expected in the near future. Essentially, imaging should be understood as the capability of these 
miniature devices to monitor metabolite or drug concentration changes in specific regions of the 
tissue with minimum invasiveness (i.e. spatial resolution information). If the object is sufficiently 
large, the damage caused by insertion can be considered negligible or sufficiently minimized, 
allowing for multiple samplings to be subsequently performed to investigate changes in the system 
as a function of time or applied stimuli. We foresee the SPME-tip device as a tool capable of 






Section 3.4 Open Port Probe Sampling Interface for the Direct Coupling of Biocompatible 
Solid-Phase Microextraction to Atmospheric Pressure Ionization Mass Spectrometry 
 
3.4.1 Introduction 
Within the last twenty years, different strategies aimed at direct and efficient coupling of Solid 
Phase Microextraction (SPME) devices to mass spectrometry (MS) instrumentation have been 
explored for analysis of a broad range of matrices with high relevance in clinical, forensic, 
environmental, and food analysis.80,136,151,173,183,184,192,210 To date, most reported direct couplings 
of SPME fibers are based on work performed either by Górecki et al 183,184 (“classical” thermal 
desorption used in gas-chromatography,164,174) or by Chen et al.339 (solvent desorption, suitable for 
thermally labile compounds). In the latter, the desorption of extracted/enriched analytes occurs by 
placing the fiber on a desorption chamber (e.g. port, valve, or syringe),114,172,180–182 filled with a 
solvent with high affinity for the analytes of interest, prior to the atmospheric pressure ionization 
event (either electrospray ionization (ESI) or atmospheric pressure chemical ionization (APCI)). 
Aiming to take full advantage of the molar fraction enrichment offered by SPME,151 two of our 
recently reported endeavours applied the methodology initially proposed by Walles et al.,210 where 
nano-electrospray ionization (nano-ESI) is used in combination with biocompatible-SPME (Bio-
SPME) fibers/tips for fast quantitation of target analytes extracted from biofluids.151,173 Although 
the combination of SPME with nano-ESI is fundamentally “ideal” for analysis of known/unknown 
substances from complex matrices, in that it yields high ionization efficiency319 with minimal 
solvent consumption and long spray events that allow for numerous MS and MSn experiments,5,318 
drawbacks of this coupling should also be considered in the development of further analytical 
applications. First, poorly wettable coatings, such as C18-coated fibers,113,304 have been found to 
135 
 
be capable of  generating bubbles inside the nano-ESI emitter (i.e. ‘ambient-air’ collected inside 
the particles is released when immersed onto the desorption solvent), which may possibly distort 
the Taylor-cone formation and, consequently, the electrospray ionization process. Second, the high 
cost per analysis (i.e. due to the non-reusability of the emitters), as well as the difficulties 
associated with automatization of the process are additional factors that could thwart the high-
throughput implementation of SPME-nano-ESI. Aiming to solve the aforementioned concerns, 
this manuscript introduces the open port probe (OPP) sampling interface36 as a novel, robust, 
sensitive, and ready-to-use interface for the direct coupling of Bio-SPME fibers to mass 
spectrometry. As a proof-of-concept, SPME-OPP is herein reported for the first time for 
determination of controlled substances in relevant clinical assays for urine: treatment of opioid-
dependence (i.e. buprenorphine), pain management (i.e. fentanyl), and doping control (i.e. 
clenbuterol). Given that chromatography can be circumvented by using SPME-OPP, MRM3 or 
DMS336,340,341 were implemented to enhance compound selectivity while keeping with the speed 
and simplicity of traditional MS/MS analysis.  
 
3.4.2 Experimental section 
Materials and Supplies The following compounds were selected as model analytes to evaluate 
Bio-SPME-OPP: clenbuterol, fentanyl, and buprenorphine. Deuterated analogues of each analyte 
were used for correction of intra- and inter-experiment variability. Further details regarding 
compound suppliers, properties, multiple reaction monitoring (MRM), MRM3 transitions, and 
DMS parameter settings are provided in Table 3.10 and 3.11. All LC-MS grade solvents 




Table 3.10 Manufacturers, LogP, mass spectrometry, and DMS conditions monitored for each analyte. 





DP [V] EP [V] CE [V] CXP[V] SV [V] CV [V] 
Buprenorphine Cerillianta  4.53 468.3 396.2 120 10 55 
10 NA NA 
Buprenorphine-d4 Cerillianta  - 472.3 400.2 120 10 55 
10 NA NA 
Fentanyl Cerillianta  3.82 337.3 188.2 120 10 32 
10 NA NA 
Fentanyl-d5 Cerillianta  - 342.2 188.2 120 10 32 
10 NA NA 
Clenbuterol Cerillianta  2.33 277.1 203.1 60 10 24 
10 4000 13.0 
Clenbuterol-d9 Cerillianta  - 286.1 204.1 60 10 24 




Table 3.11 MRM3 conditions for clenbuterol analysis. 
Compound MRM3 transition CE [V] DP [V] EP[V] 
Clenbuterol 277.1-203.1-168.1 24 100 10 
Clenbuterol – d9 286.1-204.1-169.1 24 100 10 
 
a Cerilliant (Round Rock, TX, USA); b Log P, logarithm of its partition coefficient between n-octanol and water (data taken from 
www.drugbank.ca). Dwell time was 50 ms for all analytes. DP: Declustering potential, EP: Entrance potential, CE: Collision energy, 
CXP: Collision cell exit potential. All experiments were performed using an SCIEX QTRAP® 6500+ MS/MS system with Ion Drive™ 





Biocompatible SPME mixed-mode probes (i.e. C18-SCX particles, 45 μm thickness, 4 mm coating 
length) were kindly provided by Supelco (Bellefonte, PA, USA). Although non-biocompatible 
SPME devices could also be interfaced to OPP, the present work exclusively focuses on 
bioanalytical applications where the use of biocompatible devices is essential.173 Urine samples 
were collected from six healthy volunteers (three female and three male). Collection of urine from 
healthy volunteers for this particular study was under the approval of the Office of Research 
Ethical Board of University of Waterloo.   
 
DMS-MS system  
A DMS system (SelexION+™, SCIEX, Concord, ON) was mounted in the atmospheric region 
between the sampling orifice of the QTRAP 6500+ (SCIEX) system and its electrospray ionization 
(ESI) source. The ESI probe was maintained at a voltage of 5500 V. A constant gas flow in the 
DMS cell was achieved by curtain gas flow (N2; 30 psi, 7.1 L min−1) and the primary stage vacuum 
pumping of the MS system. The temperature of the transport gas in the DMS cell was maintained 
at 100 °C (DMS heater setting of 150 °C). For the experiments conducted in this study, the 
separation voltage (SV) was set at 4000 V, and the compensation voltage (CV) was set at 13.0 V 
for optimal transmission of clenbuterol and clenbuterol-D9.  
 
Open-Port-Probe (OPP) sampling interface  
As shown on Figure 3.17, the OPP sampling interface used in our experiments is similar to the one 
reported by Van Berkel and collaborators.36,45 It is composed of a vertically aligned co-axial tube 
arrangement that enables solvent delivery to the sampling end through the tubing annulus (304 
stainless steel, 1.75 mm i.d. × 3.18 mm o.d. × ~9 cm long; Grainger, Lake Forest, IL, USA), and 
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aspiration down the center tube (capillary tube; 254 μm i.d. x 361 μm o.d. × ~25 cm long; Upchurch 
Scientific, Oak Harbor, WA, USA) into the Ion Drive™ source driven by the nebulizer gas.36 Each 
tube was secured within a PEEK Tee (Upchurch Scientific, Oak Harbor, WA, USA) so that solvent 
could be delivered by a solvent pump (200 Series; Perkin Elmer, Santa Clara, CA, USA). The 
aspiration force through the inner tube of the sampling probe was controlled by the flow rate of 
the nebulizing gas (nitrogen) into the ion source (90 psi), and the rate of the flow-in solvent was 
adjusted to achieve a dome-shaped sampling surface to maximize the contact area with SPME 
coatings (200 µL/min). The standard ESI electrode (100 μm i.d.) was replaced by one of equivalent 
length but with 150 μm i.d. to increase the accessible self-aspiration flow rate range of the system36. 
Positive ion mode ESI was used with ion source nitrogen gas settings GS1 = 90, GS2 = 70; curtain 
gas = 25; heated nebulizer temperature = 350 °C; and electrospray voltage = 5500 V.  
Figure 3.17 Schematic of the Open-Port-Probe interface used for desorption-ionization of Bio-
SPME fibers. All experiments were performed using an SCIEX QTRAP® 6500+ MS/MS system 
with Ion Drive™ source and Electrospray Ionization (ESI) probe (SCIEX, Concord, Canada).  
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SPME extraction and desorption/ionization  
The analytical workflow for SPME-OPP consisted of three simple steps: extraction/pre-
concentration, rinsing, and desorption/ionization (Figure 3.18). First, the coating of the Bio-SPME 
fiber was preconditioned on a methanol-water (50:50) solution for about thirty minutes prior to 
analysis as described elsewhere123. Then, the Bio-SPME fiber was inserted in a vial containing the 
urine sample (Vext ~ 300 μL), and quick extraction/enrichment of the analytes was performed by 
agitating the sample at high speed (agitation at 1500 rpm, t≤ 5 min). Next, the fiber was rinsed in 
a vial containing LC/MS grade water (t ≤ 10 s) to remove matrix components that could potentially 
adhere to the coating surface. Finally, analyte desorption was achieved by placing the SPME fiber 
for 5 seconds into the sampling dome of the OPP, such that it touched the continuous flowing 
stream. Thus, all the analytes extracted on the SPME fiber were desorbed and moved 
simultaneously from the open-port section of the probe (Figure 1) to the electrospray needle, where 
they were ionized via ESI mechanism. However, it is important to clarify that the desorption rate 
of each compound extracted on the fiber would mostly depend on its affinity for both the 
desorption solvent and the fiber coating. As shown in Figure 3.18, typical full width at half 
maximum (FWHM) occurs within 6 seconds with minimal peak broadening, so a new injection 
can be theoretically performed every 10-15 seconds. It should be noted that incomplete desorption 
of analytes was observed under the conditions used in this manuscript (i.e. ~ 80% eluted in 5 s). 
However, this was not a limitation in obtaining quantitative results, as the calibration functions 
were constructed on the basis of the signal ratio of the analyte and its isotopologue (A/Is) for 
twelve concertation levels in three independent replicates covering, in this way, the range between 




Figure 3.18 Experimental set-up for Bio-SPME extraction from complex matrices and desorption–
ionization via OPP. 
 
To determine the accuracy of the method, three validation points were evaluated. Although SPME 
fibers were used as consumables in this study (single use), it is worth mentioning that Bio-SPME 
fibers can be reused by implementing a cleaning step after the desorption/ionization cycle (i.e. 
mixture of methanol, isopropanol, and acetonitrile; 50:25:25). According to previous studies by 
Reyes-Garcés et al.304, Souza-Silva et al.143,  and Musteata et al.342, a Bio-SPME device can be 
reused at least 20 times. However, the reusability of the Bio-SPME fibre would depend on multiple 
factors (e.g. matrix of interest, effectiveness of the cleaning process, and efficiency of the 
desorption conditions). Therefore, in applications where fibres might be reused, the cleaning step 
should be carefully optimized according to both the matrix, the chemistry of the coating and its 
affinity towards the target compound.148  
 
3.4.3 Results and discussion 
SPME-OPP: a simple, fast, and sensitive coupling  
Certainly, the greatest advantage of the OPP interface, particularly in comparison to other SPME 
direct couplings to MS,173,174,182 is that it requires no modifications to the conventional ionization 
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source setup employed by most analytical labs, allowing the switch between LC-MS and OPP-MS 
to be achieved in just a few seconds. Indeed, the OPP herein described can be readily built by any 
skilled user, using mostly commercially available parts.36 In addition, the OPP interface can be 
easily attached to the ESI/APCI source, and no expertise, other than that posed by an average 
LC/MS user, is required to operate it. Although a conventional LC pump was used in this study 
for solvent delivery, due to the low back pressure of the system (<30 psi), low-cost/back pressure 
pumps can also be implemented to reduce cost and avoid potential problems associated with high-
pressure systems (e.g. leaking, expensive parts). Unlike nano-ESI emitters,173,211,212 the OPP 
interface can be used for a long period of time with negligible inter-analysis carry-over owing to 
its continuous flowing principle.36 In addition, the OPP interface is suitable for multi-SPME-fiber 
automation161 and provides minimal risk of ionization interruption upon insertion of dry-fibers 
since it operates with large-size electrodes (i.e. 100-150 μm i.d. for ESI/APCI versus 1-2 μm i.d. 
for nano-ESI emitter; then, accounting for bubble formation). Building upon previous research,36 
the current study seeks to demonstrate that a noteworthy idea (direct-sample-introduction to MS 
by OPP) can be remarkably improved by using a sample preparation technology (i.e. Bio-SPME 
fibers) capable of isolating/enriching target analytes from complex matrices (e.g. biofluids, tissues, 
food samples) with minimal processing time (i.e. less than 2 minutes for the entire analytical 
process), and adequate sample clean-up (i.e. minimizing matrix effects and instrument 
contamination for long-term operation). Succinctly, the SPME-OPP coupling merges two 
attractive technologies to provide limits of quantitation at the low-part-per-billion level, or even 
part-per-trillion (depending on the analyte affinity for the coating and its ionization efficiency), in 
substantially short periods of time. Unlike the Open Probe device developed by Amirav’s research 
group30 for rapid coupling to electron ionization mass spectrometry, the OPP sampling interface 
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described in this study was designed for ESI or APCI. Although a triple quadrupole/linear ion trap  
was used in this study, the OPP system can also be coupled to any other mass analyzers such as 
single quadrupole, ion-traps, or time-of-flight as recently demonstrated by Van Berkel and 
collaborators343 
 
Determination of controlled substances in urine samples  
When monitoring controlled substances, such as in applications related to doping in sports, pain 
management, or abuse of illicit drugs, urine is most often selected as a matrix due to the non-
invasive nature of its sample collection, and the large sample volumes available.304 However, given 
the complexity of this matrix, as well as the low amount of parent drug excreted, analytical 
technologies capable of providing quantitative results in the sub-nanogram per milliliter range are 
highly desired. Recently, Reyes-Garcés et al.131,304 and Boyacı et al.148 demonstrated that different 
geometrical formats of SPME devices are capable of meeting the Minimum Required Performance 
Levels (MRPL) set by the World Anti-Doping Agency (WADA) for the analysis of multiple 
prohibited substances in urine by LC-MS. Although SPME-OPP coupling has yet to be perfected, 
still requiring parameters to be optimized (e.g. ideal fiber-coating thickness, strength of desorption 
solution, and shape of the open-port that allows for the smallest possible desorption volume), 
herein we demonstrated that limits of detection (LODs) in the sub-nanogram per millilitre range 
were achieved for fentanyl and buprenorphine upon performance of 2 min extractions from 300 
µL of urine (Table 3.12, Figure 3.19). In addition, great accuracy (i.e. 93-108% at 3, 40, and 80 ng 
mL-1, Figure 3.20) and linearity were attained for both analytes in the assessed range (R2 ≥ 0.9987).  
As can be seen in Table 3.12, our limits of quantitation (LOQ) are certainly below the MRPL 
values set for fentanyl and buprenorphine in urine (2 and 5 ng mL-1, respectively148), which  
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Figure 3.19 Fentanyl (A) and buprenorphine (B) ion-chronograms signals corresponding to a 5 
min extraction at 1500 rpm from 300 µL of pooled urine spiked with 0.05 and 0.5 ng mL-1 of 
fentanyl and buprenorphine, respectively. Extractions were performed using a 4 mm Bio-SPME 














Figure 3.20 A. Quantitative analysis of urine spiked with fentanyl (50 pg ml−1 to 100 ng mL−1) 
and its isotopologue [D5] fentanyl (10 ng mL−1). B. Quantitative analysis of urine spiked with 
buprenorphine (500 pg ml−1 to 100 ng mL−1) and its isotopologue [D4] buprenorphine (10 
ng mL−1). Blue squares represent the obtained accuracy levels (3, 40, and 80 ng mL−1, 





Table 3.12 Figures of merit for the concomitant analysis of fentanyl and buprenorphine in urine 
by Bio-SPME-OPP in MRM mode. 
Compound  
Concentration accuracy (, ± SD) LOD 
[ng/mL] 
LOQ 
[ng/mL] 3 [ng/mL] 40 [ng/mL] 80 [ng/mL] 
Fentanyl 3.2 ± 0.2 37.2 ± 1.4 83.1 ± 0.2 0.05 0.25 
Buprenorphine 2.8 ± 0.1 37.9 ± 0.2 80.4 ± 0.3 0.25 0.50 
 
proves the suitability of SPME-OPP-MS/MS for the quantitative determination of controlled 
substances in human urine. 
Unlike fentanyl and buprenorphine, the quantitation of clenbuterol in urine is not a trivial task.304 
Indeed, in order to reach the required LOQ (0.2 ng mL-1) for this compound, our group 
demonstrated that chromatographic separation in combination with tandem mass spectrometry are 
needed for the isolation of matrix interferences co-extracted by the SPME coating.304 Although 
different direct sample-to-MS methods have reported the most abundant transitions (m/z 277→259 
or 277→203) for the characterization/quantitation of clenbuterol in complex matrices,111,257 our 
experience has shown that these transitions may lead to false positive results and untrustworthy 
LOQs (see Figure 3.21). Thus, aware of the extra challenges provided by the lack of a separation 
step, MRM3 (m/z 277→259→168) was employed to overcome the lack of specificity encountered 
when exclusively performing MS/MS.34,344,345 As shown in Figure 3.22, we demonstrated that Bio-
SPME-OPP-MRM3 can reach a LOQ value of 100 pg mL-1 upon performance of a 5 min extraction 
from 300 µL of urine spiked with clenbuterol. Furthermore, exceptional linearity in the range of 
100 pg mL−1 up to 100 ng mL−1 and good accuracy (i.e. 82-96 %) at three different levels (i.e. 0.25, 
2.5 and 75 ng mL−1) were attained (see Table 3.13). Certainly, higher concentration levels are not 
a limitation. In cases where the affinity of the coating for the analyte is high and target compounds 
are present at concentrations larger than 100 ng mL−1, shorter extraction times could be employed.  
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Figure 3.21 Ion-chronograms for clenbuterol obtained using (A) MRM (277.1-203.1), (B) MRM3 
(277.1-203.1-168.1) for a double-blank of urine (no standard or internal standard spiked) and (C) 
MRM3  (277.1-203.1-168.1) for 0.2 ng/mL clenbuterol spiked in urine. Extraction conditions were  
5 min extraction time and 1500 rpm from 300 µL of pooled urine, using a 4 mm Bio-SPME mix 
mode fiber.  
 
Figure 3.22 Quantitative analysis of urine spiked with clenbuterol (100 pg ml−1 to 100 ng mL−1) 
and its isotopologue [D9] clenbuterol (10 ng mL−1). Analyses were performed using SPME-OPP-
MRM3 (m/z 277→259→168). Blue circles represent the obtained accuracy levels (0.25, 2.5 and 
75 ng mL−1, respectively). Bars represent the standard deviation of analyses for three replicates 





Table 3.13 Figures of merit for the analysis of clenbuterol in urine by Bio-SPME–OPP-MRM3  
Compound  
Concentration accuracy (± SD) LOD 
[ng/mL] 
LOQ 
[ng/mL] 0.25 [ng/mL] 2.5 [ng/mL] 75 [ng/mL] 
Clenbuterol 0.3 ± 0.1 2.5 ± 0.2 73.1 ± 0.8 0.03 0.1 
 
It is worth emphasizing that extraction on Bio-SPME fibers can also be performed under static 
conditions (e.g. during in vivo tissue analysis113), or at lower speeds of agitation. High-speed 
agitation was selected in this study with the aim to achieve the required LOQs with minimal total 
analysis time.136,151  
In addition to MRM3, it was demonstrated that DMS in combination with MS/MS could also be 
used for the quantitation of clenbuterol in urine via SPME-OPP. By tuning the adequate 
compensation voltage (CoV), transmission of the clenbuterol ions through the DMS cell can be 
achieved while co-extracted interferences are deflected.341 As shown in Figures 3.23 and 3.24, no 
interference signals were detected and acceptable signal-to-noise ratio at the lowest quality control 
point tested (S/N ~ 4.8 for 0.25 ng mL−1) was attained when using DMS.  
 
 
Figure 3.23 Ion-chronograms obtained for clenbuterol obtained using (A) only MRM (277.1-
203.1) and (B) DMS and MRM (277.1-203.1) for a double-blank of urine (no-internal standard 
spiked). Extractions conditions were 5 min extraction time at 1500 rpm from 300 µL of pooled 





Figure 3.24 Ion-chronograms obtained using Bio-SPME-OPP and DMS-MS/MS. Extraction were 
performed from pooled urine blank (A) and pooled urine spiked with 0.25 ng mL-1 of clenbuterol 
(B). Extractions conditions were 5 min extraction time at 1500 rpm from 300 µL of pooled urine, 
using 4 mm Bio-SPME mix mode fiber.  
 
Application of SPME-OPP towards analysis of tissue samples 
Aiming to have a better understanding of the suitability of SPME-OPP for the study of tissue 
samples, extractions from agarose gel (2%) and homogenized brain tissue were performed. Both 
matrices were spiked with fluoxetine in concentrations ranging between 10 and 1000 ng mL-1. 
Extractions were performed for 8 minutes using 4 mm mix-mode fibres, followed by a quick rinse 
in LC-MS water and quick wipe with a paper tissue. Right after sampling, fibres were stored at -
80˚C until desorbed on the OPP interface. As can be seen in Figures 3.25 and 3.26, rewarding 
preliminary results were attained for the quantitation of fluoxetine. Future work will include 
determining the suitability of this approach to perform in vivo studies and validate a suitable 
calibration approach for such examinations. For instance, given the great sensitivity provided by 
SPME-OPP, one could consider the sampling rate approach, which allows performing calibration 
while within the linear region of the absorption profile128. The sampling-rate approach, validated 
under both laboratory and in situ environment, implies that the mass transfer rate remains constant 
throughout the duration of sampling, and that there is a simple relationship between the 
concentration of the target analyte in the sample matrix and the extracted amount of analyte2,113. 
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Hence, in such scenario, the internal standard would need to be preloaded on the coating as to 












Figure 3.25 Quantitative analysis of agarose gel spiked with fluoxetine (10 ng ml−1 to 1000 













Figure 3.26 Quantitative analysis of homogenized brain tissue spiked with fluoxetine (20 ng ml−1 




Similar to the work presented in Section 2.4, SPME-OPP can also be used for profiling studies of 
complex matrices. As a proof-of-concept, 30 minute extractions were performed from tissue 
samples from different animals purchased on a local market (i.e. salmon, beef, pork and chicken). 
After extraction, the fibres were rinsed in water, clean with a Kim-wipe and subsequently inserted 
on the interface. These studies were carried out on a SCIEX TripleTOF® 5600+ system located at 
SCIEX facilities. As can be seen in Figure 3.27 and 3.28, characteristic profiles of each kind and 
good separation between different tissues was attained on the PCA plot. Undeniably, these results 
are only a taste of multiple applications that can be carried on with this system. Certainly, by using 
SPME-OPP-HRMS with real-time recognition software, such the LiveID recently launched by 
Waters, the proposed profiling methodology has great potential to be used in food fraud 












Figure 3.27 Mass spectra profile obtained after 30 min extraction from a piece of tissue of pork, 

























Figure 3.28 2 Three-dimensional PCA plot for identification of meat samples from different 
species (i.e. beef, pork, fish and salmon) using Bio-SPME-OPP-HRMS. 
 
 
3.4.4 Summary  
Unquestionably, application of Bio-SPME-OPP has tremendous potential in bioanalytical 
laboratories for fast determination of therapeutic drugs and prohibited-substances in complex 
matrices. Its suitability is owed to the multiple advantages it affords,8,233,326 such as the simplicity 
of the coupling, its aptness for high-throughput analysis (i.e. less than 20 s per sample when 
running 96-samples at once), high sensitivity (i.e. sub-ng mL-1), and moderate cost per analysis 
(i.e. reusability of the source and price of each SPME device).131,304 Moreover, by using in-line 
technologies, such MRM3 or DMS, enough selectivity enhancement can be achieved, thus making 
SPME-OPP a much faster alternative to classical LC-MS/MS based approaches. Certainly, the 
complete quantitation capabilities of SPME-OPP have yet to be discovered. Although this work 
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has been strictly focused on Bio-SPME fibers provided by the commercial vendor, fundamental 
work on SPME155 has shown that lower LOQ values can be accomplished either by using SPME 
devices with a larger coated surface area (e.g. blades, mesh, or membranes 146,151,192), increasing 
extraction time, enhancing the affinity of the coating for the analyte, or consuming larger sample 
volumes. Consequently, our future work will focus not only on achieving better figures of merit 
by employing novel SPME geometries amenable to OPP, but also in exploiting the versatility of 
analytes and matrices that can be analyzed by having ESI/APCI capabilities and DMS integrated 
into a single source. We foresee the combination of SPME-OPP with robotic platforms for non-
assisted time-resolved mass spectrometry applications,334 as well its implementation for fast 
















Section 3.5 Fast quantitation of opioid isomers in human plasma by differential mobility 
spectrometry/mass spectrometry via SPME/open-port probe sampling interface 
 
3.5.1 Introduction 
Simple, robust and high-throughput sample preparation workflows capable of yielding reliable 
quantitative analysis results are highly desired for the determination of pain-management 
substances and drugs of abuse in biological fluids233. Although dilute-and-shoot procedures have 
been evaluated for this purpose21,22, most assays still require a sample clean-up step (e.g. solid-
phase extraction or liquid-liquid extraction) for removal of biological matrix components that 
could cause contamination of the chromatographic column or ionization suppression41. Solid-
phase microextraction (SPME), a green technology that combines sampling, sample clean-up, and 
analyte enrichment into a single step, has been widely used for high-throughput  sample 
preparation with minimum handling173, including in-vivo sampling, and on-site monitoring of 
several substances in different environmental, clinical and food applications.113,228 Although 
SPME devices are capable of performing fast sample extraction from biological matrix, 
chromatographic separation (i.e. GC or HPLC) still is the platform of choice for the analysis of 
drugs of abuse, because the specificity may suffer from the loss of a chromatographic dimension 
(e.g. interferences can be observed when analyzing isomeric species with common fragment ions 
such as codeine and hydrocodone).233,347 Therefore, the chromatography process has become the 
bottleneck to further improve the analysis throughput.348   
Differential mobility spectrometry (DMS) is a gas-phase ion separation technology based on the 
mobility difference of target ions under high- and low-electrical fields,341,349 and it has been proven 
to be a powerful tool to improve the selectivity of  LC-MS analysis and remove endogenous 
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chemical interferences from samples to yield significant improvements in S/N and limits of 
detection.350 In this study, a novel DMS device is introduced for the in-line separation and 
quantitation of isomeric opioids with shared fragment ions (i.e. codeine and hydrocodone, Figure 
3.29) without requiring chromatographic separation. An open-port probe (OPP) sampling 
interface36,343 was used to couple the high-throughput sample preparation based on SPME and the 
fast analysis based on DMS/MS. Employment of the OPP system allows merging the steps of 
analyte desorption and elution into the instrument by simply placing the SPME device in the open-
end of the system for several seconds, without employment of high-pressure parts or injection 
valves. Good sensitivity, accuracy, and precision were demonstrated for the targeted analytes, with 

















3.5.2 Experimental section 
Reagents and supplies 
Codeine, hydrocodone and their deuterated analogues were purchased from Cerilliant (Round 
Rock, TX, USA), and used without further purification. HPLC grade acetonitrile and methanol 
were bought from Caledon Laboratory Chemicals (Georgetown, ON, Canada). Distilled deionized 
water (18 MΩ) was produced in-house using a Millipore (Billerica, MA, USA) Integral 10 water 
purification system. Plasma samples were purchased from Bioreclamation IVT (Baltimore, MD, 
USA). Target analytes and internal standards (deuterated analogues) were spiked in the plasma 
(v/v) the day before extraction. Bio-SPME mixed mode probes (i.e. C18-SCX particles, 45 μm 
thickness, 15 mm coating length) were kindly provided by Millipore-Sigma (Supelco; Bellefonte, 
PA, USA).   
 
Open-port probe sampling interface 
The OPP sampling interface used in this work was constructed based on the design introduced by 
Van Berkel and co-workers36, and the device is described in Figure 3.17. This OPP sampling 
interface uses a vertically aligned, co-axial tube arrangement enabling solvent delivery to the 
sampling end (open-port) through the tubing annulus (304 stainless steel, 1.75 mm i.d. and 3.18 
mm o.d., Grainger, Lake Forest, IL, USA), and aspiration down the centre tube (PEEK, 255 µm 
i.d. and 510 µm o.d., IDEX, Lake Forest, IL, USA) into the ion source driven by the nebulizer gas 
(fixed at 90 psi) through a 635 µm i.d. nozzle, and the ESI electrode i.d. was 150 µm. The rate of 
the flow-in desorption solvent (methanol) was adjusted (Perkin Elmer 200 LC pump, Waltham, 
MA, USA) to achieve a dome-shaped sampling surface to maximize the contact area with SPME 









Sample preparation with SPME and OPP sampling 
The workflow of SPME based sample preparation consists of several steps including fibre 
conditioning, analyte extraction, fibre rinsing, analyte desorption and analyte elution into the mass 
spectrometer. By using OPP as the MS interface for SPME, the two latter steps are combined (see 
Figure 3.30), allowing for better analysis throughput and enhanced sensitivity (i.e. minimal analyte 
dilution). In addition, since the step of solution transfer is eliminated, chances of additional sample 
loss are avoided. In this study, a preconditioned SPME fibre was first inserted in a vial containing 
plasma sample (250 µL) for 5 min with vortex agitation (1500 rpm). Next, the fibre with extracted 
target analytes was rapidly rinsed in a vessel containing 0.3 mL water for 5 seconds to remove 
matrix components that could have potentially adhered to the coating surface. For the above two 
steps, multiple samples were processed simultaneously aiming to increase the analysis speed and 
reduce sample-to-sample variations. Finally, the SPME fibre was placed into the sampling port 
containing dome-shaped continuous-flow desorption solvent (i.e. methanol) for 5 seconds, and the 




Table 3.14 Mass spectrometry parameters used to monitor each analyte in the CoV ramp test. 
Compound Parent Product DP [V] CE [V] EP [V] CXP [V] 
Codeine 300.1 165.0 200 50 10 15 
Hydrocodone 300.1 199.0 200 40 10 15 
Norcodeine 286.1 268.1 180 40 10 11 
Morphine 286.1 268.1 180 40 10 11 
Hydromorphone 286.1 268.1 180 40 10 11 
 
Table 3.15 DMS-MS parameters used to monitor codeine and hydrocodone in the SPME-OPP-
DMS-MS experiments. 
Compound Parent [m/z] Product [m/z] SV CV DR 
Codeine 300.1 165.0 6300 14.5 0 
Hydrocodone 300.1 199.0 6300 16.5 0 
 
DMS-MS system 
A research grade DMS system (dimension of the DMS cell was 1.5 x 20 x 63 mm, gap height x 
electrode width x cell length) developed by SCIEX was mounted in the atmospheric region 
between the Turbo VTM ion source (ESI) and the QTRAP® 5500 system’s (SCIEX, Concord ON, 
Canada) sampling orifice. The ESI probe was maintained at a voltage of 5500 V. A constant gas 
flow in the DMS cell was achieved by the curtain gas flow (N2; 20 psi, 5.5 L min-1) and the primary 
stage vacuum pumping of the MS system. Nitrogen was also used as the throttle gas. The 
temperature of the transport gas was set at 100 °C. The analysis with conventional DMS cell was 
performed on a QTRAP® 6500+ system equipped with SelexION+TM technology. The 
fundamental behaviour of DMS and the asymmetrical SV waveform has been thoroughly 
described in previous studies341. For the experiments conducted in this study, the optimal 
compensation voltage (CoV) for the ion transmission was determined first by scanning the CoV 
from 5 V to 20 V in 0.15-V increments with the separation voltage (SV) set at 6300 V (p-p). 
Analytes were dissolved in solution (methanol) to a concentration of 100 ng mL-1, and infused into 
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the ESI source at a rate of 10 µL min-1. During every CoV step, multiple-reaction monitoring 
(MRM) signals for each analyte (Table 3.14) were recorded, yielding an ionogram. The optimal 
CoV for the transmission of each analyte through the DMS device was determined and used for 
the SPME-OPP sampling experiments as shown in Table 3.15 (fixed SV and CoV settings for each 
individual ions without scanning process). 
 
3.5.3 Results and discussion 
Isomeric separation with DMS 
DMS is a technology that can be used to separate gas-phase ions prior to analysis by MS.341,351 In 
a DMS cell, a high frequency asymmetric waveform (SV), varying between high- and low-electric 
field regimes is applied across the ion transport channel between the two planner electrodes, 
perpendicular to the direction of the ion transport flow. The different mobilities exhibited under 
high- and low-electric field results in ions acquiring a “zigzag” trajectory between the electrodes. 
For successful transmission through the DMS cell and sampling into MS, a DC CoV can be applied 
to steer ions back on axis. This technology has been successfully used for both chemical noise 
elimination and isomeric ion separation (e.g. stereoisomers, structural isomers, and tautomers)341.  
Several approaches have been introduced aiming to enhance the resolving power of DMS, by either 
increasing the CoV difference (ΔCoV) or reducing the peak width in volts at half height (FWHM) 
in a CoV ramp scan. The modified transport gas has been widely used to improve the resolving 
power of DMS by adding a polar solvent (modifier) to the curtain gas352. Therefore, the analyte 
ions cluster with modifier molecules during the low-field portion of the waveform and undergo 
de-clustering during the high-field half-cycle, thus amplifying their differential mobilities with 
increased ΔCoV (i.e. better separation). Alcohols (e.g. methanol, isopropanol) are most frequently 
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used as modifiers, but their high proton affinity may induce a charge stripping from the analyte, 
which leads to a lower sensitivity.353 The reduction of FWHM of a CoV peak is another approach 
for resolving power enhancement that is typically achieved by extending the ions’ residence time 
within the DMS cell by reducing transport gas flow rate with the throttle gas.354 It is important to 
highlight that although better separation can be attained, long in-cell ion residence time also 
directly leads to significant ion losses. In certain applications, chemical modifier and a throttle gas 
can be used simultaneously to  further improve DMS resolving power.355  
In this study, an alternative approach to enhance resolving power was developed by modifying the 
dimensions of the DMS cell from 1 mm x 10 mm x 30 mm (gap height x electrode width x cell 
length) to 1.5 mm x 20 mm x 63 mm. The enlarged volume of the DMS cell extends the residence 
time, which reduces the FWHM of studied analytes from 3.0 V to 0.8 V (Figure 3.31) without 
application of a throttle gas. Similar FWHM could be reached with the original cell (commercial 
cell with smaller volume) using 34 psi of throttle gas. However, due to the small ∆CoV attained 
with the commercial cell (0.8 V), even when using a throttle gas of 34 psi, it was not possible to 
detect codeine and hydrocodone individually at their optimum sensitivity (CoV peak apex). As an 
alternative, the CoV can be enlarged by increasing the gap height of the DMS cell. In the presented 
study, owing to the larger gap between the two electrodes, CoV as well as ∆CoV were increased 
to 1.5x for the same field strength. Thus, the combined benefits of both reduced FHWM and 
increased ∆CoV enabled the complete separation of these analytes (Figure 3.32). As can be seen 
in Figure 3.33, the interference between codeine and hydrocodone analysis was observed to be less 
than one percent. Although adequate separation for these isomers was accomplished by only 
modifying the geometry of the DMS cell, a chemical modifier and/or throttle gas can also be 










Figure 3.31 A. Overlapping ionograms generated from infusion of codeine or hydrocodone 
individually with the conventional DMS cell (1 x 10 x 30 mm) without applying throttle gas. SV 
was set at 4000 V. B. Overlaid ionograms generated from infusion of codeine or hydrocodone 
individually with the conventional DMS cell (1 x 10 x 30 mm) with 34 psi throttle gas applied. SV 
was set at 4000 V. C. Ionograms generated from infusion of a mixture of codeine and hydrocodone 
with the same condition of B. SV was set at 4000 V. D. Ionograms generated from infusion of a 
mixture of codeine and hydrocodone with the modified DMS cell (1.5 x 20 x 63 mm) without 








Figure 3.32 Ionogram generated from infusion of a methanolic solution containing a mix of 











Figure 3.33 A. Ionograms of analytes extracted by an SPME fiber from human plasma spiked with 
480 ng mL-1 codeine, with the optimal settings for the detection of codeine and hydrocodone, 
respectively. B. Ionograms of analytes extracted by an SPME fiber from human plasma spiked 
with 480 ng mL-1 hydrocodone, with the optimal settings for the detection of codeine and 











Figure 3.34 Ionogram generated from the infusion of a methanolic solution containing mixture of 
norcodeine (a), morphine (b) and hydromorphone (c). SV was set at 6300 V with psi throttle gas 
applied. 
 
As an example, Figure 3.34 presents the separation of other opioid isomers (i.e. norcodeine, 
morphine, and hydromorphone) with shared fragment ions on the modified DMS cell with a 10 psi 
throttle gas. 
 
Isomeric separation with DMS 
The simultaneous quantification of codeine and hydrocodone from human plasma was chosen as 
the example assay to demonstrate the potential of the introduced SPME-OPP-DMS-MS platform 
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for the fast analysis of pain management drugs from biological matrix. As shown in Figure 3.35, 
our results met the analytical requirements set by the World Anti-Doping Agency (WADA). A 
limit of quantification (LOQ) of 1 ng mL-1 and linear dynamic range between 1 and 500 ng mL-1, 
were demonstrated with good accuracy (85-106%) and linearity (R2 > 0.99) (Table 3.16). Given 
that SPME devices can be arrange in a high-throughput assembly (e.g. 96 samples at the same 
time),131 and there is no need for additional separation step other than that offered by DMS, the 
analysis can be as fast as 10-15 seconds per sample.  
 
Figure 3.35 A. Quantitative analysis of plasma spiked with codeine (1 ng ml−1 to 500 ng mL−1) 
and its isotopologue d3-codeine (50 ng mL−1). B. Quantitative analysis of plasma spiked with 
hydrocodone (1 ng ml−1 to 500 ng mL−1) and its isotopologue d3-hydrocodone (50 ng mL−1). Red 
triangles represent the accuracy QC levels (30, 200, and 450 ng mL−1, respectively). 
 
Table 3.16 Figures of merit for the analysis of codeine and hydrocodone in plasma by SPME-
OPP-DMS-MS analysis. 
Compound  
Concentration accuracy (ng/mL, ± SD) LOD 
[ng/mL] 
LOQ 
[ng/mL] 15 [ng/mL] 200 [ng/mL] 450 [ng/mL] 
Codeine 12.7 ± 2.1 184.6 ± 9.8 476.0 ± 13.7 0.2 1.0 





3.5.4 Summary  
A simple, robust and high-throughput technology based on SPME and DMS-MS was introduced 
for quantitative analysis of drugs of abuse and pain-management drugs in biofluids. Following 
extraction, SPME devices with isolated and enriched target analytes were directly coupled to the 
MS system via an OPP sampling interface, without further requirement of injection valves or high 
pressure parts. A modified DMS cell, with significantly improved resolving power, successfully 
distinguished isomeric species with shared fragment ions such as codeine and hydrocodone, 
without the assistance of lengthy LC gradients. The results presented here demonstrate the great 
potential of coupling SPME to DMS-MS in targeted analysis where regular SPME-MS, without 
the assistance of chromatographic separation, might fail to provide a true picture of the sample 
scrutinized. Similarly, this platform could be used for the application of SPME-OPP-DMS-MS 














Chapter 4 Development of Coated Blade Spray and its application towards 
the analysis of complex matrices 
 
4.1 Preamble  
Chapter 4 consists of 5 sections that correspond to four manuscripts published in Angewandte 
Chemie (2), Analytical Chemistry, and Journal of Pharmaceutical and Biomedical Analysis, two 
submitted manuscripts and one manuscript in preparation. Most of the data, tables, and text 
presented within this chapter have already been incorporated in the aforementioned manuscripts, 
the details of which are listed below. Section 4.2 describes the development of Coated Blade Spray 
and its first implementation towards the quantitation of xenobiotics in PBS, urine, and plasma 
samples. Likewise, this section presents preliminary information regarding the fundamental 
operation of CBS. Section 4.3 describes the first application of CBS towards the determination of 
amitriptyline in droplets of blood. Further, the following chapter presents the development of a 
novel strategy that allows for the quantitation of multiple compounds at low part-per-billion levels 
in plasma and blood droplets. Section 4.4 presents the implementation of these technologies 
towards the ultra-fast quantitation of voriconazole in plasma samples, with achieved MS analysis 
times of less than 5 seconds per sample. Section 4.5 presents the development of a novel device 
that allows for the simultaneous performance of 96-CBS extractions, resultantly reducing total 
analysis time per sample to under 1 minute. Finally, section 4.6 introduces the application of HT-
CBS towards the analysis of immunosuppressive drugs in blood samples. This method introduces 
the first instance where extraction with an SPME device is carried out from a matrix modified with 
organic solvent, a practice which was implemented with aims to release analytes heavily bound to 
red-blood cells, such as sirolimus and everolimus. 
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Section 4.2 include the following manuscripts: 
1. Gómez-Ríos, G.A, Pawliszyn, J. Development of coated blade spray ionization mass 
spectrometry for the quantitation of target analytes present in complex matrices, Angew. 
Chem. 2014, 53, 14503-14507, DOI: 10.1002/anie.201407057 
Text, tables, and figures are reprinted from this publication with permission from John Wiley and 
Sons (Copyright 2014 John Wiley and Sons). 
I participated at all stages of the manuscript preparation process: the planning of experiments, 
manufacturing of devices, method development, sample preparation and analyte extraction 
procedures, data processing, manuscript writing and submission, as well as in manuscript replies 
to reviewers.  
 
2. Piri-Moghadam, H.*, Ahmadi, F.*, Gómez-Ríos, G.A.*, Boyacı, E., Reyes-Garcés, N., 
Aghakhani, A., Bojko, B., Pawliszyn, J. Fast Quantitation of Target Analytes in Small Volumes 
of Complex Samples by Matrix-Compatible Solid-Phase Microextraction Devices, Angew. 
Chem. 2016, 128, 7636-7640, DOI: 10.1002/ange.201601476. *Equal contribution 
Text, tables, and figures are reprinted from this publication with permission from John Wiley and 
Sons (Copyright 2016 John Wiley and Sons). 
I participated at all stages of the manuscript preparation process: the planning of experiments, 
manufacturing of the ionization source, manufacturing of CBS devices, method development for 
CBS-MS/MS and HRMS, sample preparation and analyte extraction procedures, data processing, 
manuscript writing and submission, as well as in manuscript replies to reviewers. Dr. Ezel Boyacı 
and Nathaly Reyes-Garcés participated in the manufacturing of CBS devices used in the 
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manuscript, and in the performance of selected experiments for direct coupling. Other authors, as 
listed in Chapter 3, did not participate in the CBS experiments mentioned in this chapter.  
I, Barbara Bojko, authorize German Augusto Gómez-Ríos to use this material for his thesis. 
I, Nathaly Reyes-Garcés, authorize German Augusto Gómez-Ríos to use this material for his 
thesis. 
I, Ezel Boyacı, authorize German Augusto Gómez-Ríos to use this material for his thesis. 
I, Fardin Ahmadi, authorize German Augusto Gómez-Ríos to use this material for his thesis. 
I, Hamed Piri-Moghadam, authorize German Augusto Gómez-Ríos to use this material for his 
thesis. 
I, Ali Aghakhani, authorize German Augusto Gómez-Ríos to use this material for his thesis. 
 
Section 4.3 includes the following manuscript: 
3. Tascon, M.*, Gómez-Ríos, G.A*, Reyes-Garcés, N., Boyacı, E., Poole, J., Pawliszyn, J. Ultra-
fast quantitation of voriconazole in human plasma by coated blade spray mass spectrometry. 
J Pharmaceut. Biomed., 2017, 144, 106-111, DOI: 10.1016/j.jpba.2017.03.009. *Equal 
contribution 
Text, tables, and figures are reprinted from this publication with permission from Elsevier 
(Copyright 2017 Elsevier).  
I participated at all stages of the manuscript preparation process: the planning of experiments, 
manufacturing of CBS devices, method development for determination of voriconazole, sample 
preparation and analyte extraction procedures, data processing, manuscript writing and 
submission, as well as in manuscript replies to reviewers. Dr. Marcos Tascon participated in the 
planning of experiments, in sample preparation procedures, and manuscript writing and 
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submission. Dr. Ezel Boyacı, Justen Poole, and Nathaly Reyes-Garcés participated in the 
manufacturing of CBS devices used in the manuscript.  
I, Marcos Tascon, authorize German Augusto Gómez-Ríos to use this material for his thesis. 
I, Justen Poole, authorize German Augusto Gómez-Ríos to use this material for his thesis. 
I, Nathaly Reyes-Garcés, authorize German Augusto Gómez-Ríos to use this material for his 
thesis. 
I, Ezel Boyacı, authorize German Augusto Gómez-Ríos to use this material for his thesis. 
 
Section 4.4 includes the following manuscript: 
4. Tascon, M.*, Gómez-Ríos, G.A*, Reyes-Garcés, N., Boyacı, E., Poole, J., Pawliszyn, J. High-
Throughput Screening and Quantitation of Target Compounds in Biofluids by Coated Blade 
Spray-Mass Spectrometry. Anal. Chem., 2017, 89 (16), 8421-8428, DOI: 
10.1021/acs.analchem.7b01877. *Equal contribution 
Text, tables, and figures are reprinted from this publication with permission from American 
Chemical Society (Copyright 2017 American Chemical Society).  
I participated at all stages of the manuscript preparation process: the planning of experiments, 
manufacturing of the high-throughput holder, method development for CBS, in sample preparation 
and analyte extraction procedures, data processing, manuscript writing and submission, as well as 
in manuscript replies to reviewers. Dr. Marcos Tascon participated in the planning of experiments, 
sample preparation procedures, and manuscript writing and submission. Dr. Ezel Boyacı, Justen 
Poole and Nathaly Reyes-Garcés participated in the manufacturing of CBS devices used in the 
manuscript.  
I, Marcos Tascon, authorize German Augusto Gómez-Ríos to use this material for his thesis. 
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I, Justen Poole, authorize German Augusto Gómez-Ríos to use this material for his thesis. 
I, Nathaly Reyes-Garcés, authorize German Augusto Gómez-Ríos to use this material for his 
thesis. 
I, Ezel Boyacı, authorize German Augusto Gómez-Ríos to use this material for his thesis. 
 
Section 4.5 includes the following manuscript: 
5. Gómez-Ríos, G.A*, Tascon, M.*, Reyes-Garcés, N., Boyacı, E., Poole, J., Pawliszyn, J. Rapid 
determination of immunosuppressive drug concentrations in whole blood by Coated Blade 
Spray-Tandem Mass Spectrometry (CBS-MS/MS). (manuscript submitted), DOI: (pending). 
*Equal contribution  
I participated at all stages of the manuscript preparation process: the planning of experiments, 
method development for immunosuppressive drugs, in sample preparation and analyte extraction 
procedures, data processing, manuscript writing and submission, as well as in manuscript replies 
to reviewers. Dr. Marcos Tascon participated in the planning of experiments, in the sample 
preparation procedure, and in the writing and submission of this manuscript. Nathaly Reyes-
Garcés participated in the preparation of the CBS devices, as well as in the planning and execution 
of selected experiments. Dr. Ezel Boyacı and Justen Poole participated in the manufacturing of 
CBS devices used in the manuscript.  
I, Marcos Tascon, authorize German Augusto Gómez-Ríos to use this material for his thesis. 
I, Justen Poole, authorize German Augusto Gómez-Ríos to use this material for his thesis. 
I, Nathaly Reyes-Garcés, authorize German Augusto Gómez-Ríos to use this material for his 
thesis. 
I, Ezel Boyacı, authorize German Augusto Gómez-Ríos to use this material for his thesis. 
168 
 
Section 4.6 include the following manuscripts: 
6. Gómez-Ríos, G.A*, Tascon, M.*, Reyes-Garcés, N., Boyacı, E., Poole, J., Pawliszyn, J. 
Quantitative analysis of biofluid spots by coated blade spray mass spectrometry, a new 
approach to rapid screening. (manuscript submitted), DOI: (pending). *Equal contribution  
I participated at all stages of the manuscript preparation process: the planning of experiments, 
method development for spot analysis, sample preparation and analyte extraction procedures, data 
processing, manuscript writing and submission, as well as in manuscript replies to reviewers. Dr. 
Marcos Tascon participated in the planning of experiments, in the sample preparation procedure, 
and in the submission of the manuscript. Dr. Ezel Boyacı, Justen Poole, and Nathaly Reyes-Garcés 
participated in the manufacturing of CBS devices used in the manuscript.  
I, Marcos Tascon, authorize German Augusto Gómez-Ríos to use this material for his thesis. 
I, Justen Poole, authorize German Augusto Gómez-Ríos to use this material for his thesis. 
I, Nathaly Reyes-Garcés, authorize German Augusto Gómez-Ríos to use this material for his 
thesis. 
I, Ezel Boyacı, authorize German Augusto Gómez-Ríos to use this material for his thesis. 
 
7. Gómez-Ríos, G.A*, Tascon, M.*, Reyes-Garcés, N., Aquaro, V., Rickert, D., Kasperkiewicz, 
A., Pawliszyn, J. Lab-on-a-blade. (manuscript in preparation) *Equal contribution  
I participated at all stages of the manuscript preparation process: the planning of experiments, 
method development for analysis of ultra-small volumes, sample preparation and analyte 
extraction procedures, data processing, manuscript writing and submission, as well as in 
manuscript replies to reviewers. Dr. Marcos Tascon participated in the planning of experiments, 
in the sample preparation procedures, and in the submission of the manuscript. Nathaly Reyes-
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Garcés participated in the planning of experiments and data processing. The co-authors Vinicius 
Aquaro, Daniel Rickert, and Alex Kasperkiewicz participated in the preparation of the CBS 
devices and in the execution of selected experiments.  
I, Marcos Tascon, authorize German Augusto Gómez-Ríos to use this material for his thesis. 
I, Vinicius Aquaro, authorize German Augusto Gómez-Ríos to use this material for his thesis. 
I, Nathaly Reyes-Garcés, authorize German Augusto Gómez-Ríos to use this material for his 
thesis. 
I, Daniel Rickert, authorize German Augusto Gómez-Ríos to use this material for his thesis. 


















Section 4.2 Development of coated blade spray ionization mass spectrometry for the 
quantitation of target analytes present in complex matrices 
 
4.2.1 Introduction  
The rapid development of ambient ionization techniques during the beginning of the twenty-first 
century46,57,58,191has allowed for the introduction of new solid phase microextraction (SPME) 
applications. As recently reviewed216, different geometries of SPME have been coupled to direct 
analysis in real-time (DART), desorption electrospray ionization (DESI), surface enhanced laser 
desorption ionization (SELDI), and matrix-assisted laser desorption ionization (MALDI) in a 
broad range of applications104,144,175–177,179,194,210. The present study reports the development of a 
novel SPME configuration that allows its use, without further modifications, as an ambient 
ionization method for mass spectrometry. 
 
4.2.2 Experimental section  
Mass Spectrometry 
Experiments were carried out either on a TSQ Vantage™ or an Orbitrap mass spectrometer 
(Thermo Scientific, San Jose, CA, USA). To guarantee the accurate position of the blades in front 
of the mass spectrometer during all experiments, an in-house ionization source was built at the 
University of Waterloo (Figure 4.1 and 4.2). The 3D-moving stage (Newport Corporation, Irvine, 
CA) not only adjusts the position with a precision of 0.02 mm in each dimension (25 mm moving 
path), but also tunes the spraying tip at different angles on the Z dimension (± 0.01º per moving 
mark). In order to ensure optimum ion transmission, the position of the blade-tip should not be 















Figure 4.1 In-house ionization source for blade spray technology. The 3D-moving stage (Newport 
Corporation, Irvine, CA) not only adjust the position with a precision of 0.02 mm in each 
dimension (25 mm moving path), but also tunes the spraying tip at different angles on the Z 
dimension (± 0.01º per moving mark). In order to ensure optimum ion transmission, the position 








Figure 4.2 Schematic of the spring loading system for easy replacement and accurate positioning 




Blades were made by hand at the machine shop of the University of Waterloo. Coated blades were 
prepared in house by spraying a C18-polyacrylonitrile (C18-PAN) solution according to a protocol 
developed in our laboratory.  
 
Biological samples 
A phosphate-buffered saline solution (PBS) (pH 7.4) was prepared according to the protocol 
described in Section 2.2.2. Pooled human plasma and whole blood from healthy donors in 
potassium (K2) ethylenediaminetetraacetic acid (EDTA) were purchased from Lampire Biological 
Laboratories (Pipersville, PA, USA). Urine samples were collected from two healthy volunteers. 
Collection of urine from healthy volunteers for this particular study was under the approval of the 
Office of Research Ethical Board of University of Waterloo. 
 
Materials and supplies 
The following compounds were selected as model analytes to evaluate CBS: cocaine and 
diazepam. Deuterated analogues of each analyte were used for correction of intra- and inter-
experiment variability. Further details about compounds properties and SRM transitions are 
provided on Table 2.1. LC-MS grade solvents (acetonitrile, methanol, and water) used in all the 
experiments were purchased from Fischer Scientific. Calibration curves of each analyte were 
prepared on each matrix between 0.01 and 100 ng mL-1. 
 
4.2.3 Results and discussion 
Coated blade spray (CBS) was conceived as an ideal compromise between sample preparation and 


























Figure 4.4 Photograhps taken at the tip of a CBS while starting the ESI event. A voltage of 4 kV 





(Ø ≤ 200μm) cut as a “gladius sword” and coated with a biocompatible polymer (C18-PAN). As a 
sample preparation method, the SPME coating (Ø ≤ 80μm) simultaneously isolates and enriches 
the analytes present in the matrix without removing matrix itself150. In addition, since the coating 
is matrix compatible and tuned towards the analytes of interest and the extraction occurs via free 
form, the technique allows for clean-up of undesirable artefacts that might provide ion suppression 
or enhancement typically observed placing the matrix directly in front of mass 
spectrometer149,150,357. As an ambient ionization technique, the coated blade acts as a solid-
substrate ESI source46,58; ions of the extracted/pre-concentrated analytes are generated by applying 
a high electric field to a blade pre-wetted with a small volume (≤ 20 µL) of desorption solution 
(see Figure 4.4). As summarized on Figure 4.3, the analytical process consists of three simple 
steps: first, a pre-conditioned blade is inserted in a vial containing the sample matrix (300-1500 
µL) and quick extraction/enrichment is performed by agitating the sample at high speed (vortex 
agitation at 3200 rpm, t ≤ 1 min); then, the blade is rapidly rinsed in a vial containing water (t ≤ 
10s), aiming to remove matrix components adhered to the coating surface; finally, the blade is 
installed on the blade-holder, in which a spring-loading based system allows straightforward 
connection of high voltage (HV) to the blade and its easy and fast replacement between 
experiments (Figure 4.2). Similar to other substrate-spray methodologies, the duration and 
intensity of the analyte signal is affected by the amount extracted, the volume and chemical 
features of desorption solvent, the wetting time (time preceding application of HV), and the 
spraying voltage49,90,95,225,358,359. In fact, given that coated blade-spray is a merger between sample 
preparation and ambient ionization, the selection of adequate desorption/ionization conditions 
depends on the following: a. the chemistry of the analyte and its affinity for the desorption solvent; 
b. kinetics of the analyte partitioning between coating layer and the solvent drop (elution efficiency 
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of the analytes), and c. spray efficiency of the solvent at the tip of the blade191,358. Optimization of 
such parameters using experimental design resulted in 17.5 µL of methanol, 37.5 s wetting time, 
and 3.5 kV as the most favourable conditions for analysis of diazepam (DZP). However, it is worth 
emphasizing that these values are valid only for the compound studied in the present work, and 
during the development of a new blade-spray analytical method, all these parameters must be 
thoroughly addressed by the analyst. 
In view of the fact that CBS and paper spray (PS) have similarities in the design of the devices 
(differences and resemblances between PS and CBS were summarized on ESI, Table 4.1)191, an 
analogy in the ionization mechanism is plausible[25].There are three key resemblances among the 
techniques. First, the design of the spraying tip, which consists of a macroscopically sharp point 
with an optimum tip angled at less than 90º. Second, the desorption solution transports the analytes 
towards the tip once a high potential is applied between the device and the mass spectrometer inlet. 
Third, the electrical field created among the blade and the MS inlet induces a charge that    
accumulates at the vertex of the device, causing ionization, as previously described for 
electrospray225,358. However, provided that CBS is made of conductive materials such as stainless 
steel rather than a porous non-conductive substrate as paper, it could be assumed that a steady 
electric field is produced at the CBS tip. As a result of the stable electric field gradient between 
the metal tip and the MS inlet is generated and a more reproducible and efficient ion formation 
during the spray is expected. Consequently, method sensitivity with CBS is presumed to be 
improved not only by the enrichment factor provided by SPME, but also by the enhancement in 
ionization. It is important to highlight that similar to PS358 corona discharge can also occur in CBS 
when electrical potentials above 4.5 kV are applied to the metal blade (particularly when the 
solvent has been depleted). Although the mechanisms governing CBS ionization have not been  
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Table 4.1 Comparison of CBS to other direct-to-MS technologies. 
Features Paper Spray (PS) Coated Blade Spray (CBS) online-SPE-MS 
Substrate Paper Stainless Steel -
Ionization mechanism ESI ESI ESI/APCI 
Solvent assistance  Yes Yes Yes 
Extraction mechanism No SPME SPE 
Sample clean-up Limited Yes Yes 
Sample normalization No Yes Yes 
Sample preparation Limited Yes Yes 
Extraction selectivity No Yes Yes 
Suitable for complex matrices  Yes Yes Yes 
Small sample volumes (≤ 50 µL) Yes Yes Yes 
Typical sample volumes  (50 - 1000 µL) No Yes Yes 
Large  sample volumes (≥ 1000 µL) No Yes No 
Direct tissue analysis Yes Yes No 
in-vivo analysis No Yes No 
on-site analysis (portable) Yes Yes No 
Linear dynamic range low ppb-ppm low ppt-ppm low ppt-ppm 
Device robustness Low High High 
MS analysis time 60-120s 1-120s 10-15s 
Total analysis time 2-120 mina  0.5-90 minb 1 min ≥c 
Cost per analysis Low Moderate High 
Reusability Disposable Disposable Reusable 
Desorption/ionization automation Yes Yes Yes 
Sample preparation automation No Yes Yes 
Workflow simplicity Yes Yes Yes 
Compatibility with all MS vendors Yes Yes Nod 
Quantitation of multiple analytes (via Yes Yes Limited 
Green analytical method  Yes Yes No 
Surface sampling (rubbing) Yes No No 
Ambient ionization under small voltages Yes No No 
 
a Depending upon drying of the sample on the substrate 
b Sample preparation time can be extended until equilibrium or exhaustive extraction is attained  
c Depending upon complexity of the matrix     




thoroughly explored yet by the authors of this manuscript, the protocol for the analysis of complex 
mixtures is simple and rapid. Surely, a better understanding of the fundamentals involved in the 
coated blade spray mass spectrometry should allow for improvements in the performance of the 
technique, as well as widening the scope of its applications58,198,358. 
Since its conception, ambient ionization methods have been developed to circumvent several steps 
in the analytical process57. Indeed, sample preparation approaches coupled to MS have been 
erroneously visualized by ambient mass spectrometrists as unnecessary, byzantine, and tedious. 
Conversely to what is normally believed57, SPME extraction/enrichment can be performed in a 
short period of time, and the LOD of the method is generally constrained by the instrumental 
capabilities rather than by the intrinsic features of the coating149,228. For instance, 15 seconds are 
enough to extract a quantifiable amount of analyte at the low ppb level by a traditional LC/MS 
method (Figure 2.6). Direct coupling of SPME to MS can easily surpass these detection limits, 
since the desorption/dilution step inherent in most SPME-LC methods is removed from the 
analytical procedure. In addition, since extractions are carried-out at pre-equilibrium115, the 
amount of analyte collected is controlled by the convection conditions (i.e. boundary layer), the 
extraction time, and the surface area of the extracting phase. Hence, under an identical sampling 
setting, CBS can exceed the sensitivity achieved by other SPME geometries owing to its high 
surface area124. By merely increasing the interaction time between the coating and the sample 
matrix from 15 seconds to 1 minute, lower LODs can be achieved. As can be seen in Figure 4.5, 
LOQs as low as 1 ppt were estimated by performing 1 minute extraction from 1.5 mL of phosphate 
buffered saline (PBS) spiked with cocaine (calibration functions were constructed based on the 
signal ratio of the analyte and its isotopologue [A/Is]),  obtained with three independent CBS) . 
Furthermore, the linear dynamic range of the method, evaluated up to 1 ppm, showed astounding 
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linearity. Beyond any doubt, high concentration levels are not a limitation for SPME115. Indeed, in 
cases where the affinity of the coating for the analytes is high and analytes are present at 
concentrations superior to 50 ppb, shorter extraction times (≤ 30 s) can be performed. 
The remarkable features of blade-spray technology, in comparison to other ambient mass 
spectrometry devices, include its reusability and intra/inter-device reproducibility144,231. 
Extractions performed with three independent blades (n=12) from 1.5 mL of a PBS solution 
containing 10 ppb of DZP showed intra/inter-blade relative standard deviations (RSD) lower than 
1.8% (Table 4.2). Certainly, producing coatings having reproducible characteristics resulted in 
excellent reproducibility and repeatability. Besides, since the extraction phase normalized the 
sample matrix placed in front of mass spectrometer,  by extracting only small molecules (i.e. 
analytes of interest) in amounts corresponding to their free concentration in the sample, this ensure 


















Figure 4.5 a. Quantitative analysis of PBS spiked with cocaine (2 pg mL-1 to 1 µg mL-1) and its 
isotopologue [D3] cocaine (14.5 ng mL-1). Bars represent the standard deviation of analyses for 
three replicates with independent blades. a. Insert plot shows low-concentration range; b. 




Table 4.2 Inter- and intra-blade reproducibility (n=12). Results are reported as ratio of analyte 
(diazepam) versus internal standard isotopologue [D5] diazepam. 1 min extractions were 
performed using vortex agitator set-up at maximum speed (3200 rpm). Extraction from 1.5 mL of 
PBS spiked with10 ng mL-1of each substance. Analyses were performed using Thermo TSQ on 
SRM mode. Blade spray conditions: 17.5 μL methanol, 3.5 kV, and 37 s wetting time. SD, standard 
deviation. RSD, relative standard deviation.  
Repetition Blade 1 Blade 2 Blade 3  
1 0.99 1.01 1.00  
2 0.98 1.00 1.00  
3 1.02 0.97 0.99  
4 0.98 0.98 0.99 Summary 
Average 0.99 0.99 1.00 0.99 
SD 0.02 0.02 0.01 0.01 
RSD 1.8 1.7 0.7 1.3 
 
In addition, carry-over was negligible by implementing a cleaning step once the 
extraction/desorption-ionization cycle was completed. A mixture of methanol (MeOH, 50%), 
isopropanol (IPA, 25%), and acetonitrile (ACN, 25%) was found on preliminary experiments to 
be an ideal solution to get rid of most residual analytes from preceding extractions148. It is worth 
emphasizing that the cleaning step should be optimized according to the chemistry of the coating 
and its affinity towards the analyte of interest. In cases in which large variability exists in sample 
concentration among samples (e.g. low ppt to high ppb or even ppm levels), blades should be 
constrained to single use. Otherwise, a small amount of analyte (few pg) could potentially linger 
on the blade after the desorption/cleaning cycle, yielding possible false positives. As a solution, 
while working with compounds with high affinity towards the coating133 that are present in the 
sample at concentrations higher than 50 ppb, shorter extraction times (≤ 30 s) are recommended 
to diminish the amount of analyte enriched; this precaution would guarantee a complete removal 
of the non-sprayed analytes during the cleaning step. In addition, by using thin coatings, efficient 
equilibration of the analytes can be achieved (faster extractions), together with more effective 
desorption/ionizations. Thus, blades coated with a consistent and reproducible thinner layer of 
sorbent are under development in our laboratory (see Section 4.3).  
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In contrast to PS, another exceptional characteristic of CBS is the mechanical strength provided 
by the use of a stiff substrate in the creation of the blades. As a result, deformation/damage of the 
device does not occur, regardless of the sample dimensions. Thus, CBS could be used to perform 
extractions from small volumes (e.g. few microliters, as extractive blood spot) up to large volumes 
(e.g. hundreds of litres, as on-site monitoring of a watercourse/lake). Additionally, analogous to 
thin film microextraction (TFME)231, CBS can be implanted into tissue for in vivo monitoring of 
endogenous and exogenous substances. Indeed, the geometry of the device for in vivo applications 
might not be limited to a flat surface. For instance, a cylindrical coated device (i.e. metal pin with 
Ø ≤ 150μm) could provide mildly-intrusive access inside the tissue346, otherwise non-accessible 
by modern methods (e.g. DESI), with minimal damage. Succinctly, contrary to most ambient 
ionization techniques, SPME-based spray approaches can be used for in situ, in vivo, ex vivo and 
on-site applications independently of the sample characteristics (e.g. volume, structure, 
complexity, and viscosity) with truly minimal sample preparation. 
An exclusive characteristic of blade spray is its capability to perform reproducible and independent 
desorption/ionization from each side of the blade (Figure 4.6). Hence, analysis in duplicate of each 
sample from a single extraction is feasible when the blade is coated with the same extraction phase 
on both sides. Indeed, multiple attempts towards the development of a comprehensive coating for 
SPME have been investigated357. The universal approach for complete coverage, solid phase 
extraction (SPE), consists of combining two or more extraction phases with different affinities for 
the analytes, e.g. coatings that provide hydrophobic and hydrophilic interactions. However, by 
using this procedure, a compromise has to be often made in regards to the chemistry of both 
coatings, and generally an intermediate phase is obtained. The device herein presented can be 
coated with a different polymeric phase on each side; thus, covering two different ranges of 
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polarities and consequently providing a genuinely comprehensive analysis in a single 
experiment357. Considering the above mentioned, CBS appears to be a practical tool for 
metabolomics studies; however, further research regarding its reproducibility and quantitation 
capabilities without using internal standard (Is) is still required prior to its application for 
untargeted analysis in complex matrices. As recently reported by our group267, once the SPME 
geometrical characteristics that affect the desorption/ionization of the analytes are controlled, 
reproducible quantitation without Is is feasible. Therefore, our ongoing research is primarily 
focused on optimizing the geometry of CBS and coating characteristics to provide run-to-run and 
batch-to-batch reproducible results even when an Is is not used for signal correction. Considering 
that CBS, as a SPME device, reduces matrix effects and provides matrix normalization (i.e.  
 
Figure 4.6 A. Ion chronograms of three desorptions/ionizations of cocaine from the same side of 
the blade (blade spray conditions: 15 μL methanol, 4 kV, and 45s wetting time). 1 min extractions 
were performed using a vortex agitator set-up at maximum speed (3200 rpm). B. Ion chronograms 
of cocaine obtained from the desorption/ionization of both sides of the blade. Extractions from 1.5 
mL of PBS spiked with 100 ng mL-1of cocaine using a single blade. Analyses were performed 




analytes are extracted/pre-concentrated in a well-defined non-interfering matrix which is the 
coated sorbent), precise geometrical conditions (e.g. thin homogenous layer of particles267) will 
facilitate its application as a quantitative tool in metabolomics research. Given the simplicity and 
speed of analysis with CBS, the technique can be said to be an ideal device for the screening of 
pharmaceutical drugs or illicit compounds in biological samples. Blade spray was used for the 
quantification of cocaine and diazepam in urine and plasma. As can be seen in Figure 4.7, 
exceptional linearity was achieved in both matrices.  
 
Figure 4.7 A. Quantitative analysis of plasma spiked with cocaine (500 pg mL-1 to 100 ng mL-1) 
and its isotopomer [D3] cocaine (14.5 ng mL-1). B. Quantitative analysis of plasma spiked with 
diazepam (500 pg mL-1 to 100 ng mL-1) and its isotopomer [D5] diazepam (16 ng mL-1). C. 
Quantitative analysis of urine spiked with cocaine (500 pg mL-1 to 100 ng mL-1) and its isotopomer 
[D3] cocaine (14.5 ng mL-1). D. Quantitative analysis of urine spiked with diazepam (500 pg mL-










Figure 4.8 Ion chronograms of a blade sprayed after 10s rinsing step in water (green) versus blade 
sprayed without rinsing (blue). 1 min extraction from 1.5 mL of PBS spiked with500 pg mL-1of 
cocaine using a single blade. Analyses were performed using a Thermo TSQ on SRM mode.  
 
 
Similar to the results obtained in PBS, LOQs of 0.5 and 2 pg mL-1 were estimated for cocaine in 
plasma and urine, respectively. As expected, in a comparison made with nanopure water spiked 
with target analytes (Figure 4.8), it was found that the rinsing step was critical in the diminishment 
of ionization suppression from salts (e.g. from urine/PBS) and attachment of biomolecules to the 
coating surface (e.g. from plasma). In summary, by using a microextraction device to 
extract/transfer the analytes from the sample matrix to the MS system, matrix effects for analytes 
with low binding are significantly minimized, and detection limits are similar independently of the 
matrix (e.g. cocaine, 5 % protein binding)131. Indubitably, sample clean-up provided by CBS is 
convenient not only for quantitation purposes, but also to extend the operative time of the mass 
spectrometer by minimizing instrument maintenance and providing steady instrumental 
sensitivity. Unlike cocaine, LOD/LOQ for DZP in plasma were estimated in 15 and 50 ppt, 
respectively. Certainly, the quantification limit is higher in comparison to urine and PBS (LOQ ~ 
5 ppt). However, it is worth emphasizing that DZP is 98% bound to plasma proteins and, as an 
SPME device, CBS equilibrates only with the free-portion of analyte in the sample2. Total analysis 
time (extraction from a complex matrix without pre-treatment, rinsing, desorption/ionization, peak 
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integration, and quantitation of total concentration) is less than 2 minutes per sample when 
performing manual operation of the blades. 
Nowadays, multiple efforts are directed towards the development of powerful LC-MS/MS or GC-
MS/MS methods that allow for the analysis of controlled substances in complex matrices. Given 
the complexity of the samples, such procedures entail cumbersome and extensive sample 
preparation steps. Consequently, approaches that allow fast, quantitative, and direct analysis are 
highly demanded. As a proof of concept, blade spray was used to screen 21 compounds controlled 
by the World Anti-Doping Agency (WADA) and the United Nations Office of Drugs and Crime 
(UNODC)131,360. Selected reaction monitoring (SRM) mode was used to uniquely identify each 
substance (see Table 2.1). Although desorption/ionization conditions were not optimized for each 
analyte, all substances were detected at 20 ppb, and 14 of these compounds provided hypothetical 
LODs lower than 50 ppt (e.g. clenbuterol, 6-acetylcodeine, and toremifene). As blade spray derives 
its selectivity and sensitivity from the chemical and physical properties of the coating used, current 
research is directed towards coatings with higher affinity for the target compounds in order to 
reach lower limits of detection131. Undeniably, the capability of CBS to simultaneously screen 
multiple substances of interest in a single analysis, without sacrificing sensitivity or increasing the 
analysis time, is an outstanding characteristic of this technique. Thus, the application of CBS for 
the concomitant monitoring of numerous pesticides in food commodities, personal care products 
in wastewater, or doping substances in high-performance competitions is foreseen in the near 
future (as discussed in Section 4.4)81.  
Fundamentally speaking, CBS is capable of quantifying even more compounds in a single analysis 
because the electrospray event can be extended by using a continuous solvent supply. As a proof-
of-concept, a glass capillary was connected to a syringe pump which was continuously supplying  
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Figure 4.9 Experimental set-up used for segmented CBS desorption. Glass capillary was moved 
by hand from the tip of the blade towards the back of the coating while high-voltage was on.   
 
 
Figure 4.10 Ion chronograms for cocaine (top) and fentanyl (bottom) obtained from a CBS that 




a flow of 10 µL/min of desorption solvent (see Figure 4.9). Unlike the previous experiments, where 
a finite amount of desorption solvent was added with a pipette, the capillary was moved by hand 
from the tip of the blade towards the back. Thus, by performing a segmented desorption, rather 
than a “complete” desorption, a continuous signal was attained. As can be seen in Figure 4.10, 
after approximately 2.5 minutes, signal drops as a result of analyte depletion. Certainly, increase 
and decrease on the ion signal are a consequence of either: inaccurate position of the capillary on 
the blade, imprecise speed while moving the capillary, or irregular distance from the capillary to 
the coating area. Although preliminary, these results showed the potential of CBS of performing 
long spray events which is critical when hundreds of compounds need to be monitored243. Our 
efforts are currently focused on developing an interface that allows having a steady analyte signal 
for no less than 2 minutes.  
 
Towards small sample volumes 
SPME Micro tips, discussed in Chapter 3, can effectively sample small volumes of selected parts 
of a living object. If the object is sufficiently large, the damage caused by insertion can be 
considered negligible or sufficiently minimized, allowing for multiple samplings to be 
subsequently performed to investigate changes in the system as a function of time or applied 
stimuli. However, if the sample is so small as to be substantially disturbed or consumed during 
extraction, or if the living object is so small as to not withstand sampling without loss of life, 
repetition of the sampling procedure is not possible. For such cases, exhaustive extraction on a 
coated larger flat surface might be a more attractive approach. To pursue this line of inquiry, 
CBS136 was implemented for the first time as a novel strategy for the analysis of small volumes of 
biofluids136. Unlike applications involving the tips, no additional instrumentation (i.e. LC or nano-
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ESI emitter) or sample containers (e.g. vial) are needed to perform CBS analyses. As summarized 
in Figure 4.11, the analytical process consists of three simple steps: first, a drop of sample (≤ 10 
μL) is placed on the coated blade for 5 minutes (static conditions); then, the blade is rapidly rinsed 
in a vial containing water (t ≤ 10s); and finally, the blade is installed in front of the MS system for 
analysis, as described in the experimental section136. As a sample preparation method, the coating 
(thickness ≤ 10μm) simultaneously isolates and enriches the analytes present in the sample. Indeed, 
given the high affinity of HLB304 for a broad range of compounds, multiple rinsing steps can be  
performed to wash off matrix components potentially adhered to the surface with minimal to no 












Figure 4.11 a. Experimental set up for analysis of small volumes with coated blade spray. b. 
Quantitative analysis of whole blood spiked with amitriptyline (5 ng ml−1 to 250 ng mL−1) and its 
isotopologue [D6] amitriptyline (100 ng mL−1). 5 µL of sample were spotted on the blade, and 5 
min static extraction/enrichment conducted using HLB-PAN coated blades. Bars represent the 
standard deviation of analyses for three replicates with independent blades. c. Ion chronogram of 
amitriptyline; acquisition time of 30 s in positive mode SRM (278 → 233 m/z); d. Ion chronogram 
of quercetin; acquisition time of 30 s in negative mode; SRM (301 → 251 m/z). 
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Our results demonstrated that not only was good reproducibility attained (RSD ≤ 2%, calculated 
based on the signal ratio of the analyte and its isotopologue [A/Is]), but also noteworthy 
improvement of the LOQ for amitriptyline was achieved in comparison to that obtained with use 
of the tips (LOQ ~ 5 ng mL-1 versus 25 ng mL-1 attained with the tips). Essentially, the extraction 
efficiency of SPME techniques can be enhanced by increasing the affinity of the coating for the 
analytes (chemistry of the extraction phase) and/or by increasing the volume or active surface area 
of the extraction phase. Certainly, the coated area of the blade where the droplet is placed 
significantly surpasses the total area of the SPME-tip. Therefore, in cases where both the affinity 
of the analyte for the coating and the extraction recovery are high (e.g. low matrix-binding), CBS 
should conceptually be considered as an open-bed SPE device, rather than as an SPME device. 
Finally, as a proof-of-concept, CBS was used for the qualitative determination of quercetin in 5 
μL of homogenized onions (Figure 4.11). Negative ionization was used for identification of the 
analyte collected by the blade (301 → 251 m/z) after 5 minutes of contact. The obtained results 
evidence the great potential of CBS for finger-printing and population studies of microorganisms 
such as cells, fungi, and bacteria. Hence, instead of inserting a mini-probe into a cell, 
single/multiple cells can be placed on top of the coated surface, and then burst to release their 
cytoplasmatic content. After allowing some time for extraction, the remaining cell components 
can then be washed, enabling subsequent determinations to be performed either by high-resolution 
(i.e. metabolite profiling) or tandem mass spectrometry (i.e. target-analysis). 
 
4.2.4 Summary  
Other major future applications of CBS involve in situ applications within the medical field. The 
ability to deliver a rapid prognostic metric of clinical condition is certainly important in the critical-
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care setting (emergency and surgery units)152. Thus, molecular diagnostic and prognostic 
instruments, which are able to provide doctors with fast and reliable results, are highly desired in 
such facilities for personalized diagnosis and treatment of patients. Although CBS reusability is 
undoubtedly beneficial in fields where high-throughput is needed and hundreds of samples need 
be processed on a daily basis, blade spray is also envisioned as a splendid single use device for 
trace analysis. For this reason, our group is currently working on the development of a cost-
effective disposable device. By coupling disposable blade spray (dCBS) to portable/easily-
deployable mass spectrometers361, fast, reliable and “real-time” measurements will be provided on 
site. Thus, due to their speed, sensitivity, selectivity, and linear dynamic range, dBS-MS/MS will 
be an avantgarde tool not only for point-of-care therapeutic drug monitoring, but also in diverse 
forensic, food, medical and environmental applications. Indeed, the many advantages of using 
CBS and other SPME-MS configurations will certainly encourage analytical scientists around the 
world to choose these swifter sample preparation approaches prior to direct introduction to MS 












Section 4.3 Ultra-fast quantitation of voriconazole in human plasma by coated blade spray 
mass spectrometry 
 
4.3.1 Introduction  
Voriconazole is an antifungal drug from the family of the triazoles. As a derivative of fluconazole, 
voriconazole possesses a fluoropyrimidine group rather than a triazole moiety in addition to an 
alpha methylation on the tertiary carbon 362. In contrast to the first generation of triazole 
antifungals, voriconazole has a broader spectrum of action363,364 and has been demonstrated as 
effective against fungal infections caused by Aspergillus365 and Fusarium species364. The 
mechanism of action consists of the inhibition of cytochrome P450 enzyme lanosterol 14-alpha-
demethylase, which prevents the conversion of lanosterol to ergosterol, an essential component of 
cell membranes366. Although the effectiveness of this antifungal drug has been widely proven, 
toxicity risks and a narrow therapeutic concentration window have been reported. Indeed, plasma 
concentrations above 6 μg/mL have been associated with clinical events such as visual impairment 
or photopsia, abnormal hepatic function, and higher bilirubin levels367,368. On the other hand, in 
cases where voriconazole plasma concentrations were below 2 μg/mL, a great proportion of 
patients suffered a significant progression in their infections369. In addition, high pharmacokinetic 
variability of this drug due to erratic bioavailability and variation in drug metabolism has also been 
documented370. Consequently, the development of an accurate, reliable, fast, and cost-effective 
analysis of voriconazole in plasma is highly desirable.  
Most of the methods for voriconazole determination to date involve the use of liquid 
chromatography (LC) with either ultra-violet (UV)362 or mass spectrometry (MS)371–374 detection. 
In addition, methods employing gas chromatography-MS (GC-MS)375 and capillary 
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electrophoresis (CE)376 have also been reported. Within the LC-MS applications, the fastest LC 
separation was attained in 3 minutes377 and the sample volume consumption was in the range 
between 20 µL371 and 200 µL377 of plasma. However, when the sample preparation step is 
considered in the total analysis time, none of the published methodologies can be completed in 
less than 15 minutes considering that even in the simplest approaches protein precipitation and 
centrifugation steps are required in order to have an extract suitable for liquid chromatography373. 
Recent developments in bioanalytical applications using solid phase microextraction (SPME) have 
demonstrated that this technology is an attractive alternative to conventional methods due to its 
simplicity, sensitivity and speed of analysis136. In SPME, a device coated with a polymeric material 
is used to extract/enrich analytes from a given sample prior to instrumental analysis. By using 
novel ultra-thin biocompatible coatings, faster and efficient extractions of small molecules from 
biofluids can be easily attained113,119,151. Despite the well-known advantages of using LC, 
emerging technologies such ambient mass spectrometry46,58,94,95,378 and the direct coupling of 
SPME to very sensitive and selective mass spectrometers have shown outstanding results when 
aiming to decrease the total analysis time173. Among the recently developed SPME-MS 
technologies, coated blade spray (CBS)136, SPME-TM-direct analysis in real time (SPME-
DART)267, Bio-SPME-nano-ESI173, Bio-SPME-OPP36 and SPME-DBDI379 excel by the limits of 
detection achieved. Succinctly, CBS was developed as an ideal compromise between sample 
preparation and direct coupling to mass spectrometry and it behaves as an SPME device for 
extraction and as a solid-substrate ESI source when performing ionization. When comparing CBS 
to other SPME-MS technologies, the former offers additional advantages such as simplicity of the 




Figure 4.12 Schematic of the experimental set-ups for extraction/enrichment of voriconazole from 
plasma and desorption–ionization via Coated Blade Spray-Mass Spectrometry. 
 
minimal solvent use (≤ 20 µL), and no-need of expensive parts for the construction of the 
ionization source136.  In addition, CBS is the device with the largest coated surface area available 
for extraction when compare to the other SPME-devices used for direct coupling to MS; therefore, 
low or even sub parts per billion levels can be easily achieved when rapid extractions (time ≤ 2 
min) are performed from small sample volumes (≤ 300 µL).          
In this work, we propose the ultra-fast determination of voriconazole in human plasma by two 
different CBS-based approaches. In the first strategy, voriconazole is extracted on the CBS device 
by fully immersion of the coated blade in 300 µL of human plasma during 1 minute under vortex 
agitation. In the second approach, analytes are enriched on the CBS by placing a 10 µL droplet of 
plasma for 2 minutes on the coated area. After the completion of the extraction process in both 
cases, a quick rinsing step is performed in order to remove matrix components potentially adhered 
to the surface. Once complete, analytes were directly desorbed/ionized from the CBS device and 
analyzed by mass spectrometry without the need of additional sample preparation or 
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chromatography. Both methodologies were fully validated in terms of linearity, LOD, LOQ, 
repeatability, reproducibility, relative matrix effects and accuracy employing 5 different lots of 
plasma and 4 different patients.  
 
4.3.2 Experimental section 
Mass Spectrometry 
All the experiments were performed using a TSQ Quantiva (Thermo Scientific, San Jose, 
California, USA). Data was processed using Trace Finder version 3.0 (Thermo Scientific, San 
Jose, California, USA). A home-made coated blade spray interface was built at University of 
Waterloo, and a thorough description of the operation of this system can be found elsewhere136.     
 
Materials and supplies 
Methanol (MeOH), acetonitrile (ACN), isopropanol (IPA) and water were all LC-MS grade and 
purchased from Fisher Scientific. Formic acid was purchased from Sigma Aldrich (Saint Louis, 
USA). Voriconazole and the deuterated analogue voriconazole-d3 were obtained from Sigma 
Aldrich (Milwaukee, USA) and Cerilliant (Saint Louis, USA), respectively. Individual stock 
standard solutions of voriconazole at a concentration of 5000 µg·mL-1 were prepared in methanol 
and stored at -80 ºC. Human plasma (with K2-EDTA as anticoagulant) from different patients was 
purchased from Bioreclamation IVT (Westbury, New York, USA). All the plasma samples were 
spiked and stored overnight at 4 ºC prior to use to reach drug-protein binding equilibrium. HLB 
particles (~ 5 µm particle diameter) were kindly provided by Waters Corporation (Wilmslow, UK). 
Stainless steel blades were purchased from Shimifrez Inc. (Concord, Ontario, Canada). Blades (15 
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mm length) were coated with HLB-polyacrylonitrile (HLB-PAN) slurry according to a protocol 
developed in our laboratory (see Section 4.4.2).  
Sample preparation 
All the CBS devices were cleaned after manufacturing for 30 minutes using a 40:40:20 
(MeOH/ACN/IPA, v/v/v) solution and then conditioned for 30 minutes with a 50:50 
(MeOH/water, v/v) solution prior to extraction process. It is important to point-out that, regardless 
of the application, CBS can be dried prior to the extraction step. The first of two methodologies to 
be described consisted of the extraction/enrichment of voriconazole from 300 µL of human plasma 
for 1 minute using vortex agitation (3200 rpm), followed by two independent rinsing steps in 
300µL of water (under agitation, t ≤ 5s). The second approach involved the spotting of a 10 µL 
droplet of plasma onto the coated surface of the CBS device. After 2 minutes of extraction, two 
rinsing steps of 5 seconds using water were performed. A schematic of both procedures is 
presented in Figure 4.12. After extraction, the CBS devices were positioned in the home-made 
interface and 10 µL of a 95:5 MeOH/water v/v 0.1% formic acid solution were added on the coated 
area to desorb the analytes (t ≤ 20 s). Subsequently, a voltage of 5.5 kV was established between 
the CBS and the MS entrance to electrospray the target analytes from the tip of the blade. All the 
analysis were carried out exclusively in positive ionization mode. Optimum collision energy and 
RF-lenses conditions were tuned for each compound by direct infusion of methanolic standards. 
MS/MS transitions, optimum collision energy (CE), and RF-lenses voltage were 350.18→281.05, 
16.5 V, and 58 V for voriconazole, respectively; and 353.18→284.12, 16.5 V and 59 V for 
voriconazole-d3, respectively. The total MS/MS event was 3 seconds with a dwell time of 100 ms 
for each compound. Xcalibur software (Thermo Scientific, San Jose, California, USA, version 4.0) 
was employed for data acquisition. Calibration curves were prepared in the range between 0.1 
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µg/mL and 50 µg/mL. Extractions from each calibration point were performed using three 
independent replicates. The linear regression was plotted as the area of the analyte divided by the 
area of the internal standard as a function of the concentration (unweighted linear least squares). 
Voriconazole-d3 was spiked in plasma samples as an internal standard at a concentration of 5 
µg/mL. Both approaches were validated in terms of LOD, LOQ, linearity, repeatability, 
reproducibility, accuracy and relative matrix effects. The latter was evaluated by following the 
criterion proposed by Matuszewski, B. K. which consists in the comparison of the RSD associated 
to the slopes of five calibration curves from five different lots of biofluids 131,380. 
 
4.3.3 Results and discussion 
Aiming to develop an ultra-fast analysis, while monitoring two MS/MS transitions (i.e. compound 
of interest and its internal standard), the electrospray event was set to 3 seconds using a dwell time 
of 100 ms for each compound. Thus, a minimum of 15 scans per compound is obtained without 
significantly increasing the total analysis time. Ion chronograms related to the selective reaction 
monitoring (SRM) of voriconazole at different concentration levels, including the plasma blank, 
are presented in Figure 4.13. As can be seen, the full width at half maximum (FWHM) of each 
pulse is exactly three seconds and the instrumental signal increases with an increase in the plasma 
concentration of voriconazole.  
In order to optimize the enrichment step, extraction time profiles were constructed at the extraction 
conditions of both CBS approaches: extraction with forced convection (~ 3200 rpm) and spot 
sampling. As can be seen in Figure 3A, equilibrium between the coating and the plasma sample is 
not reached even with an extraction time of 300 seconds for high speed extraction. Taking into 











Figure 4.13 Ion chronograms related to the selective reaction monitoring (SRM) of voriconazole 
(350.18→281.05) at different concentration levels, including the plasma blank.   
 
calibration curve (i.e. 0.1 µg/mL) and, consequently, all the extraction times fulfilled the LOQ 
required (i.e. 1 µg/mL), the optimum extraction time for the first CBS approach was selected based 
on the lowest relative standard deviation (RSD, %) attained with the raw data (non-corrected by 
internal standard) at the shortest extraction time. Thus, the best compromise between speed and 
reproducibility was obtained with 60 seconds of extraction where the RSD for the raw data was 
below 15% and the signal-to-noise ratio (S/N) was about 1000. On the contrary, for spot analysis 
(10 µL of plasma), given the high surface-to-volume ratio, a plateau on the amount extracted was 
reached after 120 seconds of extraction (see Figure 4.14B) 151.  Therefore, this time point was 
chosen for spot analysis, as it is the extraction time at which equilibrium was achieved and that 
provides the lowest RSD (~ 3%) and a S/N of 500. It is worth to emphasize that in spot analysis 
long extraction times can lead to drying of the biofluid droplet on the coating surface. This 
undesired effect can promote the co-extraction of analytes that could cause matrix effects (e.g. ion 
















Figure 4.14 Extraction time profile of A) regular sample volume approach and, B) droplet 
approach. Concentration of voriconazole in plasma 0.1 µg·mL-1. 
 
Thus, to avoid a significant decrease on the instrumental sensitivity and a detriment to the 
experimental reproducibility extraction times shorter than 5 min are recommended for SPME spot 
sampling. Once both extraction times were optimized, full calibration curves in plasma samples 
were constructed to qualify the most relevant figures of merit of each approach. As can be seen in 
Table 4.3, LOD and LOQ of 0.003 and 0.1 µg/mL, respectively, were obtained for the regular 
sample volume strategy (~ 300 µL). It is worth highlighting that despite the short extraction time 
(t ≤ 60 s) the LOQ is at least ten times lower than the required concentration range (i.e. 1-6 µg/mL). 




Table 4.3 Figures of Merit for Plasma Analysis of voriconazole using HLB CBS-MS/MS.  
*LOQ was the lowest calibration point tested 
Table 4.4 Relative matrix effects for five different lots of plasma (n=3). 
 Relative matrix effects 
Methodology Lot A Lot B Lot C Lot D Lot E 
Average SD 
RSD
, %  slope RSD, % slope RSD, % slope RSD, % slope RSD, % slope RSD, % 
Regular volumes 0.194 1.4 0.200 1.7 0.218 2.7 0.215 0.8 0.178 0.9 0.20 0.02 8.1 
Spot volumes 0.191 0.8 0.196 1.4 0.213 2.5 0.206 0.6 0.181 1.0 0.20 0.01 6.3 
 
Table 4.5 Accuracy and relative standard deviation values obtained for four patient plasma samples spiked at five different concentration 
levels (n=3).  
Methodology 
  Patient 1 Patient 2 Patient 3 Patient 4 
Concentration 54/180a 85/137a 675/189a 569/197a 
(µg·mL-1) 56/C/Mb 29/B/Mb 40/B/Mb 52/H/Fb 
  Accuracy %RS Accuracy %RSD Accuracy %RSD Accuracy %RSD 
Regular volume 
analysis 
0.5 120.6 0.8 115.6 5.5 118.2 4.8 115.7 3.9 
1 93.6 0.4 102.5 1.5 100 0.8 111.5 2.5 
2.5 91.8 1.4 90.6 0.5 101.9 1.0 104.3 2.0 
5 97.4 1.5 90.5 15.9 96.4 1.9 110.8 0.4 
10 103.3 2.4 106.7 2.4 116.7 1.9 114.5 1.0 
Spot volume analysis 
0.5 117.2 0.9 122.3 8.3 107 3.9 112.8 3.5 
1 93.7 0.6 101 1.1 97.9 0.3 111.8 1.8 
2.5 95.4 0.7 90.6 3.3 100 1.3 103.6 1.4 
5 102.8 0.9 101.8 1.9 97 1.0 110.5 0.8 
10 104.5 0.5 107.4 0.4 116.6 0.7 112.4 0.3 
a Triglycerides/cholesterol levels, respectively (mg/dL); b Age/Race/Gender  













RSD, % (n=3) 
Reproducibility RSD, % 
(n=3) 
Regular volumes 0.003 0.1 0.1-50 y=0.1877 x - 0.0889 0.990 0.3-2.3 6.2-7.7 
Spot volumes 0.006 0.1 0.1-50 y=0.1824 x - 0.0009 0.999 0.5-0.9 4.5-7.0 
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0.9904, 0.3-2.3% and 6.2-7.7%, respectively. In the case of the spot sampling, although the LOD 
was two time higher (0.006 µg/mL) and LOQ were the same as those obtained with the fast 
convection approach, the figures of merit were slightly improved. Certainly, lower experimental 
error values can be explained due to the fact that the extraction on the spot sampling is performed 
under virtually exhaustive extraction conditions while the extractions in regular sample volumes 
were performed under non-equilibrium conditions and without automation 131. 
 
Aiming to evaluate relative matrix effects, the slopes of the calibration curves of voriconazole 
prepared in five different lots of plasma were compared. As can be seen in Table 4.4, acceptable 
relative matrix effect were found for both methods, with slightly lower inter-slope errors attained 
for the spot approach in accordance with the already discussed results. With the objective of 
studying the accuracy of the proposed methodologies, five validation points within the therapeutic 
range of voriconazole (i.e. 0.5, 1, 2.5, 5, and 10 µg/mL) were prepared in plasma samples from 
four different patients and analyzed by CBS-MS/MS (n=3; each level). Thus, plasma samples from 
patients with different medical background (e.g. diverse triglycerides/cholesterol levels, race, 
gender, and age) were selected in order to investigate possible lack of accuracy at such conditions. 
As can be seen in Table 4.5, the accuracy values were in the ranges of 90.5 - 120.6% and 90.6 - 
122.3 % for regular volumes and spot approach, respectively. It is important to point out that of 
the twenty accuracy experiments performed, only two of them showed accuracy results slightly 
higher than 120% at the lowest validation point (i.e. 0.5 µg/mL). Therefore, it can be concluded 




The total time of analysis in the case of regular sample volumes, when performing the experiments 
one-by-one, is in the order of 120 seconds per sample. It comprises 60 seconds of extraction, 20 
seconds of rinsing, 20 seconds of desorption and 3 seconds of mass spectrometry analysis. 
However, if both processes are automatized (i.e. extraction in 96-well system and 
desorption/ionization) 129,131,133, the total analysis time can be reduced to just 25 seconds per 
sample 95. Although our spot sampling approach cannot be as fast as the aforementioned 
technology, diminutive sample volumes can be analyzed with a total analysis time of only 180 
seconds per sample. Hence, when comparing the proposed CBS-based approaches against other 
analytical strategies used for the determination of voriconazole in plasma samples (most of them 
addressed by means of LC), the former can unquestionably outperform the total analysis time (~ 
10 minutes) 371,377,381 attained by those technologies.   
 
4.3.4 Summary  
In this work, two methodologies for the ultra-fast quantitation of voriconazole in human plasma 
were developed. Both approaches have all the advantages of SPME such as analyte enrichment 
and sample clean-up, as well as the speed and simplicity of direct coupling to mass spectrometry 
offered by CBS. Although the current set-up permits the quantitation of voriconazole down to 0.1 
µg/mL in 120 seconds, in the near future fully automated systems will reduce the total analysis 
time to only 25 seconds per sample. Certainly, the regular volume approach would prove extremely 
convenient for the quantitation of this antifungal drug in routine clinical analysis, while the droplet 
approach is more appropriate to perform in vitro pharmacokinetic studies in small animals, as it 
allows for great temporal resolution since the total procedure do not last more than 180 seconds 
and the sample employed can be as small as 10 µL. In summary, our results demonstrated that 
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CBS-MS not only has a remarkable potential for the fast determination of therapeutic drugs in 
biofluids, but also eliminates the analytical burden of the classical sample preparation (e.g. tedious 
procedures) and liquid chromatography approaches (e.g. usage of complex fluidics and large 






















Section 4.4 High-Throughput Screening and Quantitation of Target Compounds in 
Biofluids by Coated Blade Spray-Mass Spectrometry 
 
4.4.1 Introduction  
High-throughput analysis of complex samples via mass spectrometry (MS) is becoming 
increasingly relevant across a broad range of fields where large sets of compounds must be 
identified and quantitated382. Although high-throughput analysis has many applications, the most 
relevant include screening for contaminants in environmental samples383 and pesticides in food 
matrices384, as well as the determination of drug panels in biofluids25. Ideally, screenings should 
not only be fast, sensitive, and capable of being automated, but they must also provide acceptable 
precision and accuracy. Thus far, most of the analytical technologies developed for quickly 
screening target compounds in biofluids via MS require at least one sample preparation step prior 
to a chromatographic separation process360,385,386. Unavoidably, the sum of all these stages 
typically results in analytical workflows that cost more and take longer than is ideal. Moreover, 
some of these methods involve substantial labor and a significant amount of consumables (e.g. 
solvents, sorbents, salts, cartridges)387. Thus, it is unsurprising that MS-based screening 
technologies are currently shifting towards faster and cheaper methodologies. One example is 
ambient mass spectrometry (AMS)52,388, which is a group of technologies that promote ion 
generation from untreated samples under atmospheric conditions. AMS requires no sample 
preparation or separation steps (no-analyte enrichment or matrix alteration), which makes it 
applicable for biofluid analysis, for example, by spiking/spotting a portion of the sample on a solid 
substrate, which is then interfaced with the mass spectrometer to generate ionic species via 
electrospray ionization (e.g. Paper Spray (PS)49,83,90). Indeed, multiple PS can be arranged in an 
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autosampler in order to perform high-throughput determinations83,95. Likewise, biofluid can be 
spotted on a substrate (e.g. mesh or glass slide) that is then automatically placed between a jet of 
charge species and the mass spectrometer (e.g. via desorption electrospray ionization (DESI)344,389, 
or via direct analysis in real time (DART))209. Furthermore, automated analysis can be conducted 
by using a continuous flowing liquid to sample a surface containing a dried sample (e.g. dried 
blood spot) such as liquid extraction surface analysis (LESA)24, or via a liquid microjunction 
surface sampling probe (LMJ-SSP)390). Despite AMS’s simplicity, it can fail to provide adequate 
sensitivity when trying to quantify concentrations of target compounds at low or sub parts-per-
billion (ppb) in biofluids101,214. In addition, the lack of sample preparation not only leads to 
significant ion suppression, but it also makes AMS-based technologies prone to requiring 
instrument maintenance more frequently. Aiming to enhance the performance attained by PS in 
terms of sensitivity, some applications have recently reported the use of coated PS, yet increasing 
the cost and decreasing the simplicity of the technology214,217. Moreover, while several AMS 
procedures have notably claimed analysis times in the range of a few seconds per sample, these 
times refer only to the instrumental period and do not take into account the sample pretreatment 
step (e.g. drying time of the biofluid spot on the paper214,391). Therefore, there is a great need for 
proficient sample preparation approaches that can deliver high-throughput MS analysis; as such 
approaches will enable rapid screening without compromising the method sensitivity or the mass 
spectrometer’s integrity. In response to these issues, technologies that efficiently combine on-line 
solid-phase extraction (SPE) and MS102,392—such the RapidFire (RF)29,40,41 by Agilent 
Technologies, or the TurboFlow by Thermo Fisher Scientific33,38—have been developed as 
potential solutions. For instance, the entire SPE-MS process in the RF is automated, and the 
instrumental analysis time range is between 10 and 15 seconds per sample40. Since these 
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technologies inherently preconcentrate the analytes of interest, quantitative screening at low ppb 
concentrations in complex matrices is feasible41. In spite of these systems’ swiftness and 
simplicity, pure sample matrices cannot be directly injected on them, and at least one or two sample 
pre-treament steps are required in order to prevent damaging either the fluidics or the SPE 
cartridges. For example, in the case of urine, a diluting step is sufficient to introduce the sample 
into the MS system. However, matrices containing high protein concentration require special 
handling to prevent SPE clogging (e.g. protein precipitation and centrifugation). Moreover, 
unmanned instruments and multiple high-pressure pumps tend to contain intricate 
electromechanical systems that may require frequent maintenance, which can contribute to higher 
operational costs. The above-mentioned factors and challenges clearly demonstrate the ongoing 
need for the development of novel technologies that can address them. Solid-Phase 
Microextraction (SPME) is one such potential solution. SPME embraces solventless 
microextraction technologies with different geometrical configurations that combine sampling, 
analyte extraction, sample clean-up, and compound enrichment in a single step228, and it has been 
proven to be effective for the anaysis of complex biological matrices on multiple occasions393. 
Furthermore, the direct coupling of SPME to MS has recently been demonstrated to be an 
extremely powerful tool in bioanalytical determinations. Combining these technologies improves 
the limits of quantitation, accelerates analysis throughput, and diminishes potential matrix effects 
when compared to direct sample introduction coupled to MS136,151,173,178,192,220. Coated blade spray 
(CBS) is an SPME-based device that can be directly interfaced with MS instruments. Essentially, 
CBS is a stainless steel sheet (350 µm, Ø) with a swordlike geometry (Figures 4.15 and 4.16) that 
is coated with polymeric adsorbent particles. However, unlike other SPME devices, it can also be  
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Figure 4.15 Experimental set-up for CBS-MS analysis of complex matrices, rapid diagnostics, 
and high-throughput configuration. 
 
Figure 4.16 (A) CBS-brush with 8 rows of 12 blades each (96 blades total); (B) Concept 96-










Figure 4.17 In house CBS-96 holder. Picture depicts the system for simple CBS 
installation/removal based on a press fit ball plunger. 
 
 
used as a solid-substrate ESI source136,220. In this study, we assess CBS’s suitability for use in high-
throughput screening and in the quantiation of multiple compounds. Essentially, we perform 96 
extractions simultaneously, which allows us to not only decrease the total analysis time per sample, 
but also to enhance the method’s precision, accuracy, and LOQs. For this purpose, we selected a 
panel of compounds, including controlled substances, pain-management drugs, and therapeutic 
medications (i.e. mixture of anabolics, β-2 agonists, diuretics, stimulants, narcotics and β-
blockers)25,304. In order to ensure that this assessment was as chemically comprehensive as 
possible, the list of proof-of-concept substances comprises a broad range of molecular weights, 
moieties, protein binding, and polarities. Furthermore, we tested our system in common 
bioanalytical matrices, such plasma and urine. Unlike online SPE-MS, no additional sample 
pretreatment is needed, and the entire analytical process is completed in less than 1 min. 
 
4.4.2 Experimental section 
Materials and supplies 
Formic acid was purchased from Sigma-Aldrich (Saint Louis, USA), and LC-MS-grade methanol 
(MeOH), acetonitrile (ACN), isopropanol (IPA) and water were purchased from Fisher Scientific. 
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The following compounds were selected as model analytes for evaluating high-throughput-CBS 
(HT-CBS): methamphetamine, methamphetamine-d5, carbamazepine, carbamazepine-d10, 
propranolol, propranolol-d7, clenbuterol, clebuterol-d9, diazepam, diazepam-d5, codeine, codeine-
d3, cocaine, cocaine-d3, sertraline, sertraline-d3, citalopram, citalopram-d6, fentanyl, fentanyl-d5, 
buprenorphine, buprenorphine-d4, morphine, morphine-d6, methadone, methadone-d3, oxycodone, 
lorazepam, bisoprolol and stanozolol were acquired from Cerilliant Corporation (Round Rock, 
TX, USA). As noted, deuterated analogues of most analytes were used to correct for intra- and 
inter-experiment variability. In cases where no deuterated analogues were available as to correct 
for differences during extraction/ionization, the analyte and the internal standard paired were 
denoted in Table S1 with a superscript lowercase letter. For further details regarding compound 
properties, and selected reaction monitoring (SRM) transitions, see Table 4.6. Individual stock 
standard solutions were prepared in methanol at a concentration of 1000 µg·mL-1 and stored at -
80 ºC.  The phosphate-buffered saline solution (PBS) (pH 7.4) was prepared according to the 
procedure outlined in the Section 2.2. Human plasma (with K2-EDTA as anticoagulant) that had 
been pooled from different batches was purchased from Bioreclamation IVT (Westbury, New 
York, USA). All the plasma samples were spiked and stored overnight at 4 ºC in order to achieve 
the drug-protein binding equilibrium. Urine samples were collected from 10 healthy donors (five 
female and five male). The urine collection process for this particular study was conducted with 
the approval of the University of Waterloo’s Office of Research Ethical Board.  
 
CBS manufacturing 
Stainless steel blades, which were purchased from Shimifrez Inc. (Concord, Ontario, Canada), 
were then coated using a slurry of hydrophilic lipophilic balance particles and polyacrylonitrile  
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Table 4.6 Target analytes and internal standards, polarities (LogP), minimum required 
performance levels (MRPL), and SRM transitions monitored for each model compound in positive 
ionization mode. 
Compound Log P MRPL Precursor Product Collision Energy RF-Lens 
Methamphetamine a 2.07 100 150.373 91.040 20 30 
Oxycodone a 1.07 50 316.098 241.054 27 71 
Metamphetamine-d5 (IS) a   154.970 92.040 20 30 
Carbamazepine b 2.45 - 237.304 194.097 19 57 
Lorazepam b 2.39 50-240 321.054 274.889 21 72 
Carbamazepine-d10 (IS) b   247.106 204.146 21 65 
Propranolol c 3.48 100 260.070 116.111 18 62 
Bisoprolol c 1.87 100 326.035 116.200 17 66 
Propanolol-d7 (IS) c   267.137 116.111 19 61 
Clenbuterol 2.94 0.2 276.971 202.995 16 60 
Clenbuterol-d9 (IS)   286.092 204.015 17 48 
Diazepam 2.82 5 284.995 193.054 32 82 
Diazepam-d5 (IS)   290.090 198.111 32 86 
Morphine d 0.89 50 286.049 152.060 55 79 
Salbutamol d 0.44 100 240.071 148.071 18 41 
Morphine-d6 (IS) d   292.076 152.060 55 86 
Codeine 1.19 2 300.385 165.054 39 78 
Codeine-d3 (IS)   303.122 165.071 41 82 
Cocaine 1.97 100 304.089 182.093 18 60 
Cocaine-d3 (IS)   307.055 185.111 20 50 
Sertraline e 5.06 ≤300 306.356 159.000 26 51 
Stanozolol e 4.33 2 329.192 81.037 43 116 
Sertraline-d3 (IS) e   309.030 158.929 31 106 
Methadone  3.93 50 310.048 265.007 15 57 
Methadone-d3 (IS)   313.272 268.166 15 57 
Citalopram 3.5 ≤300 325.094 109.071 28 73 
Citalopram-d6 (IS)   331.119 109.071 28 92 
Fentanyl 4.12 1 337.468 188.183 22 70 
Fentanyl-d5 (IS)   342.261 188.111 24 72 
Buprenorphine 4.63 5 468.250 396.111 38 119 
Buprenorphine-d4 (IS)   472.336 400.093 39 147 
 
 
(HLB-PAN) according to procedure described below. HLB particles were kindly provided by 
Waters Corporation. The coating length and thickness was 15 mm and 10 µm, respectively. The 
dipping solution is prepared by mixing 5 g of polyacrylonitrile (PAN) solution and 72.5 mL of 
dimethyl formamide (DMF) on a container. This mixture is heated at 90 °C for 1 hour. After 
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cooling down, 6.3g of the solution are mixed with 0.65g of HLB particles (5 µm) on a 20 mL vial 
overnight prior to start the coating procedure. Preceding to any coating application, CBS should 
be etched with hydrochloric acid (HCl, 37 %) for 15 minutes. After etching the devices must be 
thoroughly clean with water and acetone and they should be kept on a desiccator with nitrogen 
flow prior to execute the coating process. Ideally, the coating solution should be continuously 
stirred during the coating procedure. For coating, the desired coated area (e.g. 15 mm) is immersed 
onto the slurry solution for approximately 10 seconds and subsequently remove and cure at 125 
°C for 1 min. For the preparation of CBS used in this manuscript a single dipping step was 
followed.  
 
Bioanalytical protocol  
The workflow for the biofluid analysis consisted of four simple steps: extraction/preconcentration, 
coating rinsing, analyte desorption, and subsequent ionization. In the case of non-automated 
processes, extraction is performed by inserting the CBS into a vial containing 300 µL of biofluid 
and agitating it for 1 minute (3200 rpm, vortex agitation). Once this step has been completed, the 
blades are then placed into a vial containing water and agitated under vortex conditions twice (t ≤ 
5s each) in order to remove matrix components that are physically attached to the coating surface. 
After this washing step, the blades are manually installed on the interface for MS analysis. As 
shown in Figure 4.17, automated CBS extractions were carried out using a Concept-96 system 
(Professional Analytical Systems (PAS) Technology, Magdala, Germany). This robotic sample 
preparation unit has been described in detail elsewhere131,304. Unlike the manual protocol, 
automated experiments were performed using 96-well plates (volume of 500 µL). A holder capable 
of arranging up to 96-CBS devices was constructed at the University of Waterloo’s machine shop 
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(Figure 4.16). As can be seen in Figure 4.17, each blade can be manually positioned in a groove 
where a press-fit ball plunger fixes the blade via a clicking mechanism. An additional feature of 
the 96-CBS holder is that it can be easily installed/removed from the automatic arm by means of 
a rail-like mechanism. In contrast to manual experiments, the Concept-96 system cannot achieve 
much higher agitation speeds, with a maximum speed of 1500 rpm (orbital agitation); therefore, 
longer extraction times were selected in order to guarantee the best quantitation capabilities. 
 
Mass Spectrometry analysis  
All the experiments described in this manuscript were carried out using a TSQ Quantiva mass 
spectrometer (Thermo Fisher Scientific, San Jose, California, USA), and data processing was 
performed using Trace Finder 3.3 (Thermo Fisher Scientific, San Jose, California, USA). To 
guarantee that the blades were accurately positioned in front of the mass spectrometer during all 
experiments, an in-house ionization source was built at the University of Waterloo (see Figure 
4.18). As a matter of fact, aiming to improve the spray stability, which might have been affected 
by the air conditioner flows on the laboratory, a plastic enclosure was built. Figure 4.19 portray 
the results obtained with and without the enclosure. Undeniably, by enclosing the CBS interface 
lower signal variability can be attained. Hence, the aforementioned device was used otherwise 
stated. Once the CBS had been installed on the interface, 10 µL of a 95:5 MeOH/water v/v 0.1% 
formic acid solution was applied to the coated area in order to desorb the analytes (t ≤ 20 s). After 
analyte elution on the desorption solution, a voltage of 5.5 kV was established between the CBS 



























Figure 4.18 CBS-MS interfaces used for the direct coupling of CBS to Thermo Fisher TSQ-
Quantiva and Thermo Fisher LTQ with multiple degrees of freedom (top). CBS-MS interface with 





Figure 4.19 Ion chronograms of (A) methamphetamine (m/z 150), (B) diazepam (m/z 285) and 
(C) fentanyl (m/z 337) obtained by direct infusion of a 1 µg mL-1 solution of the compounds listed 
on Table 4.16. In this experiment, CBS was used as an ESI source with a set-up similar to the one 
presented in Figure 4.9. A spray voltage of 5.5 kV was applied. Pink and blue lines represent the 
signal obtained with and without the enclosure system displayed on Figure 4.18, respectively. 
 
All analyses were carried out in positive ionization mode. Optimum collision energy and RF-lens 
conditions were tuned for each compound via the direct infusion of methanolic standards. MS/MS 





The methodologies were characterized with respect to linearity, precision, accuracy, and LOQ. 
Calibration functions were constructed on the basis of the signal ratio of the analyte and its 
isotopologue (A/Is) for 12 concertation levels in three independent replicates from 0.05 ng·mL-1 
to 100 ng·mL-1. Furthermore, three different concentrations levels (3, 40, and 80 ng·mL-1) were 
analyzed in order to assess precision and accuracy. LOQs were calculated as the lowest calibration 
point with precision values lower than 20%. 
 
4.4.3 Results and discussion 
CBS-MS: a novel technology for concomitant and rapid screening  
CBS has numerous advantages over most SPME-MS couplings, such as: low solvent consumption 
per analysis (≤ 15µL)182; no fluidics requirements (no pumps, valves or tubes are used)178; no gas 
or heating requirements174,192; no need for a desorption chamber114,173,182; no need of a pumping 
mechanism during the sample preparation process114,197,394; and no need for a sampling vessel 
when analyzing small sample volumes114,173,182. In addition, CBS can be coated with any extractive 
material, thus offering broader analyte coverage than other devices114,197,211,212 Furthermore, as 
presented in this manuscript, CBS is capable of quantifying multiple compounds in a single 
analysis because the area under the curve used for quantitation purposes lacks the shape of a 
Gaussian peak with a limited peak width114,164,167,174,178, and the electrospray event can be extended 
by using a continuous solvent supply. Perhaps the greatest advantage of CBS is that the blade acts 
as both the extraction device and the ionization source. Given all its features, CBS demonstrates 
to be  a good alternative  for sample preparation and direct-to-MS technologies395. In order to use 
the full potential of CBS important variables such coating type and speed of extraction should be 
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carefully optimized. For instance, if a reduction of the extraction time is aimed, fast convection 
conditions are required. Thus, either vortex agitation or high-speed orbital agitation (i.e. 1500-
3200 rpm) are strongly recommended (see Figure 4.15). Furthermore, based on previous work 
done in our group131, HLB coated blades were selected with the objective of providing a wide and 
balance analyte coverage (i.e. extraction of compounds with octanol-water partition coefficient 
ranging between 0.44 to 5.06, see Table 4.6).  
 
Non-automated analysis  
In this study, two workflows (manual and automated) suitable for completely different 
bioanalytical scenarios have been proposed. The non-automated methodology, which consists of 
performing analyte extraction by hand (Figure 4.15), is chiefly intended for point-of-care 
therapeutic drug monitoring or any application where the rapid assessment of an analyte 
concentration needs to be performed8,9. Certainly, it is quite useful when single or a small number 
of analyses are required, as this keeps the total analysis time for the extraction and quantitation 
under 2 minutes per sample. As can be seen in Table 4.7, LOQs below 0.5 ng/mL were attained 
for the majority of the analytes when performing 1 min extractions from 300 µL of PBS. Moreover, 
good accuracy (82.3 to 116.2 %) and precision (≤ 8%) were attained at the three tested quality 
control (QC) levels (3, 40 and 80 ng/mL).  
 
Urine analysis Since urine is widely available and uninvasive to collect, it is the most suitable 
matrix for performing multi-residue analysis of prohibited substances233. However, urine is also 
one of the most challenging biological matrices; as such, it was unsurprising that urine’s LOQ 
median (3.75 ng/mL) was 10 and 7 times higher than in PBS and plasma, respectively (see Table 
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4.8). Although the minimum required performance levels (MRPLs) set by the World Antidoping 
Agency (WADA) were not achieved for all the controlled substances (e.g. clenbuterol), all drugs 
of abuse were quantified  at the cut-offs set by the most common currently used screening assays 
(e.g. 5 ng/mL is the lowest cut-off level in urine; i.e. fentanyl)396. Likewise, good accuracy (83-
110%), and great precision (≤ 10%) were achieved at the three QC levels tested for all the studied 
probes (3, 40 and 80 ng/mL).  
 
Plasma analysis Plasma samples are a great alternative to complement urine analysis in prohibited 
substances determinations360. In fact, plasma, or serum, has been the preferred matrix over whole 
blood samples and, as a result, most clinical reference data is based on either plasma or serum 
concentrations304,347. However, plasma samples pose their own set of challenges. For instance, 
since SPME-based technologies extract via free concentration, substances characterized by high 
protein binding are expected to exhibit higher limits of quantification397. Furthermore, due to 
plasma’s intrinsic characteristics (e.g. viscosity due to protein content), rinsing steps are critical 
for removing clusters of macromolecules/salts that might be lingering on the coating surface during 
the extraction process, which can potentially cause ion suppression or instrument contamination. 
As expected, LOQs in plasma are equal to or considerably better than in urine; however, 
compounds that are heavily bound to proteins stand as an exception to this trend (e.g. diazepam or 
buprenorphine, see Table 4.9). Nonetheless, our results are in perfect agreement with the 
quantitation requirements for both drugs of abuse in blood samples and the therapeutic cut-off 
levels of most medications396. In addition to the quantitation capabilities, the characterization of 
our experiments showed good accuracy (80 to 120 %), precision (≤ 8%), and linearity for all study 
probes at the three tested QC levels (3, 40, and 80 ng/mL).  
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Table 4.7 linear regression slopes, intercepts, and correlation coefficients (R2). Limits of quantitation (LOQ), accuracy (%), and 
precision (percentage relative standard deviation, RSD %) values for three different concentration levels. All values were calculated 
based on the protocol in the experimental section for the non-automated approach and PBS as a sample.  
Compound name Slope Intercept R2 
LOQ 
(ng·mL-1) 













Methamphetamine 0.546 0.509 0.9995 0.5 95.7 101.2 87.8 19.3 9.1 3.6 
Carbamazepine 0.018 0.026 0.9952 0.5 109.9 105.8 93.9 17.9 3.9 4.8 
Propranolol 0.151 0.041 0.9968 0.25 116.2 107.1 100.5 4.4 4.9 3 
Clenbuterol 0.121 0.008 0.9971 0.25 100.3 101.5 94.9 1.5 2.3 1.7 
Diazepam 0.009 0.001` 0.9967 0.1 104.7 106.7 97 2.3 4.5 0.7 
Codeine 0.084 0.002 0.9980 0.5 113.7 105.5 99.4 4.9 1 1.5 
Cocaine 0.093 -0.009 0.9977 0.25 107.4 101.3 96.5 5.4 1.7 4.2 
Sertraline 0.063 0.022 0.9962 0.25 92.1 101.8 96.4 2.9 8.3 2.6 
Citalopram 0.095 -0.024 0.9979 0.25 112 104.4 98.7 1.3 5.4 0.9 
Fentanyl 0.098 0.009 0.9980 0.5 110.6 106.4 97.1 1.2 3.8 0.7 
Buprenorphine 0.012 0.003 0.9982 2.5 88.4 106 101.6 9.2 3 0.9 
Morphine 0.076 0.017 0.9996 1 105.2 97.4 103.8 4.8 12.7 13.3 
Methadone 0.105 -0.005 0.9948 0.25 102.9 107 99.2 6.7 1.4 3.5 
Salbutamol 0.263 0.370 0.9949 0.5 82.3 105.2 90 23.4 14 14.9 
Oxycodone 0.072 0.032 0.9992 0.25 110.2 93.4 93.6 36.5 21.8 22 
Lorazepam 0.004 0.004 0.9938 2.5 110.3 110.6 91.6 8.7 33.1 37.3 
Bisoprolol 0.292 -0.178 0.9997 0.25 115 97 84.4 17.7 11.8 14.2 






Table 4.8 linear regression slopes, intercepts, and correlation coefficients (R2). Limits of quantitation (LOQ), accuracy (%), and 
precision (percentage relative standard deviation, RSD %) values for three different concentration levels. All values were calculated 
based on the protocol in the experimental section for the non-automated approach and plasma as a sample. 
Compound Slope Intercept R2 
LOQ 
(ng·mL-1) 













Methamphetamine 0.43 -0.18 0.9996 0.5 110.8 91.8 95.4 2.7 2.5 6 
Carbamazepine 0.017 0.0019 0.9992 0.5 101.8 97.3 91.4 8.5 4.7 6.2 
Propranolol 0.14 0.098 0.9991 0.5 88.7 81.7 78.8 8.5 13.2 10.9 
Clenbuterol 0.11 -0.025 0.999 0.5 110.5 79.4 82.6 9.3 9.6 8.9 
Diazepam 0.0077 0.045 0.9914 10 - 77.1 81.2 5.6 17.1 7.9 
Codeine 0.078 0.074 0.9993 1 69.9 93.7 99.4 3.8 4.6 1.5 
Cocaine 0.082 0.063 0.9992 0.5 87.1 84.1 85.2 4.9 9.3 10.6 
Sertraline 0.06 0.19 0.9961 2.5 25.5 80.9 83 14.4 13.6 9.2 
Citalopram 0.08 0.083 0.9952 0.25 79.7 87.6 84.9 8.1 12.4 1.9 
Fentanyl 0.087 0.089 0.9983 0.25 81 83.8 77.8 12 3.3 6.4 
Buprenorphine 0.012 0.15 0.9877 25 - 79.2 71.6 - 3.3 3.1 
Morphine 0.11 12 0.9998 2.5 89.9 98.2 101.7 6.4 0.9 4.1 
Methadone 0.078 0.19 0.9883 0.5 55.3 79.2 88.1 11.7 11.4 9.7 
Salbutamol 0.13 0.19 0.981 0.5 54.3 89.5 104.5 4 7.1 4 
Oxycodone 0.04 0.12 0.9984 1 100.8 88.8 101.2 1.8 21.2 9.8 
Lorazepam 0.0012 0.011 0.9865 25 - 99.9 121.9 - 12.9 18.3 
Bisoprolol 0.37 0.59 0.9983 0.25 55.7 97.7 103 15.9 3.3 13.9 






Table 4.9 linear regression slopes, intercepts, and correlation coefficients (R2). Limits of quantitation (LOQ), accuracy (%), and 
precision (percentage relative standard deviation, RSD %) values for three different concentration levels. All values were calculated 
based on the protocol in the experimental section for the non-automated approach and urine as a sample.  
Compound Slope Intercept R2 
LOQ 
(ng·mL-1) 













Methamphetamine 0.42 0.44 0.9991 2.5 87 93 100 3.3 2.8 3.5 
Carbamazepine 0.014 0.077 0.998 10 - 99 104 4.7 5.8 5.7 
Propranolol 0.13 -0.077 0.9981 0.5 132 96 108 3.1 12.9 5.9 
Clenbuterol a 0.12 0.065 0.9983 2.5 102 94 103 6.6 0.8 3.8 
Diazepam 0.0092 0.0085 0.9996 2.5 93.8 95.8 99.9 8 1.3 1.9 
Codeine 0.083 0.14 0.9986 10 - 94.9 99.9 - 1.3 3.4 
Cocaine 0.086 0.028 0.9986 0.5 98.2 96.1 105.1 4.5 1.5 1.4 
Sertraline 0.063 0.1 0.9978 5 - 92.9 97.6 4.5 5.8 0.9 
Citalopram 0.061 0.0045 0.9964 1 107.8 91.8 98.6 6.7 15.7 8.4 
Fentanyl 0.096 0.021 0.9991 0.25 102.4 94.3 104.7 5.4 2.3 1.2 
Buprenorphine 0.014 0.1 0.9985 10 - 88.5 98.2 - 1.7 2.1 
Morphine 0.086 0.13 0.9965 10 - 98.8 105.6 - 6.6 4.1 
Methadone 0.09 0.062 0.9996 0.5 89.6 94.8 106.1 2.7 2.1 2.1 
Salbutamol 0.14 0.23 0.9921 10 - 93.2 105.9 - 27.5 17.8 
Oxycodone 0.017 -0.0075 0.9997 5 - 104.6 108.7 - 13.4 13 
Lorazepam 0.0021 0.027 0.9992 25 - 90.4 83.7 - 10.5 28.9 
Bisoprolol 0.18 0.0042 0.9995 0.25 109.4 91.1 94.3 3.8 3.3 7.6 
Stanozolol 0.075 0.58 0.9943 10 - 85.5 101.9 - 3 9.7 
 




High-throughput analysis  
The automation of a given analytical method decreases operating costs, minimizes experimental 
error during measurement, and increases the analysis throughput14,95. For the past ten years, 
researchers have explored the use of SPME devices for high-throughput analysis by using robotic 
autosamplers that enable parallel analyte extraction in a 96-well plate format 25,129,131,133,157,162,304. 
However, prior studies have generally introduced the sample extract into the MS system via gas 
or liquid chromatography133. To the best of our knowledge, this is the first application where, after 
the unmanned high-throughput sample preparation process, the SPME devices are directly coupled 
to the mass spectrometer. As shown in Figure S1, a novel holder was designed to facilitate rapid 
and independent CBS installation; thus, unlike the original blade system25,131, our proposed 
prototype is electrically isolated and can be effortlessly uninstalled from the holder to performed 
MS analysis. Besides, unlike previous designs133, the holder can be mounted on the Concept-96 
autosampler in just a few seconds (see Figure 4.17). Moreover, since automation is able to process 
multiple samples simultaneously, it allows for an increase in extraction/enrichment time of the 
SPME process without dramatically increasing the total analysis time25,393. Consequently, an 
extraction time of 15 minutes (~9 s per sample) was selected with the goal of increasing the amount 
of analyte extracted and decreasing the LOQs previously attained by the manual procedure. As can 
be seen in Tables 4.10 and 4.11, our results demonstrate that HT-CBS not only decreased the 
median LOQ (3.5 and 1.5 fold decrease for urine and plasma, respectively), but it also improved 
the precision and accuracy attained at all the QC concentration levels (2.5% and 3% median 
precision for plasma and urine, respectively; 98.5% and 100.6% median accuracy for plasma and 
urine, respectively). Moreover, as shown in Figure 4.20, great linearity was attained for all 
compounds over the assessed range in both matrices, even when their deuterated analogues were  
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Compound Slope Intercept R2 
LOQ 
(ng·mL-1) 













Methamphetamine 0.11 -0.0353 0.9964 1.0 106.9 90.4 98.3 0.4 0.2 0.8 
Carbamazepine 0.07 -0.0003 0.9961 0.1 103.6 96.8 95.0 1.5 3.8 2.5 
Propranolol 0.20 -0.064 0.9944 1.0 106.4 91.4 97.6 0.6 1.4 0.7 
Clenbuterol 0.11 -0.013 0.9956 0.5 103.8 91.3 97.5 1.3 0.2 1.2 
Diazepam 0.13 -0.032 0.9953 1.0 106.0 91.8 99.4 0.1 1.8 1.2 
Codeine 0.09 -0.031 0.9955 1.0 103.3 90.8 98.0 0.5 0.3 1.4 
Cocaine 0.09 -0.013 0.9961 0.5 104.7 92.3 96.5 0.8 0.6 0.2 
Sertraline 0.06 -0.023 0.9950 1.0 105.6 89.7 98.5 4.2 0.6 1.7 
Citalopram 0.10 -0.019 0.9967 0.5 104.4 90.3 98.9 0.8 1.0 0.4 
Fentanyl 0.07 -0.014 0.9953 0.5 101.3 91.0 96.6 2.0 0.7 0.7 
Buprenorphine 0.09 -0.029 0.9927 2.5 121.8 91.3 93.9 7.5 2.9 4.3 
Morphine 0.07 0.081 0.9940 1.0 104.4 90.7 94.8 2.4 2.4 0.7 
Methadone 0.01 -0.001 0.9959 0.5 103.3 91.4 99.4 0.5 0.5 0.5 
Salbutamol 0.03 -0.002 0.9916 0.5 111.4 101.1 93.4 6.7 9.1 2.5 
Oxycodone 0.17 -0.018 0.9957 0.5 104.2 92.6 100.3 3.3 4.1 2.3 
Lorazepam 0.10 0.054 0.9822 1.0 104.1 97.8 108.6 9.2 14.3 3.4 
Bisoprolol 0.10 -0.028 0.9973 0.1 106.3 93.5 101.5 2.7 6.2 2.3 
Stanozolol 0.04 0.134 0.9741 10 - 84.6 95.4 - 6.0 8.2 
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Table 4.11 Figures of merit for the high-throughput quantitation of multiple analytes in human urine via CBS-MS/MS. 
 
 
Compound Slope Intercept R2 
LOQ 
(ng·mL-1) 













Methamphetamine 0.12 0.009 0.9961 0.25 91.4 102.6 97.8 0.3 1.4 1.6 
Carbamazepine 0.06 0.067 0.9943 2.5 85.4 111.4 95.2 4.9 0.5 4.9 
Propranolol 0.21 -0.003 0.9965 0.25 89.5 104.7 98.9 0.2 1.1 0.6 
Clenbuterol 0.11 0.038 0.9961 0.25 91.5 103.1 98.1 1.0 0.6 0.6 
Diazepam 0.12 0.014 0.9942 0.5 95.2 103.6 101.1 1.3 0.4 1.9 
Codeine 0.09 0.018 0.9932 1.0 94.3 101.3 96.0 1.5 0.3 0.9 
Cocaine 0.09 -0.003 0.9953 0.25 93.5 103.3 98.3 0.7 1.0 0.1 
Sertraline 0.06 -0.003 0.9904 2.5 115.6 105.9 97.7 1.4 2.9 1.5 
Citalopram 0.06 0.0004 0.9929 0.5 90.3 111.5 96.4 1.7 10 3.8 
Fentanyl 0.07 -0.003 0.9961 0.25 92.6 103.2 97.1 0.7 0.6 0.3 
Buprenorphine 0.11 -0.008 0.9929 0.5 92.4 102.7 100.0 2.2 0.7 2.8 
Morphine 0.06 0.173 0.9938 1.0 94.4 104.0 102.4 8.1 1.5 5.2 
Methadone 0.01 -0.0003 0.9962 0.25 94.5 104.3 99.5 0.6 1.0 0.4 
Salbutamol 0.04 0.014 0.9909 10 - 88.9 89.0 - 15.6 7.3 
Oxycodone 0.13 0.098 0.9972 1.0 92 112.8 103.0 3.7 0.9 1.3 
Lorazepam 0.08 0.443 0.9908 10 - 121.8 122.1 - 19.9 10 
Bisoprolol 0.06 -0.007 0.9925 0.5 94.5 104.8 90.4 4.0 1.2 0.3 
Stanozolol 0.10 0.175 0.9952 5 - 115.5 110.7 - 5.5 11 
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Figure 4.20 A. Quantitative analysis of plasma spiked with sertraline (0.5 to 100 ng mL−1) and its 
isotopologue [D3] sertraline (10 ng mL−1). B. Quantitative analysis of plasma spiked with 
oxycodone (0.5 ng ml−1 to 100 ng mL−1) and [D3] codeine as internal standard (10 ng mL−1). C. 
Quantitative analysis of urine spiked with fentanyl (0.25 to 100 ng mL−1) and its isotopologue 
[D5] fentanyl (10 ng mL−1). D. Quantitative analysis of urine spiked with buprenorphine (0.5 
ng ml−1 to 100 ng mL−1) and its isotopologue [D6] buprenorphine (10ng mL−1). Three replicates 
with independent CBS devices were run for each calibration and accuracy point. The red and 
orange triangles represent the accuracy levels evaluated for all compounds on each matrix. 
 
not used for correction (e.g. oxycodone). Furthermore, since CBS bypasses the chromatographic 
and desorption steps of the former SPME protocol133, HT-CBS can offer the same or better 
quantitative results than those attained by Boyacı et al. for HT-SPME, but in 1/33 of the time (less 
than 55 s per sample)25. Given the number of compounds and internal standards screened in our 
method (i.e.30), a cycle time of 1.5 seconds is required when using a dwell time of 50 ms. Hence, 
if the desired target is 15 scans per compound, the fastest electrospray event possible will be 22.5s. 
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Thus, with a total sample preparation time of less than 10 s per sample, the MS time now becomes 
the bottleneck in our methodology. Undeniably, the speed of the analysis can be further enhanced 
by decreasing the dwell time at the expenses of the attainable LOQ. For instance, by decreasing 
the dwell time from 50 to 10 ms, one could shorten the MS analysis time to less than 5 s; at the 
same time, the LOQ might only increase by a factor of 2.2 times as the signal-to-noise ratio is 
proportional to the square root of the dwell time (S/N ~ ). Theoretically, the LOQ attained via 
the HT-CBS methodology would allow for a decrease in dwell times because the WADA and 
clinical laboratory reference values were met below requirements25,396. However, this is just a 
conjecture, and full experimental validation will be indispensable in determining the LOQ for a 
given application that uses shorter dwell times. 
Notwithstanding the good results attained, it is important to bear in mind that no technique is 
perfect, and the lack of a separation step (e.g. chromatography) may result in insufficient 
selectivity for some compounds when exclusively performing MS/MS analysis34,178. Interferences 
could be observed when the target analyte is co-extracted from the matrix with isomeric species 
that share the same fragmentation pattern. Certainly, this is an issue inherent of any direct-sample-
to-MS approach and not only observed by SPME-MS. Although CBS is capable of performing 
ultra-fast extraction/enrichment from biofluids, it is important to highlight that the coatings 
developed up to date are not selective enough to discriminate between the compound of interest 
and a potential isobar or isomer. For instance, as shown in Table 4.10, the HT-CBS method could 
not meet the MRPL set for clenbuterol in urine (0.2 ng/mL)25,233,345 as isobars that share the 
MS/MS transition set for clenbuterol (m/z 277→ 203) were co-extracted from urine25,178,344. 
Hence, the “blank” signal in urine samples is significantly higher than the one observed on PBS 




Figure 4.21 Quantitative analysis of urine spiked with clenbuterol (50 pg ml−1 to 2.5 ng mL−1) and 
its isotopologue [D9] clenbuterol (10 ng mL−1). Analyses were performed using CBS-MS4 
(m/z 277→259→203→132).  
 
This lack of specificity can be overcome by using tandem MS in time8,34,178. As can be seen in 
Figure 4.21, we achieved an LOQ of 0.05 ng/mL by using MS4 (277→259→203→132) on a linear 
trap quadrupole (LTQ). Certainly, other on-line technologies, such as ion-mobility based 
approaches, can also be used to enhance instrumental selectivity without compromising total 
analysis time29,178,336,341.  
 
4.4.4 Summary 
Compared to other SPME-MS couplings, CBS offers additional features that allow it to be 
implemented in a broader range of applications114,174,178,267. For instance, CBS can hold longer 
acquisition times (t ≥ 15s), which allows it to monitor more MS events and, consequently, more 
compounds per analysis. Moreover, when compared to direct-sample-to-MS approaches83, CBS 
offers efficient compound enrichment, better sensitivity, wider sample volume range, and 
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negligible contamination of the MS system. Furthermore, as with other SPME devices313,393, CBS 
can be used as a means of transporting the “sample” from the sampling site to the laboratory, and 
it can be shipped by mail with no reasonable expectations of occupational exposure to the biofluid 
or any other potentially infectious materials398. In this work, we have demonstrated that CBS-
MS/MS is a suitable platform for rapidly and accurately quantitating multiple target compounds 
in complex matrices. The methodology was characterized for 18 compounds of interest, including 
therapeutic medications, pain management drugs, and prohibited substances in plasma and urine 
samples151. Essentially, CBS-MS can be used either as a rapid diagnostic tool in point-of-care 
applications (e.g. single extraction on-site, 2 min per sample), or for high-throughput 
determinations via a robotic autosampler (96-well approach, 55s per sample). Indeed, the HT-CBS 
method met both the WADA25 and clinical laboratory396 minimum required performance levels 
for all the assessed substances. Thus, our current work is focused on the development of a CBS-
autosampler that allows up to 96-samples to be processed simultaneously without supervision of 
each CBS’s MS event. We hypothesize that a fully optimized system that includes all the sample 
prep and MS steps will enable us to achieve a 15 s sample-to-sample duty cycle. It must be 
highlighted that in this manuscript our goal was to demonstrate the quantitation capabilities of 
CBS towards a wide range of compounds with different physicochemical properties; though, when 
developing clinical applications, metabolites of each drug under study should also be considered 
and included on the determination of the parent drug total concentration. For instance, an 
enzymatic hydrolysis (e.g. using a β-glucuronidase) can be implemented on the workflow prior to 
the enrichment step148. Finally, we demonstrated that, when dealing with compounds with known 
interferences (e.g. clenbuterol), on-line technologies such tandem MS in time34,65 can be used to 
enhance selectivity and reach the required limits of quantitation. Undeniably, the methodology 
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described in this paper is not limited to bioanalytical applications; indeed, it can be easily 
implemented for fast screening/quantitation in other analytical applications, such determining 























Section 4.5 Rapid determination of immunosuppressive drug concentrations in whole blood 
by Coated Blade Spray-Tandem Mass Spectrometry (CBS-MS/MS) 
 
4.5.1 Introduction 
Immunosuppressive drugs (ISDs) are a class of medication that control or reduce the immune 
system’s activity399. ISDs are regularly used to prevent the rejection of transplanted organs and 
tissues, as well as to treat autoimmune diseases or illnesses, such as psoriasis, lupus, and 
rheumatoid arthritis. Traditionally, ISD therapy requires drug concentrations to be closely 
monitored due to their narrow therapeutic range27. Essentially, an under-dose of ISDs can lead to 
graft (i.e. a piece of living tissue that is transplanted surgically) rejection/impairment and an over-
dose can cause severe nephrotoxicity and/or overimmunosuppresion, which can subsequently 
result in an excessive risk of infection and malignancies13. Therefore, frequent Therapeutic Drug 
Monitoring (TDM) of ISDs in whole blood concentrations is essential for patients who have 
recently experienced organ transplantation6,44,400. Historically, immunoassays have been used to 
assess ISD concentrations in a patient’s blood27,399. However, a report recently published by Seger 
et al. shows that approximately 50% of tacrolimus (TAC) and cyclosporine (CycA) determinations 
are currently performed using liquid chromatography-tandem mass spectrometry (LC-MS/MS) 
13,401. Furthermore, determinations for sirolimus (SIR) and everolimus (EVR), which are both 
mTOR (mechanistic target of rapamycin), are conducted using by LC-MS/MS in a range of 70 to 
75%400. On average, approximately 60% of ISD determinations are performed via LC-MS/MS; 
this is largely due to immunoassay determinations’ high level of risk for showing either matrix-
induce method bias (i.e. susceptibility to false-positives caused by other matrix components)13, or 
cross-reactivity-induced method bias (e.g. interaction of metabolites of the ISDs), which  displays 
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higher concentrations than those reported by LC-MS/MS13,401. State-of-the-art MS instruments 
have allowed limits of quantitation (LOQ) as low as 0.1 ng mL-1 for TAC 402,403, 0.2 ng mL-1 for 
SIR/EVR16,404, and 2 ng mL-1 for CycA405 to be reached. Despite the outstanding quantitative and 
selective capabilities provided by MS systems, these high-tech analytical instruments require clean 
sample extracts in order to generate reproducible and reliable results for long periods of time. 
Hence, there is a need for adequate sample preparation approaches that guarantee the following 
parameters: a.) the satisfactory release of ISDs from the erythrocytes; b.) acceptable enrichment 
of the drugs on the extractive phase (i.e. solvent or particles); and c.) removal of potential matrix 
interferences. Most of the methods developed to date rely on protein precipitation (PP) followed 
by either liquid-liquid extraction (LLE) or solid-phase extraction (SPE). According to a survey 
conducted by Seger et al.13, approximately 72% of the sample preparation work currently 
performed in clinical laboratories for ISD determinations is done manually by the analyst rather 
than by an automated liquid handling platform13,27; as such, this manual analytic procedure is both 
more tedious and prone to increased error in the determination406. Although the chromatographic 
step is not necessarily the bottleneck of the entire analytical process, the time required for each 
chromatographic run is between 2 and 4 minutes per sample27. Hence, the turnaround times can be 
anywhere from two hours up to multiple days, depending on the laboratory protocols13. 
Undeniably, there is a need for a method that can provide faster throughput—not only in the 
analysis stage, but also during the sample-preparation steps8. Methods that allow rapid interfacing 
with mass spectrometry407—for example, Paper Spray (PS)94,408, Rapid-Fire (RF)44, Turbo-Flow 
(TF)409,410, and Laser Diode Thermal Desorption411—have been recently developed as alternatives 
for the rapid determination of immunosuppressants in whole blood6. Unfortunately, none of these 








Coated Blade Spray (CBS) is a technology that efficiently integrates sample preparation and direct 
coupling to MS on a single device 395. Essentially, CBS consists of a stainless-steel sheet carved 
in a sword-like fashion which is coated with a biocompatible extractive composite polymer (Figure 
4.22). As a solid-phase microextraction (SPME) device, CBS simultaneously isolates and enriches 
analytes of interest present in the matrix without collecting the matrix itself 151; as an ambient 
ionization device, CBS acts as a solid-substrate electrospray ionization (ESI) source 8,9. Owing to 
its simplicity, CBS-MS/MS results suitable for fast (≤ 1 min per sample) and quantitative (low or 
sub-ng/mL) determinations of various substances have been previously demonstrated in urine, 
plasma, and whole blood samples151,220,395. In this study, we present CBS-MS/MS as a novel tool 
for the rapid and simultaneous determination of TAC, SIR, EVR, and CycA. By using a fully 
automated sample preparation procedure, we dramatically simplify the method and enable total 















Figure 4.23 Chemical structure of the target ISD  
 
4.5.2 Experimental section 
Materials and supplies 
LC-MS grade Methanol (MeOH), acetonitrile (ACN), isopropanol (IPA), and water were 
purchased from Fisher Scientific. Formic acid was purchased from Sigma–Aldrich (Saint Louis, 
USA). TAC, SIR, EVR, and CycA (see Figure 4.23) were obtained from Sigma–Aldrich 
(Milwaukee, USA). Deuterated analogs, namely tacrolimus-d2C1, sirolimus-d3, everolimus-d4, 
and cyclosporineA-d4 were purchased from TRC-Chemicals (Toronto, ON, Canada). Liquichek™ 
whole blood immunosuppressant quality control (4 levels QC) standards purchased from Bio-Rad 
(Mississauga, ON, Canada). Human whole blood (with K2-EDTA as the anticoagulant) from 
different patients was acquired from Bioreclamation IVT (Westbury, New York, USA). All blood 
samples were spiked and stored overnight at 4 °C prior to use in order to reach drug-protein binding 
equilibrium. HLB particles ( 5 μm particle diameter) were kindly provided by Waters Corporation 
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(Wilmslow, UK). Stainless steel blades (15mm), which were purchased from Shimifrez Inc. 
(Concord, Ontario, Canada), were coated with HLB-polyacrylonitrile (HLB-PAN) slurry 
according to a proprietary protocol described in Section 4.4.  
 




All the experiments reported herein were performed using a TSQ Quantiva mass spectrometer 
(Thermo Scientific, San Jose, CA, USA), and the acquired data was processed using Trace Finder 
version 3.0 (Thermo Scientific, San Jose, CA, USA). A custom-made coated blade spray interface 
was built at the University of Waterloo; a thorough description of the operation of this system can 
be found elsewhere395. Each drug was detected as a single charged ammonium adduct400, with one 
selected reaction monitoring transition recorded for each analyte (dwell time ~ 50ms): m/z 
821→768 for TAC; m/z 931→864 for SIR; m/z 975→908 for EVR; and m/z 1219→1202 for 
CycA. Further details regarding collision energy and RF-lens values are presented in Table 4.12. 
 
Sample preparation  
All of the CBS devices were cleaned for 30 min using a 40:40:20 (MeOH/ACN/IPA, v/v/v) 
solution before being conditioned for an additional 30 min with a 50:50 (MeOH/water, v/v) 








Tacrolimus Positive 821.488 768.350 19.9 85 
Tacrolimus-d2C1 Positive 824.522 771.481 20.4 85 
Sirolimus Positive 931.540 864.425 16.5 85 
Sirolimus-d3 Positive 934.606 864.497 16.1 88 
Everolimus Positive 975.578 908.454 16.4 87 
Everolimus-d4 Positive 979.609 912.528 15.5 88 
Cyclosporine A Positive 1219.80 1202.729 16.3 96 
Cyclosporine A-d4 Positive 1223.87 1206.854 11.4 97 
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solution prior to the extraction process. It is important to point out that, regardless of the 
application, CBS can be dry prior to the extraction step. The analytical workflow consisted of three 
stages (see Figure 4.22): a.) analyte enrichment; b.) coating cleaning, wherein nonspecific 
attachments of matrix components were quickly removed from the coated surface (10 s water-
rinse); and c.) MS analysis, in which a minute droplet of elution/ionization solvent (10 µL of 
methanol:water 95:5, 0.1% FA, 10 mM AcNH4) was placed onto the coating220,395. Following 
analyte desorption (~20s), a high-voltage was applied (~5.5 kV) to the non-coated area of the blade 
in order to generate an electrospray from the CBS tip for 20s (see Figure 4.24)395. The extraction 
procedure was performed using a 1:9 mixture of 150 µL of EDTA-anticoagulated blood sample 
with a water-acetonitrile solution (Water:ACN, 85:15, 0.1M ZnSO4); the objective of this 
procedure was to burst cells that were present in the matrix and to denature proteins that were 
bound to the target analytes400, thereby increasing the free concentrations of ISDs151. Next, analyte 
enrichment was performed by immersing the CBS in the denatured sample for 90 minutes at 25 
ºC. This process was done by working in batches (i.e. automated 96-samples; see Figure 4.25), 
producing an average analysis time of 90s, and an individual sample turnaround time of 
approximately 90 min. The MS analysis time was approximately 30s. Automated CBS extractions 
were carried out using a Concept-96 system (Professional Analytical Systems, PAS, Magdala, 
Germany). This robotic sample preparation unit has been described in detail elsewhere131,304. 
Matrix-match whole-blood calibration functions were constructed based on the signal ratio of the 
analyte and the isotope-labelled internal standard (A/Is) with seven calibrators in four independent 
experiments covering a range between 1 and 100 ng/mL for EVR/SIR/TAC and 10-1000 ng/mL 
for CycA (see Tables 4.13, 4.14 and 4.15). Linear regressions were plotted using weighted linear 
least squares (1/x). The quantitation of the ISDs was validated in terms of LOD, LOQ, linearity, 
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repeatability, reproducibility, accuracy, and relative matrix effect for whole blood containing 
different hematocrit levels.  
 
Table 4.13 Calibration points for levels of tacrolimus, everolimus, and sirolimus. 
Calibration points 1 2 3 4 5 6 7 
ng/mL 1 2.5 5 10 15 25 50 
 
Table 4.14 Calibration points for levels of Cyclosporine A. 
Calibration points 1 2 3 4 5 6 7* 
ng/mL 10 25 50 100 150 250 500 
 
Table 4.15 Liquid check quality control (QC) standards acquired from Bio-Rad.  
Calibration points [ng∙mL-1] Level 1 Level 2 Level 3 Level 4 
Cyclosporine 55.6 179 324 699 
Everolimus N/A 3.14 6.78 17.6 
Sirolimus 3.62 7.74 13.1 N/A 
Tacrolimus 3.94 9.05 17.0 26.7 
 
 
Figure 4.24 Ion chronograms for TAC and CycA in whole blood spiked at 1 and 10 ng mL-1 (red 
line), respectively, overlay with representative chronograms from blank blood (blue line). 
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Figure 4.25 Automated CBS sample preparation set-up for ISDs analysis. 
 
4.5.3 Results and discussion 
The quantitative determination at low concentration levels (e.g. low part-per-billion) of drugs 
heavily bound (≥80%) to plasma proteins is a challenge for any sample preparation technology 
that extracts via-free concentration, like CBS134. This challenge is particularly great if the targeted 
drugs are not only bound to proteins, but are also partitioned into the red blood cells, as is the case 
with ISDs. As a consequence, the most commonly used methods for ISD analysis involve protein 
precipitation using a solution consisting of methanol and zinc sulfate (ZnSO4), in order to break 
the cell walls and denature the proteins that bind the drugs. Once this has been done, sample clean-
up using online-SPE and analyte separation/detection via LC-MS/MS analysis is conducted. 
Unsurprisingly, early attempts at quantifying ISDs in intact blood samples using protocols that had 
previously been designed for plasma and urine220,395 were not successful. Given that SPME has 
traditionally been a solvent-free sample preparation technology, our next step consisted in 
conducting extraction using a water-modified matrix (mixture 1:1 of 100 µL blood and 100 µL of 
a 0.1M ZnSO4 solution). However, as can be seen in Figure 4.26, we only attained acceptable 
results for CycA, while the LOQs for TAC and EVR were significantly above the therapeutic range 




Figure 4.26 Quantitative determination of (A) TAC, (B) SIR, (C) EVR, and (D) CycA. Extractions 
were performed from 100 µL of whole human blood pre-mixed with 100 µL of a 0.1M ZnO4-
solution. 20 min of extraction at 2000 rpm was followed by three rinsing steps in fresh water of 5s 
each. 
 
Figure 4.27 Quantitative determination of (A) TAC, (B) SIR, (C) EVR, and (D) CycA. Extractions 
were performed from 200 µL of whole human blood pre-mixed with 500 µL of a 0.1M ZnO4-
solution and 500 µL of LC-MS water. 30 min extraction at 2000 rpm was followed by three rinsing 




Moreover, SIR, the analyte with the largest partitioning with erythrocytes (~95%), was barely 
detected using this protocol. Therefore, we increased the sample volume (i.e. 200 µL of blood) and 
the volume of “denaturing” mixture (500 µL 0.1M ZnSO4 solution and 500 µL of water) in an 
attempt to increase the free-concentration of SIR. Although these conditions allowed us to improve 
the LOQ for TAC and EVR (~5-10 ng mL-1)—and to slightly improve the detectability for SIR 
(see Figure 4.27)—the results fell far short of the required values. As an alternative, we also 
evaluated extraction using whole blood samples that had been frozen (-80 °C) and thawed. 
Nonetheless, as shown in Figure 4.28, the results were only satisfactory for CycA. In order to 
determine if the HLB-coated blades were effective for the extraction of ISDs, extractions were 
performed using non-modified human plasma samples that had been spiked with four ISDs. As 
can be seen in Figure 4.29, the results revealed that HLB-CBS was capable of extracting ISDs 
from plasma with LOQs in the order of 1 ng mL-1 for SIR/ TAC, 5 ng mL-1 for EVR (~74% protein 
binding in plasma400), and 10 ng mL-1 for CycA. This results suggest that the poor extraction of 
ISDs in whole blood was undoubtedly linked to their partitioning into the erythrocytes (see Table 
4.13). Thus, we were compelled to defy the traditional solventless philosophy of SPME113 as a 
result of the complexity of the matrix-analyte interactions.  
Essentially, this class of compounds can only be quantified via SPME-based technologies under 
the following conditions: the matrix consists of blood cells that are fully denatured; the analytes 
have been released into the solution phase; and the CBS devices are used as open-bed SPE 
substrates151. Basically, this approach entails adding a mixture of water, 0.1M ZnSO4 solution, and 
organic solvent (e.g. methanol or acetonitrile, MeOH or ACN) to the biofluid in order to modify 






















Figure 4.28 Quantitative determination of (A) TAC, (B) SIR, (C) EVR, and (D) CycA. Extractions 
were performed from 200 µL of whole human blood frozen (-80 °C, 1h) and thawed. 30 min 






















Figure 4.29 Quantitative determination of (A) TAC, (B) SIR, (C) EVR, and (D) CycA. Extractions 
were performed from 300 µL of human plasma. 30 min extraction at 2000 rpm was followed by 
three rinsing steps in fresh water of 5s each. 
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This approach results in a marked increase in the free concentration of the ISDs, which promotes 
their extraction onto the coating particles. Nevertheless, the addition of solvent to a matrix creates 
extra challenges for analyte extraction. For instance, if the amount of organic solvent is too large, 
analyte partition may be driven onto the solvent layer rather than onto the extractive particles due 
to a dramatic decrease in the analyte partition coefficient (Kfs). This will result in a notable 
reduction in the amount that is extracted. Likewise, an insufficient amount of organic solvent will 
lead to an unsatisfactory release of the analytes, and, consequently, inadequate LOQs. Our initial 
assessments were performed using diverse ratios of MeOH. As shown in Figure 4.30, a mixture 
containing 50% MeOH allowed for the highest recoveries for all ISDs. Based on these 
observations, and knowing that more than 50% organic solvent will dramatically affect the 
extraction recovery, we also studied ACN as a substitute for MeOH. Our results indicated that, 
when using ACN only 25% of organic solvent was sufficient to get the best recovery (see Figure 
4.31). Furthermore, and more importantly, ACN-denaturing mixtures displayed better 
performance than MeOH-based mixtures (see Figure 4.31).  
Hence, this ratio was selected as the ideal compromise for quantitating ISDs, and it was used to 
determine the best extraction time. Our results indicate that extraction times around of 100 minutes 
are necessary to collect a sufficient amount of ISDs to allow us to reaching the required LOQs (see 
Figure 4.33)27. Longer extraction times were not evaluated as this will increase the turn-around 
time beyond what traditional methods can attained. A further comparison under optimum 
extraction conditions showed that HLB coatings performed approximately two times better than 
C18 coatings for the enrichment of ISDs (see Figure 4.34). Additionally, we found that using a 
larger amount of blood is a viable alternative strategy for increasing the amount of analyte 




















Figure 4.30 Optimization of organic content (MeOH, %) required to achieve the highest 
instrumental response. Extractions were performed from 100 µL of whole human blood spiked at 
50 ng mL-1 with TAC/SIR/EVR and 500 ng mL-1 for CycA, and pre-mixed with a 0.1M ZnO4-
solution and MeOH according to their respective ratios. 30 min extraction at 2000 rpm was 










Figure 4.31 Optimization of organic content (ACN, %) required to achieve the highest 
instrumental response. Extractions were performed from 100 µL of whole human blood spiked at 
50 ng mL-1 with TAC/SIR/EVR and 500 ng mL-1 for CycA, and pre-mixed with a 0.1M ZnO4-
solution and CAN according to their respective ratios. 30 min extraction at 2000 rpm was followed 












Figure 4.32 Comparison between two different organic solvent denaturing mixtures: 25% ACN 












Figure 4.33 Extraction time profile for three of the ISDs (10, 25, 50, 100 min). Extractions were 
performed from whole human blood spiked at 50 ng mL-1 with TAC/SIR/EVR, and pre-mixed 





















Figure 4.34 Comparison of two different coating chemistries for the extraction of ISDs from a 
modified blood-matrix. Extractions were performed from whole human blood spiked at 50 ng mL-
1 with TAC/SIR/EVR and 500 ng mL-1 for CycA, and pre-mixed with a 0.1M ZnSO4-solution and 
ACN (25%) according to their respective ratios. 90 min extraction at 2000 rpm was followed by 











Figure 4.35 Comparison of three different blood sample volumes for the determination of ISDs 
from a modified blood-matrix. Extractions were performed from whole human blood spiked at 50 
ng mL-1 with TAC/SIR/EVR and 500 ng mL-1 for CycA, and pre-mixed with a 0.1M ZnSO4-
solution and ACN (25%) according to their respective ratios. 90 min extraction at 2000 rpm was 











Figure 4.36 Comparison of four different extraction temperatures for the determination of ISDs 
from a modified blood-matrix. Extractions were performed from whole human blood spiked at 50 
ng mL-1 with TAC/SIR/EVR and 500 ng mL-1 for CycA, and pre-mixed with a 0.1M ZnSO4-
solution and ACN (25%) according to their respective ratios. 90 min extraction at 2000 rpm was 
followed by three rinsing steps in fresh water of 5s each.  
 
However, this option would be limited to the amount of sample available. Finally, we found that 
we were able to achieve a significant improvement in the extraction efficiency for all ISDs by 
increasing the extraction temperature (see Figure 4.36). Indeed, we observed that the amount of 
analyte extracted reached a maximum at 35°C. This behavior is mainly related to a compromise 
between the increasing of the diffusion coefficient of the target analytes and the reduction of the 
affinity of the coating for the ISDs as the temperature increases.  
Based on all of the above-mentioned findings, we proceeded to evaluate the capabilities of CBS-
MS/MS for the quantitation of ISDs in whole blood. Our final protocol consisted of performing 
extractions from 150 µL of blood mixed with 325 µL of ACN (25%) and 1025 µL of 0.1M ZnSO4-
solution. The extraction time used in this protocol was 90 min at 1500 rpm using a 96-well plate 





Figure 4.37 Linear regression curves for TAC, CycA, EVR and SIR in whole blood. Analyses were performed using CBS-MS/MS from 
modified blood matrix with ACN and zinc sulfate. Quantification was performed with the entire area under the curve for each analyte, 




Table 4.16 Figures of merit for the determination of ISDs in whole blood. Extractions were performed from 150 µL of blood mixed 
with 325 µL of ACN (25%) and 1025 µL of 0.1M ZnSO4-solution. Extraction time was 90 min at 1500 rpm using a 96-well plate heated 









LDR [ng/mL] RMSE 
Cyclosporine 41-58 50−350 3 10 10-1000 0.055 
Tacrolimus ~85 3−15 0.3 1 1-100 0.040 
Sirolimus ~95 3−20 1 2.5 2.5-100 0.064 
Everolimus ≥75 3−15 0.3 1 1-100 0.038 
 
Table 4.17 Validation of protocol herein proposed using Liquichek
®
 Bio-Rad standards (n=4) 
Compound QC-1 QC-2 QC-3 QC-4 
Cyclosporine 101 ± 4.3 95 ± 1.1 93 ± 5.0 87 ± 2.1 
Tacrolimus 119 ± 4.9 106 ± 1.3 106 ± 1.8 98 ± 2.8 
Sirolimus 101 ± 2.8 103 ± 1.0 109 ± 1.9 - 
Everolimus - 96 ± 1.9 100 ± 0.4 96 ± 1.5 
 
Table 4.18 Comparison of ISDs calibration curves obtained using blood with different hematocrit levels (n=4)  
Hematocrit (%) 
Linear least squares slope values 
TAC SIR EVR CycA 
70 0.0226 0.0459 0.0228 0.0101 
45 0.0219 0.0441 0.0210 0.0100 
20 0.0205 0.0499 0.0220 0.0090 
Average 0.0216 0.0466 0.0219 0.0097 
RSD (%) 5 6 4 6 
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Figure 4.37 presents the linear calibration curve attained for each of the studied compounds. The 
LOQs achieved using this methodology were 10 ng mL-1 for CycA, 1 ng mL-1 for EVR/ TAC, and 
2.5 ng mL-1 for SIR (see Table 4.16). Good linearity (R2 ≥ 0.996) was attained over the evaluated 
range for all ISDs. As can be seen in Figure 4.37, the coefficient of variation (CV) of the calibrators 
for all ISDs was in accordance with the assay precision levels prescribed by the International 
Association of Therapeutic Drug Monitoring and Clinical Toxicology Immunosuppressive Drug 
Scientific Committee (IATDMCT; ≤ 10%)13. Furthermore, this method had a median accuracy of 
100.5% (see Table 4.17), which was evaluated using third-party-prepared calibrators (i.e. 
Liquichek™ calibrators by Bio-Rad, see Table 4.15). Finally, as presented in Table 4.18, no 
statistical differences (RSD ≤ 7 %) were observed in the calibration curve slopes of ISDs in blood 
with different hct values (20, 45, and 70 hematocrit %)412. The above-mentioned result can be 
primarily attributed to the strongly denatured media employed during the extraction step. In other 
words, due to the extreme conditions of the solution, a quantitative and reproducible amount of 
analyte is released and extracted in its free form regardless of the hct level. Although this 
manuscript strictly presents a proof-of-concept of CBS’s suitability for ISD determination, a full 
validation of the technology using a certified LC-MS/MS method with real samples is presently 
being undertaken in our laboratory.  
 
4.5.4 Summary 
This study demonstrates that CBS-MS/MS is a suitable tool for routine ISD determinations in 
clinical laboratories. Moreover, CBS offers a workflow that is simpler than that of traditional 
methods by eliminating the need for chromatographic separation, while providing a clean extract 
that allows for long-term instrumental operation with minimal maintenance. Furthermore, as CBS 
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integrates all analytical steps in one device, it eradicates the risk of instrumental carry-over. Fully 
automated sample preparation simplifies the method and allows for total analysis times as short as 
3 minutes with turn-around times of less than 90 minutes. LOQs of 10 ng mL-1 for CycA, 1 ng mL-
1 for EVR/ TAC and 2.5 ng mL-1 for SIR, were obtained. Moreover, excellent linearity and more 
than acceptable CV (≤ 10%) for all the validation points evaluated within the therapeutic range. 
Finally, it was demonstrated that no statistical differences (RSD ≤ 7 %) in sensitivity were obtained 
when blood with different hct values was analyzed. However, it is worth noting that, beyond the 
analytical validation herein reported and, in order to use CBS-MS/MS in routine clinical practice 
for TDM measurements, some clinical performance parameter must be considered; for example,   
long-term stability, performance of the instrument/assay combination under typical routine 
circumstances (e.g. several samples a day), different medical conditions (e.g. co-medication, 
lipemia, jaundice, impaired renal function) or different physical blood storage approaches (e.g. 
hemolysis).13 Further validation is required using samples from real patients, as this will allow for 
more detailed examination of potential in-source fragmentation-related bias (e.g. inadvertent 
dissociation of labile conjugated metabolites in the API region). The aims of our current efforts 
have been threefold: to decrease the sample volume required to perform analysis; to provide a 
fully-automated CBS-MS platform; and to assess tacrolimus (ERM-DA110a), which is the only 









Section 4.6 Quantitative analysis of biofluid spots by coated blade spray mass 
spectrometry, a new approach to rapid screening 
 
4.6.1 Introduction 
Efficient, simple, and cost-effective methods that allow for quantitative analysis of small volumes 
of biofluids are critical for the advancement of personalized medicine and drug development. 
State-of-the-art mass spectrometry (MS) instrumentation in combination with innovative and easy-
to-use microsampling technologies have facilitated the development of new analytical 
methodologies.8,173 Applications such as new-born screening,413,414 therapeutic drug 
monitoring,173,347,415,416 and drug metabolism pharmacokinetics (DMPK)417 have greatly benefitted 
from these advances. Such microsampling devices are consisted of, or contain, a piece of paper or 
polymeric absorbent in which a droplet of biofluid can be collected then dried. Following, devices 
can be either stored for further studies or sent to the laboratory for immediate analysis. Typically, 
the analytical workflow for determination of analytes of interest collected on these devices consists 
of multiple steps prior to quantitation via MS, including liquid extraction, extract clean-up, analyte 
elution  (e.g. by using solid phase extraction, SPE), and chromatographic separation.418 Aiming to 
increase the throughput of analysis, on-line technologies that combine all these steps have been 
developed and thoroughly assessed by other researchers.419 Further, in the last ten years, scientists 
have developed multiple ground-breaking technologies allowing for the eradication of the sample-
prep/separation stages from the analytical work-flow.8 These technologies, allowing for direct MS 
analysis of dried biofluid spots (e.g. paper spray, PS), have gained remarkable popularity, being 
adapted in numerous applications.8,49 However, sample preparation cannot be entirely overlooked; 
indeed, several unavoidable effects intrinsic to ionization and detection processes can resultantly 
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emerge from a lack of sufficient sample preparation, including ion suppression, poor sensitivity, 
and potential instrument contamination.80,113 Aiming to solve these issues, a new chapter in this 
novel era of MS was written by merging micro-sample preparation technologies with ambient 
ionization MS approaches.102,173,420 However, while such methods can certainly address the 
aforementioned effects, not all of them provide a pragmatic approach to analysis (e.g. complex 
operation, long analysis times, or expensive equipment/parts required per analysis). In this regard, 
there still exists a demand for a tool that not only improves limits of quantitation (LOQ) and 
minimizes matrix effects, but that can also offer high throughput compatibility for rapid 
diagnostics.178 Coated Blade Spray (CBS), an SPME-based technology designed for enrichment 
of analytes of interest from complex sample matrices, can be directly coupled with MS instruments 
for rapid quantitative or qualitative analysis.136 CBS can be described as a sword-like stainless 
steel sheet coated with polymeric adsorbent particles, which act as a solid-substrate ESI source 
(Figure 1).46 Unlike classical microsampling devices, CBS functions by extracting/enriching 
analytes of interest from a given sample, rather than through a collection of dried sample spots.151 
Contrary to general assumptions,83,91,98 CBS has been shown to handle a broad range of sample 
volumes (i.e. µL to L).136,151,220 Herein, having accepted the challenge of employing CBS towards 
analysis of minimum amounts of sample (≤ 10 µL), we present a thorough validation of the 
quantitation capabilities of CBS for analysis of small volumes of biofluids. 
 
4.6.2 Experimental section  
Materials and reagents 
Formic acid was purchased from Sigma-Aldrich (Saint Louis, USA), and LC-MS-grade methanol 
(MeOH), acetonitrile (ACN), isopropanol (IPA) and water were purchased from Fisher Scientific. 
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The following compounds were selected as model analytes for evaluating the quantitation 
capabilities of CBS in droplet analysis: methamphetamine, methamphetamine-d5, carbamazepine, 
carbamazepine-d10, propranolol, propranolol-d7, clenbuterol, clebuterol-d9, diazepam, diazepam-
d5, codeine, codeine-d3, cocaine, cocaine-d3, sertraline, sertraline-d3, citalopram, citalopram-d6, 
fentanyl, fentanyl-d5, buprenorphine, buprenorphine-d4, morphine, morphine-d6, methadone, 
methadone-d3, oxycodone, lorazepam, bisoprolol and stanozolol were acquired from Cerilliant 
Corporation (Round Rock, TX, USA). As noted, deuterated analogues of most analytes were used 
to correct for intra- and inter-experiment variability. For further details regarding compound 
properties, and selected reaction monitoring (SRM) transitions, see Table 4.6. Individual stock 
standard solutions were prepared in methanol at a concentration of 1000 µg·mL-1 and stored at -
80 ºC. Stainless steel blades, which were purchased from Shimifrez Inc. (Concord, Ontario, 
Canada), were then coated using a slurry of hydrophilic lipophilic balance particles and 
polyacrylonitrile (HLB-PAN) according to a protocol developed in our laboratory (see Section 
4.4.2 for further details) with HLB particles kindly provided by Waters Corporation. The coating 
length and thickness was 15mm and 10µm, respectively.  
 
Biological samples 
A phosphate-buffered saline solution (PBS) (pH 7.4) was prepared by adding 8.0 g of sodium 
chloride, 0.2 g of potassium chloride, 0.2 g of potassium phosphate, and 1.44 g of sodium 
phosphate to 1 L of nanopure water. Human plasma (with potassium (K2) 
ethylenediaminetetraacetic acid (EDTA) as anticoagulant) had been pooled from different batches 
was purchased from Bioreclamation IVT (Baltimore, MA, U.S.A). Pooled whole blood from 
healthy donors in potassium K2-EDTA was purchased from Bioreclamation IVT (Baltimore, MA, 
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U.S.A.). All the plasma and blood samples were spiked and stored overnight at 4 ºC in order to 
achieve the drug-protein binding equilibrium. All the experiments and methods herein reported 
were done with the approval of the University of Waterloo’s Office of Research Ethical Board. 
 
Mass Spectrometry 
All the experiments described in this manuscript were carried out using a TSQ Quantiva mass 
spectrometer (Thermo Fisher Scientific, San Jose, California, USA), and data processing was 
performed using Trace Finder 3.3 (Thermo Fisher Scientific, San Jose, California, USA). To 
guarantee that the blades were accurately positioned in front of the mass spectrometer during all 
experiments, an in-house ionization source was built at the University of Waterloo (see Figure 
4.18). Once the CBS had been installed on the interface, 10 µL of a 95:5 MeOH/water v/v 0.1% 
formic acid solution was applied to the coated area in order to desorb the analytes (t ≤ 20 s). After 
analyte elution on the desorption solution, a voltage of 4 kV was established between the CBS and 
the MS entrance to generate electrospray from the tip of the blade. All analyses were carried out 
in positive ionization mode. Optimum collision energy and RF-lens conditions were tuned for each 
compound via the direct infusion of methanolic standards. MS/MS transitions, optimum collision 
energy (CE), and RF-lens voltages for each analyte can be found in Table 4.6. 
 
Analytical methodology 
All the CBS devices were cleaned after manufacturing for 30 min using a 40:40:20 
(MeOH/ACN/IPA, v/v/v) solution and then conditioned for 30 min with a 50:50 (MeOH/water, 
v/v) solution prior to extraction process. It is important to point-out that, regardless of the 
application, CBS can be dried prior to the extraction step. As illustrated in Figure 4.38, the  
251 
 
Figure 4.38 Experimental set-up for quantitative analysis of blood or plasma droplets via Coated 
Blade Spray-Mass Spectrometry (CBS-MS).  
 
 
analytical workflow consists of three simple steps. First, 10 µL of biofluid is spotted onto the 
coated area of the blade, then left to interact with the extracting particles for 5 minutes. Next, the 
CBS is rapidly rinsed for 10 seconds with water, aiming to remove any potential matrix that could 
have adhered to the surface. Subsequently, the blade is placed in front of the MS system for 
analysis, and a droplet (10 µL) of elution/spraying solvent is added onto the coated area. Finally, 
after 20 seconds, ions of the extracted/pre-concentrated analytes are generated by applying a high 
electric field (+ 4kV) between the blade and the mass spectrometer.136 All the methods herein 
reported were performed according to University of Waterloo safety guidelines and regulations. 
 
Method validation 
The methodologies were validated with respect to linearity, precision, accuracy, and LOQ. 
Calibration functions were constructed on the basis of the signal ratio of the analyte and its 
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isotopologue (A/Is) for 10 concertation levels in four independent replicates from 0.25 ng·mL-1 to 
100 ng·mL-1. Furthermore, three validation points at concentrations of 3, 40, and 80 ng·mL-1 were 
analyzed in order to assess precision and accuracy. LOQs were calculated as the lowest calibration 
point with precision values lower than 20%. 
 
4.6.3 Results and discussion 
An initial assessment of CBS as a tool for analysis of biofluid spots was performed by employing, 
as model, phosphate buffered saline (PBS) samples spiked with 17 compounds from different 
classes and comprising a broad range of molecular weights, functional groups, and polarities 
(Table 4.6), including controlled substances (e.g. clenbuterol), pain management drugs (e.g. 
buprenorphine), and drugs of abuse (e.g. fentanyl). As shown in Table 4.19, by using blades coated 
with hydrophilic–lipophilic balanced (HLB) particles, LOQs equal or lower than 1 ng·mL-1 and 
outstanding figures of merit were reached for all analytes under study (i.e., SPME balance 
coverage). In view of these promising results, CBS was then employed towards analysis of 
analytes spiked on human plasma. As summarized in Table 4.20, LOQs for all compounds were, 
in almost all cases, below the minimum required performance levels (MRPL) set by the World 
Andi-Doping Agency (WADA), the cut-off established by the Substance Abuse and Mental Health 
Services Administration (SAMHSA), or the analytical quantitation limits established by certified 
clinical laboratories (i.e., LOQ ~ 1-5 ng·mL-1). As shown in Table 4.21, similar results were 
obtained for analyses of blood samples spiked with the same target analytes (i.e., LOQ ~ 1-10 
ng·mL-1). Although LOQs were higher for plasma and blood spots, the validation of the 




Table 4.19 Figures of merit for determination of multiple substances in PBS spots via CBS-MS/MS. Red color denotes compounds that 




Accuracy, % Precision, % 
3 ng·mL-1 40 ng·mL-1 
1
80 ng·mL-1 3 ng·mL-1 40 ng·mL-1 80 ng·mL-1 
Methamphetamine 0.5 93 103 98.3 3 2.1 2.8 
Carbamazepine 1 107.7 102.6 97.8 9.1 1.8 1.8 
Propranolol 1 96.5 101.8 97.7 7.0 2.2 1.4 
Clenbuterol 1 102.4 104.9 97.6 6.4 1.5 1.2 
Diazepam 0.5 102.2 101.1 97.1 5.8 5 2.2 
Codeine 0.5 104.8 103.9 96.1 20.8 19.6 5.6 
Cocaine 0.5 94.1 108.1 97.8 0.9 9.9 2 
Sertraline 0.5 95.1 102.3 98.5 5.4 4.5 1.5 
Citalopram 1 97.9 106.4 97.3 3.4 5.7 2.3 
Fentanyl 0.25 95.1 110.3 100.6 1.6 1.6 2 
Buprenorphine 0.25 102.1 101.8 95.4 3.7 7.4 3 
Morphine 1 108.3 102.7 96.6 9.3 1.9 2.2 
Methadone 0.25 95.5 106.8 97.5 1.9 2.7 1.2 
Salbutamol* 5 120.3 133.3 110.5 37.5 25.2 14.4 
Oxycodone 1 109.1 105.4 103.5 2.8 7.8 4.7 
Lorazepam 25 - 95.5 88.3 - 19 7.3 







Table 4.20 Figures of merit for determination of multiple substances in plasma spots via CBS-MS/MS. Red color denotes compounds 




Accuracy, % Precision, % 
3 ng·mL-1 40 ng·mL-1 80 ng·mL-1 3 ng·mL-1 40 ng·mL-1 80 ng·mL-1 
Methamphetamine 2.5 108.5 98.7 100.9 4.3 2.7 3 
Carbamazepine 1 103.1 101.4 106.8 8.7 1.5 4 
Propranolol 2.5 110.4 97.6 106.7 1.5 3.4 3.4 
Clenbuterol 2.5 113.7 97.2 104.6 7.7 1.6 2.3 
Diazepam 2.5 113.5 97 102.9 5.9 1.2 2 
Codeine 5 - 96.2 94.1 - 8.6 11 
Cocaine 2.5 110.9 98.5 102.1 7.4 1.3 0.9 
Sertraline 2.5 100.5 91.3 107.3 5.1 1.8 3.1 
Citalopram 2.5 107.5 95.5 103.5 2.9 3.8 1.5 
Fentanyl 2.5 107.7 98.2 104.5 4.5 0.6 2.9 
Buprenorphine 2.5 92.7 102.9 101.4 15.2 7.5 7.9 
Morphine 5 - 99.5 97.4 - 5.2 5.9 
Methadone 5 - 96.9 102.8 - 1.8 0.8 
Salbutamol* 2.5 111.9 106.5 104.7 8.6 7.2 15 
Oxycodone 5 - 99.2 110.8 - 3.13 1.11 
Lorazepam - - - - - - - 








Table 4.21 Figures of merit for determination of multiple substances in blood spots via CBS-MS/MS. Red color denotes compounds 




Accuracy, % Precision, % 
3 ng·mL-1 40 ng·mL-1 80 ng·mL-1 3 ng·mL-1 40 ng·mL-1 80 ng·mL-1 
Methamphetamine 10 - 88.6 123.8 - 4.1 1.3 
Carbamazepine 1 94.8 89.8 115.5 4.2 0.5 1.2 
Propranolol 5 - 90.5 95.2 - 1.2 1.8 
Clenbuterol 1 105.7 93.8 112.6 12.3 2.3 1.1 
Diazepam 2.5 113 94.3 111 13 3.9 1.2 
Codeine 2.5 102.4 95.3 75.3 2.5 3.8 16 
Cocaine 2.5 119.8 93.3 96.8 10.9 1 4 
Sertraline 5 - 92.3 101.8 - 0.2 0.1 
Citalopram 2.5 118.6 93.1 111.6 7.7 2.5 3.7 
Fentanyl 2.5 112.7 91 110.9 3 1.1 4.4 
Buprenorphine 1 96.1 87.8 100.6 4.2 6.0 13 
Morphine 10 - 92.9 23.8* - 1.9 22 
Methadone 1 104.2 92.8 105.9 8.3 1.1 5.5 
Salbutamol* 10 - 98.4 23.1* - 1.6 11.4 
Oxycodone 10 - 93 135.0* - 1.6 17.7 
Lorazepam 10 - 95 68.04 - 4.1 8.1 

















Figure 4.39 SPME-CAN methodology towards analysis of target compounds heavily bound to 
proteins and/or red blood cells via CBS. 
 
 
Given that CBS, like any other SPME device, extracts via free concentration, analytes largely 
bound to plasma proteins or red blood cells are expected to provide lower extraction recoveries in 
comparison to those provided by PBS (i.e., worst-case scenario for SPME-related technologies).131 
Aware of the intrinsic limitations of CBS, we decided to shift the paradigm and defy the solventless 
philosophy of SPME.2 As portrayed in Figure 4.39, our idea entailed adding a minuscule amount 
of organic solvent (i.e. acetonitrile, ACN) to the biofluid spot so as to modify the matrix viscosity 
as well as the analyte-protein-binding properties, resultantly increasing the free concentration of 
the analytes under study, and thus facilitating their extraction onto the coating particles.98 
However, the addition of solvent onto an SPME surface holding a biofluid droplet brings up extra 
challenges for analyte quantitation. For instance, if the amount of organic solvent on the coating 
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is too large, analyte partition may be driven onto the solvent layer rather than onto the extractive 
particles, due to a dramatic decrease in the analyte partition coefficient (Kfs), and consequently, 
decrease the free concentration of the analyte. Likewise, if extraction/enrichment time is too long 
(t ≥ 5min),  precipitation of macromolecules (i.e., proteins347), as well as blood skeletonization on 
the coating, may occur. Such events might lead to significant ionization suppression and potential 
instrument contamination. Thus, optimization of solvent volume and interaction time were critical 
steps in the development of this method. As shown in Figures 4.40 and 4.41, the highest response 
was attained when using 2.5 µL of ACN and 5 minutes of contact time. Unquestionably, these 
results evidence the relevance of the clean-up feature intrinsic of SPME-based devices such CBS, 
which are inbuilt so as to prevent the undesired attachment of potential contaminants/interferences. 
As can be seen in Figure 4.42 and Table 4.22, employment of this new method, named SPME-
CAN, resulted in lower LOQs for all studied probes (i.e., 2-20 fold enhancement), without 
sacrificing total analysis time. It is important to point out that deuterated internal standards were 
not available for all analytes under investigation (salbutamol, oxycodone, bisoprolol, lorazepam). 
Nonetheless, the presented findings demonstrated that CBS-MS/MS was a suitable technique for 
quantitative analysis of all the studied compounds, even when the deuterated analogue of the target 
compound was not available (Figure 4.42). An additional feature of CBS for point-of-care 
applications is its ability to guarantee analyte stability on the coating prior to instrumental analysis. 
Our findings showed that the majority of the compounds were stable on the coating, even at room 
temperature, for up to 7 days (Figure 4.43). Certainly, further stability can be accomplished by 
storing the blades at low temperatures (-30/-80 ˚C).2,313 While the stability of CBS has only been 
evaluated to 30 days at freezing conditions at this time, a long-term storage evaluation experiment 
(> 6 months) is currently under way in our laboratory. 
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Table 4.22 Figures of merit for determination of multiple substances in blood spots by SPME-CAN methodology via CBS-MS/MS. 
 
 






















Salbutamol 0.44 - 10 2.5 113.6 81.7 86.3 7.1 7.5 12.7 
Morphine 0.99 30-40 10 2.5 118.6 86.9 87.2 6.5 6.3 3.6 
Oxycodone 1.04 45 10 2.5 110.7 81.9 93.6 6.9 11.4 5.6 
Codeine 1.20 7-25 2.5 0.5 94.2 80.8 93.7 6.5 4 3.2 
Cocaine 1.97 - 2.5 0.25 92.9 86.4 96.1 3.5 2.4 1.2 
Methamphetamine 2.23 - 10 0.5 90.1 84.3 95.7 2.9 2.1 1.6 
Bisoprolol 2.30 30 1 0.5 95.8 87.7 95.6 4.2 3.1 7.7 
Diazepam 2.63 98.5 2.5 0.5 95.5 80.5 93.4 3.7 4.5 2.3 
Carbamazepine 2.77 76 1 0.25 113.2 90.7 95.3 1.7 1.8 2.9 
Clenbuterol 2.94 - 1 0.5 95.9 83.3 96.4 2.8 1.7 0.9 
Lorazepam 2.98 89-93 10 2.5 128.4 91.5 103.6 8.5 8.7 16.4 
Propranolol 3.03 >90 5 0.5 92.0 83.2 92.6 1.8 1.9 1.9 
Citalopram 3.58 80 2.5 0.5 95.7 85.3 94.6 4.5 2.5 2.4 
Fentanyl 4.12 80-85 2.5 0.25 93.2 85.7 95.2 2.3 1.7 0.8 
Methadone 4.14 85-90 1 0.25 96.2 92.8 93.5 2.6 1.5 0.9 
Buprenorphine 4.53 96 1 0.5 98.4 85.8 97.8 7.2 8.3 4.1 










































Figure 4.42 Quantitative analysis of whole blood spiked with buprenorphine (0.5-100 ng mL−1), 
oxycodone (2.5-100 ng mL−1), fentanyl (0.1 ng mL−1 to 10 ng mL−1), and sertraline (0.25-10 
ng mL−1). Total sample volume was 10 µL and total analysis time ≤ 7 min via MS/MS.  
 
 
Internal standard preloading and application to on-site sampling  
All of the experiments described up to this point were achieved using blood spiked with both the 
analyte of interest and its internal standard. Given that in real case scenarios, such as drug 
pharmacokinetic studies in rats, the blood sample only contains the target drug (or its metabolites), 
and that adding an internal standard can be cumbersome due to the ultrasmall amount of analyte 
that need to be spiked, pre-loading an internal standard on the blade prior to spotting the real 
sample was evaluated.  Essentially, the internal standard was preloaded on the blade by spotting 5 























Figure 4.43 Storage stability of analytes extracted from blood spots on CBS devices for several 
days. A. Cocaine; B. Methamphetamine; C. Fentanyl 
 
As can be seen in Figure 4.44, good linearity was attained when studying rat blood only spiked 
with fluoxetine. Based on this results, this methodology was implemented towards the quantitation 
of fluoxetine in rats that were administrated with such drug. The sampling took place at the 
laboratories of the Center for Addiction and Mental Health (CAMH) as part of our collaboration 
with Doctor Clement Hamani and his team on the implementation of SPME for brain studies. 
Basically, by using CB 300 K2EDTA microvette tubes (SARSTEDT, Germany), approximately 
15 µL of blood was collected from the tail of the rats and 5 µL of such blood was placed into the 












Figure 4.44 Quantitative analysis of whole blood spiked with fluoxetine (0.01-1000 ng mL−1) and 
fluoxetine-d6 preloaded on the CBS. 
 
 
Figure 4.45 On-site monitoring of fluoxetine in whole rat blood (5 µL) using CBS preloaded with 




As described through this section, the contact time between the spot and the coating was 5 minutes, 
followed by 2 rinsing steps in fresh water. After gently cleaning the coating with a Kim-wipe, the 
blades were stored on a vial and brought to the laboratory at University of Waterloo under cold 
chain (-80 °C). It is important to point-out that the extractions were performed using the original 
protocol developed for droplet analysis (i.e. no-solvent addition). Furthermore, it must be indicated 
that the blood samples used in this study were part of another study between our group and Dr. 
Hamani’s group. Consequently, the sampling times were adjusted according to such study and I 
have no control over when the experiment starts or ends. Nevertheless, as can be seen in Figure 
4.45, this methodology allowed us monitoring over the time the concentration of fluoxetine in real 
“patients” (rats). Currently, our group is focused on evaluating this methodology towards the 
determination of multiple targets from a single droplet of blood as described below. 
Figure 4.46 Lab-on-blade workflow for the analysis of multiple analytes with different CBS from 
a single droplet of biofluid. 
264 
 
Figure 4.47 Quantitative determination of TAC, itraconazole, amitriptyline, buprenorphine, 
methadone and fentanyl in 10 µL whole human blood using Lab-on-a-blade protocol. Pink 
triangles indicate validation points plotted against the calibration curve. Each analysis was 
performed with an independent CBS with a total of three replicates (n=3) per calibrator or 





As a proof-of-concept, the methodology used for the analysis of immunosuppressants was 
implemented for the determination of multiple target compounds from a single droplet of biofluid. 
As shown in Figure 4.46, the procedure comprises mixing a droplet of blood (i.e. 10 µL) with 90 
µL of the ACN/ZnSO4 mixture disclosed in Section 4.5. After 5 minutes of homogenization under 
vortex agitation, 10 µL of the “modified sample” was applied on the coated area of the CBS. 
Finally, after 5 minutes of contact, the CBS devices were rinsed 3 times and placed in front of the 
MS for analysis. Unlike the workflows describe in the previous sections, at least 10 independent 
CBS experiments can be performed from a single droplet of blood. For instance, Figure 4.47 
presents exemplary calibration curves for TAC, itraconazole, amitriptyline, buprenorphine, 
methadone and fentanyl attained with independent blades. Certainly, these results are just 
preliminary and further optimization is undergoing in our laboratory in order to attain lower limits 
of quantitation, particularly for TAC. Undeniably, the lab-on-a-blade (LOB) protocol appears as 
an attractive method for applications where not only the sample is limited but analytes with diverse 
analytical requirements (e.g. ionization or extraction conditions) need to be analyzed 
concomitantly and in a rapid fashion.  
 
4.6.4 Summary 
In summary, the potential of CBS for analysis of various compounds present in small volumes of 
biofluids was thoroughly validated. Unlike other SPME-MS approaches, no additional 
instrumentation is required for analysis, as the blade acts as both the extraction device and 
ionization-source.174,178 Similar to dried blood spot (DBS) or PS methods, sample containers are 
not needed for sample collection, as the sample can be simply spotted onto the coated area of the 
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blade. Thus, after enriching the analytes on the coating, the CBS device can be shipped to the 
laboratory for immediate analysis, or simply stored under cold chain pending examination (Fig. 
1).391,398 Likewise, we foresee the application of CBS towards analysis of less invasive matrices 
such as urine or saliva,123,421 as an extractive matrix spot.200,422 In the same line, one could see the 
suitability of this technology for fingerprinting applications and population studies of 
microorganisms such as fungi and bacteria.59,423,424 Certainly, the SPME-CAN methodology herein 
proposed can be easily implemented with other SPME substrates consisted of a flat geometry, such 
as SPME-Transmission Mode,267 for spot analyses. As a future direction, our current work focuses 
on the development of a technology that allows for simple pre-loading of internal standards to 
facilitate quantitation of small sample volumes and a hassle-free sample manipulation 
approach.93,425 Definitely, CBS-MS is not meant to solve all analytical problems, and combinations 
with on-line technologies such as differential mobility spectrometry341 (or ion-mobility336) and 
multiple reaction monitoring with multistage fragmentation (MRM3)  may be necessary to quantify 
more challenging compounds (e.g. isobars with share fragment ions).178 Nevertheless, the findings 
herein presented are quite encouraging towards the development of a cost-effective tool that can 









5. Summary and future directions 
 
5.1 Summary  
This PhD dissertation introduced novel analytical technologies capable of delivering simplified 
and fast qualitative and quantitative analysis of complex matrices. These approaches, based on the 
direct coupling of SPME to MS, were shown to be rapid, simple to operate, deployable, cost-
effective, and able to provide results close to real-time, while causing negligible instrument 
contamination, thus guaranteeing its reliable and long-term operation. In addition to providing 
biocompatibility and adequate sensitivity, all devices herein discussed can be arranged with 
automated systems to provide high-throughput determinations (i.e. ≥ 96 samples simultaneously). 
Furthermore, workflows suitable either for analysis of semi-solid samples, such as biological 
tissues, or liquid matrices, such biofluids, were developed for use of the presented technology. 
With respect to the analysis of aqueous matrices, the developed methodologies afford sampling of 
volumes that range from micro-droplet size (V ≤ 20 µL) to hundreds of milliliters. Such advances 
are positioned to have an immediate impact on the speed, precision, and efficiency of biological 
investigations in drug development and point-of-care (POC) diagnosis. The strategies herein 
disclosed can be essentially applied to any field that requires robust, inexpensive, sensitive, and 
rapid workflows such as clinical, toxicological, doping, and forensic sciences.  
Aiming to have a quick overview of the results/observations described in this dissertation, Table 
5.1 presents a fair comparison of the SPME-MS technologies herein disclosed and those developed 
by other groups in recent years for rapid and reliable analysis of complex matrices. Succinctly, 
CBS136 stands as one of the most comprehensive SPME-MS technologies introduced to date due 
to its well-defined benefits over other SPME-MS couplings.  
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Table 5.1 Comparison between SPME-MS technologies 
a Single emitters are used for independent experiments to prevent carry-over 
b Depending on the application, CBS devices could be potentially reused 
c Depending on the desorption temperature 
d Cost per sample is determined by devices used, solvent and/or gas consumption, energy requirements, among others  
e MS/MS, MRM3, HRMS from a single device 
f Depending on the size of the blade (valid only for ultra-small CBS) 
g Depending on the geometry of the SPME device, it must be flat, with sufficient surface area to handle a droplet 





nanoESI OPP CBS DESI DBDI DART 
Ionization mechanism ESI ESI/CI ESI ESI CI CI 
Desorption mechanism Solvent Solvent Solvent Solvent Thermal Thermal 
MS front-end modification Moderate Minimal Moderate Significant Significant Significant 
Reusability of the ionization source Noa Yes Nob Yes Yes Yes 
Reusability of the SPME device Yes Yes Yes Yes Yesc Yesc 
Cost per sampled Significant Moderate Minimal Moderate Moderate Moderate 
Easiness to operate Moderate Simple Simple Complex Simple Simple 
MS-total analysis time ≥ 5 min ≤ 20 s ≥ 2 min - ≤ 20 s ≤ 20 s 
Fastest MS acquisition  ≤ 5s 15s ≤ 5s - 15s 5-15s 
Suitable for profiling applications Yes Yes Yes Yes Yes Yes 
Suitable for in-vivo applications Yes Yes Yes f Yes Yes Yes 
Suitable for mass spectrometry imaging  No No No Yes No No 
No need of a vessel for sampling Yesg Yesg Yes Yesg Yesg Yesg 
Sensitivity attained Moderate High Moderate Low High Moderate 
Requires fluidicsh  No Yes No Yes Yes Yes 
Energy consumption (Watts) Minimal Minimal Minimal Minimal Significant Significant 
Solvent consumption (µL/min) Minimal Significant Minimal Minimal - - 
Gas consumption (mL/min) - Significant - Significant Significant Significant 
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Some of these benefits include: no gas or heating requirements for the desorption/ionization 
step;174,267 low solvent consumption per analysis (≤ 15µL);182 no fluidic requirements (i.e. pumps, 
valves, syringes or tubes);178 no need for a desorption chamber;114,173,182 no need for a sampling 
vessel when analyzing small sample volumes;114,173,182 and no requisite of a pumping mechanism 
during the sample preparation process114,197,394. In addition, CBS can be coated with different 
extractive materials on each side, thus offering numberless experimental opportunities not afforded 
by other SPME interfaces.114,197,211,212 For instance, CBS offers introduction of more one replicate 
at a time in the MS instrument, simply by independently spraying each side of the sampling device. 
Likewise, a derivatization reaction could be carried out on only one side of the blade, thus 
enhancing the selectivity and sensitivity of the method for a specific group of analytes, while the 
other size can be employed for an untargeted analysis of the system under investigation. 
Furthermore, in comparison to DBDI or OPP, CBS is capable of quantifying more compounds in 
a single analysis, since the area under the curve that is used for quantitation lacks the shape of a 
Gaussian peak, which is limited in width,114,164,167,174,178  while the electrospray event can be 
extended with the use of a continuous solvent supply (i.e. analyte is introduced at a given spray 
rate). The extended electrospray event also allows for multiple MS experiments (i.e. MS/MS, 
MRM3, DMS/IMS, HRMS) to be carried out with a single device. However, it is fair to say that 
technologies that introduce all extracted analytes into the mass spectrometer within a narrow 
window of time (i.e. peak or band) allow for higher sensitivity (i.e. higher signal to noise ratio, 
S/N). Two examples of such technologies include SPME-OPP178 and SPME-DBDI.174 
Unfortunately, sensitivity is attained at the expense of the total number of compounds that can be 
analyzed, especially when using tandem mass spectrometry, as the number of analyzed compounds 
is dependent on the amount of transitions chosen per compound (i.e. single reaction monitoring, 
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SRM) and the dwell time selected for each transition. CBS is able to address this limitation by 
offering an additional feature that enables faster analysis times in comparison to DBDI or OPP. 
As shown in Chapter 4, spraying times as short as 3 seconds (or shorter) can be performed for 
small sets of analytes due to the good spray stability offered by CBS. Essentially, the total analysis 
time required for a given CBS application hinges on the total number of analytes being targeted 
for investigation. For example, for a small set of compounds (≤ 10), CBS can collect an adequate 
number of data points in 1-2 seconds when a dwell time of 25 ms is used. Indeed, it would be 
difficult for technologies that depend on fluidic systems to outperform CBS’s speed of analysis 
while maintaining the low-cost per analysis. Unquestionably, the greatest advantage offered by 
CBS is that the blade acts as both the extraction device and the ionization source. In summary, 
among all the technologies herein discussed, CBS is perhaps the SPME-MS approach with the 
highest chance of shifting the paradigm of direct sample introduction to MS. 
 
5.2 Future directions  
Great advances with respect to the development and application of diverse SPME-MS technologies 
have been presented in this dissertation. However, due to the novelty of these technologies, there 
are several factors that require further investigation. For instance, the SPME-TM devices herein 
described were strictly focused on the use of stainless steel meshes. Although the performance of 
the stainless steel SPME-TM was outstanding for direct immersion analysis, employment of this 
technology for in vivo applications (e.g. road testing) would require the use of biocompatible 
molded/extruded polymers,304 biocompatible 3D printed materials,428 or other alternative 
substrates.429 Furthermore, the SPME-TM device presented in this dissertation for direct 
immersion applications was manufactured by welding a mesh spot on a metal support blade.267 
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However, state-of-the-art manufacturing technologies, such as the one employed for the 
production of CBS (i.e. photochemical etching),219 can be used for the preparation of individual 
self-supported meshes. Furthermore, high-throughput mesh arrangements, similar to the ones used 
for liquid chromatography,131 can be constructed to enhance the manufacturing speed of these 
devices. In addition, employment of the 96-mesh on a single holder would allow for significant 
reductions in total analysis time per sample. Undeniably, further work on SPME-TM will also be 
directed towards the use of novel coating chemistries that utilize smaller particle sizes, and 
innovative mesh designs that allow for improved ion transmission.229 Yet, the development of  
novel geometries and coating characteristics will necessitate further investigations of the 
desorption and ionization fundamentals related to such devices.232 For instance, there is need for a 
deeper understanding of the physical and physicochemical parameters (e.g. proton affinity, henry’s 
constant, thermal conductivity of the substrate, polymeric phase chemistry affinity, particle size, 
porosity) that govern instrumental sensitivity. Undeniably, the employment of modeling tools, 
such as COMSOL, would be quite useful in the optimization of such parameters.135 Certainly, the 
availability of such information would enable the tuning of devices to favor the highest possible 
instrumental response.  
With respect to SPME-nanoESI, the results herein reported showed that further work is needed in 
relation to the wettability and smoothness of the tested commercial coatings. Such developments 
would help prevent the formation of droplets inside emitters, which would in turn enable 
employment of longer electrospray events, further facilitating the employment of this technique 
towards diverse MS experiments.173 In regards to the commercial applicability of this technique, 
the total cost of emitters needs to be reduced in order for employment of this technology to become 
feasible in commercial applications. To that extent, the implementation of high-throughput 
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analysis that utilizes commercially available automatized nanoESI systems might aid not only in 
enhancing the speed of analysis, but also contribute towards an overall decrease in the total cost 
per sample.37,56 Although this work was chiefly focused on targeted studies, employment of 
nanoESI will fundamentally allow for the attainment of diverse information regarding the system 
under investigation. Therefore, it is anticipated that in a foreseeable future, combinations of 
SPME-nanoESI with MS/MS, HRMS, and IMS-MS will facilitate the attainment of maximum 
amounts of information gathered from a single sample/fiber/emitter.  
Certainly, the SPME-OPP results herein presented are just a foreword for a technology with a 
bright future. As matter of fact, on-going work is focused on the optimization of desorption 
conditions (e.g. open chamber dimensions, evaluation of dynamic versus static desorption, effect 
of pump-flow and capillary inertness on band-broadening) and features of the SPME device (e.g. 
geometry, dimensions, coating thickness ad coating chemistry). As previously discussed in this 
work, owing to the inherent operational mechanism of the OPP (i.e. analytes are introduced into 
the MS system as a peak), this technology shows great potential of becoming one of the most 
sensitive SPME couplings available to date once all features listed above have been optimized. It 
is clear, at least for the author of this dissertation, that SPME-OPP has already found a niche in the 
implementation of SPME for rapid diagnosis at the surgery room, the clinical setting, or any 
application that requires the use of small SPME devices while guaranteeing adequate sensitivity 
(e.g. in vivo sampling from brain).313    
Undeniably, CBS is a technology that has great potential to replace existing direct-to-MS 
technologies and on-line SPE-MS approaches for the analysis of complex matrices. Future work 
on CBS will be directed towards improving the selectivity of the method, either by implementing 
on-coating derivatization approaches,286 through the use of smart materials as coatings (e.g. 
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molecular imprinted polymers or metal organic frameworks),430 or by addition of non-
chromatographic separations such as ion mobility or differential mobility prior to MS detection.178 
In addition, CBS is moving towards fully-automated and integrated sample preparation and MS 
events, allowing for total analysis times of less than 15s for biofluids. Novel methodologies for 
determination of drug metabolites will include an enzymatic hydrolysis step in the workflow prior 
to the enrichment step.233 This new step will not dramatically affect the total analysis time, and 
will enhance the sensitivity of the method for the target drug. Furthermore, on-going experiments 
have shown the potential of CBS for quantitation of target analytes from smaller sample volumes 
(≤ 5 µL). Moreover, by making the abovementioned enhancements, one can foresee the 
implementation of CBS in the analysis of more challenging analytes, such as testosterone and 
neurotransmitters. Much like other SPME-MS technologies, one can predict the immediate 
application of CBS as a tool for rapid profiling studies70,285 that, when used in tandem with portable 
mass spectrometers, will enable rapid qualitative or semi-quantitative on-site analysis.196 
Certainly, current efforts are concentrated on the commercialization and implementation of CBS 
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